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Abstract 
Identifying and treating infectious diseases remains a challenge for modern 
healthcare professionals. Proper identification of infectious diseases and 
understanding of the means of infection will allow for optimal use of antibiotics and 
the development of alternative therapies such as anti-adhesion therapy. It is therefore 
important to develop tools that can probe the processes involved in infection, or that 
can be used as point of care diagnostics. In vivo glycosylated surfaces are inherently 
heterogeneous, increasing the complexity of the interactions that take place, and with 
a corresponding increase in analytical difficulty. Glycopolymers and glycosylated 
nanoparticles are ideal methods for incorporating synthetic functionalisation into a 
biological setting to probe interactions between glycosylated surfaces and 
carbohydrate recognising proteins (lectins).   
This work utilises heterogeneously glycosylated polymers to probe the inhibitory 
and kinetic activity of the polymers towards various lectin targets. We see further 
evidence of the “heterocluster effect” whereby nominally non-binding sugar epitopes 
give rise to faster association rates and increase overall residence time of bound 
lectins to the polymers. Highly coloured heterogeneously glycosylated gold 
nanoparticles are used to develop a high throughput screening library for the 
identification of binding patterns with lectins that could lead to use as an 
identification system of unknown lectins. Finally, unnatural azide containing sugars 
are used to metabolically label the surface of A549 carcinoma cells and tagged using 
fluorescent polymers. This system provides a robust way of introducing polymeric 
functionality onto the surface of cells, opening the ability to probe in-depth the cell 
surface.  
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Chapter One 
Introduction 
1.1. The antibiotic resistance crisis 
The antibiotic resistance crisis has been building for several decades.  The discovery of 
penicillin by Alexander Fleming in 1928 has brought about nearly 100 years of improved 
healthcare.
1
 Despite this infectious diseases are still one of the world’s top killers. 
Respiratory tract infections (3
rd
), tuberculosis (8
th
) and diarrhoeal diseases (9
th
) are amongst 
the top 10 causes of death. Globally they alone accounted for 10.6% of deaths worldwide in 
2015.
2
 On top of this the rate of discovery of antibiotics has slowed considerably, from 33 in 
the period from 1985-2000 to just 13 from 2000-2014. 
3
 
There are a number of ways to combat this growing problem; changing industry dependence 
upon combinatorial libraries would allow access to larger synthetic spaces, as well as 
targeting a broader range of inhibition pathways,
4,5
 greater understanding of the development 
of resistance mechanisms, finding alternative methods for combating infectious disease (for 
example anti-adhesion therapy), and, more effective use of the antibiotics we currently have. 
To facilitate this we require better tools that will allow us to identify unknown samples from 
both biological sera and contaminated water supplies. We need the ability to differentiate 
quickly between bacterial and viral infections in order to effectively target our treatments.  
On top of this, cancer is the 2
nd
 leading cause of death globally. Having better tools to 
investigate the bio-markers associated with the development and metastasis of cancer related 
diseases will be vital to reduce the loss of life. The development of tools to investigate the 
interactions of infectious agents and biomarkers of cancerous cells have significant overlap, 
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and may lead to the development of point of care (POC) diagnostic and prognostic techniques 
for both.
6–9
 One of the most ubiquitous information containing biological macromolecules are 
carbohydrates (glycans, or ‘sugars’) which coat all cells and direct a vast range of infectious 
processes.  
1.2. Protein-Carbohydrate interactions 
1.2.1. Glycans 
The four main classes of cellular macromolecules are nucleic acids, proteins, lipids and 
glycans. Glycans are poly- or oligo- saccharides and are found conjugated to proteins 
(glycoproteins and proteoglycans) and lipids (glycolipids) within the body. They can have 
linear, complex branched structures or they can be free-standing entities involved in both 
metabolism and signalling.  Until recently, the main focus of biochemical research has been 
on DNA and proteins, due to the fact that they are pure and discrete macromolecules and the 
biochemical tools used to access and characterise these (PCR and mass spectrometry) are 
readily available. Conversely glycans are dynamic, changing over time and many sugars have 
the same mass, complicating analysis by mass spectrometry. Glycans are also not templated 
(e.g. DNA-RNA-protein) but are a post-translation modifications; successes in genomics and 
proteomics unfortunately cannot translate into knowledge of the genome. 
 Despite this, glycans form a major part of the extracellular matrix, as well as the external cell 
surface, and as such are vital in determining how cells interface with their environment. A 
cell’s glycosylation state affects its biological activity and can give an indication of the 
underlying cell physiology,
10–16
 and glycans play a vital role in inflammation processes.
17–20
 
For example, overexpression of sialic acid residues has been observed  in the glycome of 
cancer cells derived from gastric, colon, pancreatic, liver, lung, prostate and breast tissue, as 
well as in several types of leukemia.
21–26
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A greater understanding of glycan biology is also vital for treatment of infection. Many 
parasites, viruses, bacteria, and their toxins, initiate infection through glycan mediated 
adhesion to the cell surface, shown in Figure 1.1.  
 
Reproduced with permission from L. Otten, Pathogen Detection Based on Carbohydrate Adhesion, Thesis, 
University of Warwick, 2015.   
Figure 1.1: Protein-Carbohydrate interactions play a central role in multiple biological 
processes. 
However, analysis of glycans is not easy; glycans are not directly encoded genetically, 
instead they are directed by metabolism, signal transduction and cellular status
27–30
 and offer 
a stunning level of complexity that is orders of magnitude greater than that offered by 
proteins and DNA.
31–33
 Theoretically just four monosaccharides can create 35,560 unique 
tetra-saccharides,
34
 although in practise not all of this space is utilised in nature. This 
complexity arises from the number of structural isomers that exist for each sugar, Figure 1.2: 
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Structural Isomerism, the different arrangement of bonds (i.e. Pyranose vs Furanose)  
 Enatiomers, the non-superimposable mirror images of each other in which nature has 
favoured the d configuration  (D/L)  
 Diastereoisomers, special stereoisomers that are not mirror images  (Glucose, 
Galactose, Mannose)  
 Anomers, the stereochemistry position of the C1 substituent alcohol (Alpha vs Beta) 
 Branching, the bond formation between the C1 position and any of the C2-6 positions 
(1-2/1-3)  
This complexity greatly increases the difficulty of analysis, reducing the analytical power 
of mass Spectrometry but also complicating the interpretation of other analytical methods. 
No single method can be used to analyse the glycome. Fortunately, in mammalian 
biology the most common glycan structures are composed of only 10 monosaccharide 
base units, see Figure 1.3. This reduces the conformational space used in nature, but still 
presents a staggeringly complex array of structures.  
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Figure 1.2:  Conformational complexity of glycan structures.  
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Figure 1.3: The 10 D-mammalian monosaccharides and their consortium of functional 
glycomics (CFG) representations 
This complexity makes glycans very information dense and allows them to be used by nature 
in recognition events. This role is also how pathogenic species take advantage and attempt to 
hijack natural pathways to adhere to host cells and/or gain entry to do damage or replicate.  
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1.2.2. Lectins 
Carbohydrate binding proteins that are neither enzymes or antibodies are known as lectins.
35
 
They are ubiquitous in nature, found in plants, animals, viruses and bacteria. Lectins are 
utilised in a wide range of biological processes, including inflammation, adhesion of 
infectious agents, tumour cell differentiation and metastasis, and immune system 
interactions.
32
 They interact with carbohydrates in a reversible and non-covalent manner.  
1.2.3. Plant Lectins 
Legume lectins are the most studied group of lectins. The first pure lectin to be isolated was 
Concanavalin A (Con A) from the seeds of jack beans in 1919 by Sumner.
36
  Legume lectins 
typically consist of 2 or 4 identical subunits that associate/dissociate dependent upon pH. 
Each subunit typically contains one carbohydrate binding domain, a Ca
2+
 binding site, and a 
transition metal binding site, often Mn
2+
. Without these metals present carbohydrate binding 
is severely diminished or negated completely.  Approximately 20% of the amino acid 
residues are conserved across all legume lectins and a further 20% are similar. Of the 
conserved amino acids, several are found within the carbohydrate binding domains; aspartic 
acid, asparagine, a glycine (except in Con A) and an aromatic amino acid
37,38
 or leucine.
39
 
Almost all the metal binding domains are invariant. Despite this, lectins have a wide range of 
binding specificities and can be highly specific for di-,tri-,and tetra saccharides.  The binding 
domain itself is often a shallow depression on the surface of the protein, with the Ca
2+
 and 
transition metal in close proximity. The cations do not necessarily participate in binding, but 
help place the amino acids into the correct configuration to facilitate binding. Water 
molecules also play a vital role in carbohydrate binding by being both hydrogen bond donors 
and acceptors; in the peanut agglutinin lectin (PNA), some of the high specificity for T-
antigenic disaccharide (Galβ(1-3)GalNAc) is due to two water bridges.39  
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Legume lectins are highly abundant and provide a diverse range of saccharide specificities 
with which to probe lectin-carbohydrate interactions. This makes them ideal for use as model 
systems and developing biomedical applications.  
1.2.4. Plant Toxins 
Plant lectins can also be toxic to humans; of particular note is the lectin ricin, RCA60, derived 
from the seeds of the castor oil plant. Ricin is highly toxic with the potential to be used as a 
chemical weapon. It is a dimeric protein consisting of a lectin subunit, which allows entry to 
the cell, and a toxophoric subunit, which causes cell death by disrupting protein biosynthesis. 
It is more toxic than cyanide with an LD50 of 20 µg/Kg, meaning 1.6mg can kill the average 
adult male. 
RCA120 is a less toxic analogue to RCA60 that facilitates study of ricin within a laboratory 
setting without requiring extensive safety procedures, Figure 1.4. It shares the carbohydrate 
recognition subunit with RCA60, while the other subunit is non-toxic.   
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Figure 1.4: RCA120 protein structure (Protein data bank structure 1RZO
40
), showing location 
of β-D-Galactose binding domains.  
1.2.5. Bacterial Lectins 
Bacteria often secrete toxins to directly damage the host and its immune system. Cholera 
(Vibrio cholerae) causes between 21,000 and 143,000 deaths per year
41
 but it is the cholera 
toxin (CTx) that causes its pathogenicity. Cholera Toxin is an AB5 protein consisting of a 
dimeric, toxic, A domain bound through a sulphide bridge and a pentameric B domain of five 
α-Helices. The B domain, shown in Figure 1.5, of the toxin binds with nanomolar affinity to 
the GM-1 carbohydrate present on the surface of the intestine, where it is internalised. The 
toxic A subunit then raises the concentration of cellular cyclic adenosine monophosphate 
(cAMP). This results in fluid expulsion from the infected cells and the symptoms of cholera.  
10 
 
 
Figure 1.5: (A) Top down view and (B) Side view of the CtxB subunit and 5 binding sites 
(Protein data bank structure 1JR0
42
). 
The GM-1 binding domain of the B subunit contains a primary binding site that binds to the 
terminal galactose residue of GM-1, Figure 1.6 Blue.  It binds to this domain with a Kd of ~50 
mM, while the secondary binding domain binds to the neuraminic acid residue, Figure 1.6 
Red, with a Kd of 210 mM.  Finally the remainder of the GM-1 scaffold severely restricts the 
conformational space available to the galactose and neuraminic acid residues.
43,44
 This 
rigidity greatly reduces the entropic penalty paid when GM-1 binds to CTxB. These three 
interactions result in one of the highest avidity carbohydrate-protein interactions known.
44
 
The factors contributing to this high binding affinity will be discussed in further detail in 
section 1.3  below.  
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Figure 1.6: The GM-1 ligand, D-galactose-β(1-3)-N-acetyl-D-galactosamine-β(1-4)-D-
galactose- (α(2-3)-neuraminic acid)-β(1-4)-D-glucose-β(1-1)- ceramide. 
1.2.6. Anti Adhesion Therapy  
Anti-adhesion therapy aims to prevent the effects of pathogen infection by using a glycan 
substrate (or decoy) with a higher binding affinity for the pathogen than the intended target, 
preventing the initial engagement and hence reducing infection.
45
 Bacteria often gain 
significant resistance to antibiotics and the immune response after adherence to surfaces, due 
to the formation of intransient biofilms.
46–48
 Furthermore adherent bacteria acquire nutrients 
with more ease and thus are better able to survive and cause re-infection.
49
 
While anti-adhesion resistance may also be expected to arise, through mutation or the 
acquisition of new genetic material, it would be expected to arise at a much slower rate. This 
is due to the lack of a selection pressure being applied by not killing or slowing the growth of 
the bacterial population. This results in a lack of separation between resistant and susceptible 
stains, preventing predominately resistant strains from emerging. Considering this, glycan 
decoys are a potential target for new anti-adhesion therapies.  
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1.3. Multivalency 
The interaction between a single carbohydrate and individual lectin binding site is typically 
very weak, with a dissociation constant (Kd) in the mM range. To overcome this, nature 
utilises multiple carbohydrate binding interactions simultaneously to allow the formation of 
reversible, non-covalent, yet strong bonds. These multivalent interactions result in a total 
avidity which is greater than the sum of the individual affinities, up to a system dependent 
limit.
50
 This effect was first noted by Lee et al. 
51
 and is referred to as the “cluster glycoside” 
or “multivalency” effect. This multivalent effect is a result of the multiple binding modes that 
multivalent receptors and ligands can under-go, each leading to a non-linear increase in 
affinity, Figure 1.7. 
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From L.LKiessling, J.E.Gestwicki, L.E. Strong, Angew. Chem Int. Ed., 2006, 4, 2348-68. Reprinted with 
permission from John Wiley and sons.  
Figure 1.7: The binding interactions of multivalent ligands. 
In all of these binding events the same basic thermodynamic principles apply. As in all 
interactions, the energy of binding is governed by the Gibbs free energy as given by Equation 
1.1:  
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 ∆𝐺 = ∆𝐻 − 𝑇∆S  1.1 
 
In the binding of a multivalent ligand to a multivalent receptor, the enthalpy (ΔH) for the 
interaction of one ligand of a polyvalent ligand is equivalent to the enthalpy of the 
monovalent interaction. The enthalpy term associated with subsequent binding can be either 
enhanced or diminished depending on the relative physical dimensions of the receptor and 
polyvalent ligand. If the binding of one ligand causes a change that allows the next ligand to 
bind with greater enthalpy (more negative) then the system is said to have positive 
cooperativity.  This is most famously exemplified by the binding of oxygen to haemoglobin, 
although this is admittedly not a multivalent system. Positive cooperativity has also been 
observed in the binding of cholera toxin to its native ligand GM-1. 
52
  If the orientation of the 
polyvalent ligand is such that there is not a perfect conformational match between it and the 
receptors, any secondary binding will introduce conformational strain into the system by 
distorting either the receptor, the ligand, or both. This situation is described as negative 
cooperativity as the secondary binding has a smaller binding enthalpy. As such the more 
conformationally rigid a system, the more likely there will be a mismatch between receptor 
and polyvalent ligand, resulting in diminished enthalpy of binding.  
In contrast, in multivalent binding the entropic (ΔS) contribution is largely paid upon the 
binding of the first ligand to the receptor and secondary binding is entropically neutral. In this 
case the intramolecular binding of the second ligand will have a greater change in free energy 
as ΔS≈0 and therefore ΔG≈ΔH.  While this approximation is valid for many systems, it is 
unrealistic, as the linker between ligands of a multivalent ligand will have an associated 
flexibility. With an increase in flexibility comes a decrease in degrees of freedom after 
secondary binding. This will come with an associated entropic penalty for secondary binding 
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events. Therefore when designing multivalent ligands, consideration of rigidity of the system 
is important.  
Since the enthalpy of binding is approximately equal for both a monovalent ligand and the 
first binding event of a multivalent ligand, the rate of association (kon) will largely be the 
same for both the monovalent and multivalent ligand. Therefore any differences in the 
affinity between monovalent and multivalent ligands is due to the rate of dissociation (koff). 
However this is only true for homogeneous multivalent ligands. Considering this, multivalent 
glycopolymers (see below) offer an exciting route to high-affinity glycan mimetics.  
1.4. Heterogeneity  
In 2010 Jiménez Blanco et al. used heterogenous glycoclusters with a β-cyclodextrin core to 
probe the role of heterogenous glycoenviroments that contain nominally non-binding sugars 
alongside native ligands.
53
 From this work they reported evidence for a heterocluster effect:  
“The term heterocluster effect refers to the increase in the intrinsic binding affinity of a 
carbohydrate ligand towards a lectin in the presence of a second sugar that itself is not a 
ligand for this lectin (intrinsic affinity means in a per-ligand basis, keeping the same overall 
topology and preventing contributions to binding from aggregation phenomena.”54 
Thermodynamically, the explanation for this effect is that while the enthalpic contribution is 
lower due to the inclusion of “non-binding” sugars, this is compensated for by an increased 
entropy of binding. These observations correlate with a “bind and slide effect”, as has already 
been proposed for the binding of lectins to multivalent glyco-arrays, 
55
 whereby the lectin 
moves between binding domains along the surface, resulting in an increased residence time 
and therefore a longer macroscopic off rate, Figure 1.8.  
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Figure 1.8: The bind and slide mechanism, where-by a lectin initially binds to a surface and 
then moves or “slides” along the surface, resulting in an increased time spent “bound” to the 
overall surface and a slower dissociation rate overall.  
Therefore, it will be vital going forward to reflect the inherent heterogeneity of the cellular 
milieu when designing probes to investigate carbohydrate binding.  
Greater understanding of the multivalency mechanism and the effect of linkers, non-binding 
partners, desolvation effects, and, secondary binding domains opens up the possibility for the 
rational design of ligands. Rationally designed ligands have the potential to allow the 
development of more sensitive assays and diagnostic tools, as well as acting as anti-adhesion 
prophylactics. To do this requires an underlying scaffold, chiefly either polymeric and 
particle based. Both of these options will be discussed in further detail later, in sections 1.5 
and 1.6 In particular synthetic glycopolymers and glycoparticles, where the sugars are 
presented pendant to the polymer backbone, are an established class of multivalent probes 
which often present significant binding enhancements.  
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1.5. Polymerisation techniques 
1.5.1. Living Radical Polymerisation 
The development of living radical polymerisation (LRP) techniques has given chemists 
unprecedented control over polymer architecture. Living polymerisation techniques allow the 
synthesis of polymers with linear, branched or more complex architectures while maintaining 
strict molecular weight control with narrow dispersity. Added to this is the ability to 
introduce functionality to either chain ends or side-chains on the backbone, making polymer 
chemistry a versatile platform from which to develop new materials for medicinal 
applications. Living polymerisation techniques have already found medicinal uses in the 
cases of biodegradable implants
56–59
  and as drug conjugates to improve pharmacokinetics.
60
  
Living radical polymerisation techniques all use different modes of action to achieve ‘living’ 
status: but they aim to limit termination and transfer reactions and can continue to polymerise 
after the initial monomer stock has been depleted upon the addition of more monomer. LRP 
techniques are based around several different mechanisms of action: (1) Stable free-radical 
polymerisation, for example nitroxide mediated polymerisation (NMP); (2) Reversible chain 
transfer polymerisation such as reversible addition – fragmentation chain transfer (RAFT), 
also known as macromolecular design via the interchange of xanthates (MADIX) depending 
on the class of chain transfer agent (CTA) used; (3) Metal mediated polymerisation such as 
atom transfer radical polymerisation (ATRP) and single electron transfer living radical 
polymerisation (SET-LRP). Each of these categories contains many more examples of LRP 
systems but these examples are the most commonly used due to their applicability to a wide 
range of monomers and solvent systems.  
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1.5.2. Reversible Addition Fragmentation Chain Transfer 
Polymerisation 
RAFT is a LRP technique that is particularly well suited to the synthesis of polymers for use 
in a biological setting. RAFT does not require the use of a toxic copper catalyst as in ATRP 
and SET, and the chain transfer agents used allow facile introduction of end group 
functionality at both the α and ω positions.  The RAFT mechanism is shown in Figure 1.9:  
 
 
 
 
 
 
 
 
Figure 1.9: Mechanism of RAFT polymerisation showing initiation, pre-equilibrium, 
propagation and termination. 
The first step is the initiation step where radicals are generated. Thermal decomposition or 
photolysis of the initiator is typically used. Following this, the oligomeric radicals add to the 
chain transfer agent (CTA). Evidence in the literature suggests that all RAFT agents are 
consumed in this step before any propagation of the polymer chain occurs.
61
 This is due to 
the reactive C=S bond being favoured over any vinyl monomer bonds. Following this the R 
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group can leave to initiate another growing polymer chain or Pm can fragment and propagate. 
The R group should be a good reinitiating group and must fragment at a similar rate to the 
initiator or growing polymer chain.  The Z group must activate the C=S bond towards radical 
addition and stabilise the radical adduct as little as possible. By keeping the number of 
propagating chains as low as possible, compared to the number of stabilised radicals 
termination is reduced, imparting control over the polymerisation. However termination does 
still occur, either by combination between two propagating radicals, or by disproportionation. 
This mechanism allows us to easily introduce α-end group functionality simply by modifying 
the R group of the RAFT agent while ω-end group functionality can be introduced by 
changing the Z group or by post polymerisation modification of the thiocarbonyl end group. 
RAFT polymerisation is particularly useful if you wish to coat gold nanoparticles (AuNPs) 
with polymer, as the ω-end group is easily reduced to a thiol, which will spontaneously self-
assemble onto the gold surface,
62
 and is exploited later in this thesis. 
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1.5.3. Post polymerisation modification  
When designing a polymeric system for a diagnostic application, the inherent dispersity of 
polymer samples must be taken into account. While LRP gives us access to almost any 
polymer architecture we wish, even at low dispersity the polymer sample is inherently a 
mixture of many chain lengths. If two different monomers are polymerised then each 
resulting polymer will not be identical in terms of distribution. This is crucial in glycoscience, 
as valency (i.e number of sugars) plays a dramatic role in affinity, hence small differences in 
dispersity might translate to false positive/negative results in binding assays. This means 
using a single batch of master polymer with a reactive monomer unit that allows varying 
functionality to be added in a post polymerisation modification process, enables an extra level 
of control to be imposed, assuming the modification reactions are efficient, and go to 
quantitative conversion.  
1.5.4 Glyco-polymers  
Glycopolymers offer a route to well-defined multivalent glycoassemblies. The vast array of 
polymeric architectures available means that glyco-polymers can offer almost any array and 
orientation of carbohydrate, through either pendant or terminal carbohydrates. 
Glycopolymers have the advantage of being easy to synthesise and can they can be produced 
on a large scale. They can easily span large dimensions, which is vital for probing the 
multivalent interactions with lectins, which can have large distances between binding sites, 
such as RCA120 which has two binding domains separated by 110 Å.
63
  
Initial work using glycopolymers was focussed on glyco-mimetics of natural carbohydrate 
ligands, as a method for probing carbohydrate-lectin interactions.
51,64
 Work by Cameron and 
co-workers used synthetic glycopolymers to probe the binding interaction of both RCA120
65
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and peanut agglutinin (PNA)
66
. In the case of RCA120 it was observed that the enhancement in 
binding of multivalent galactosides over the monovalent sugar was a result of contributions 
from both the chelation mechanism and the bind and slide mechanism. Meanwhile for PNA, 
the 50-fold increase in affinity observed for the galactosides were attributed to the cross-
linking of proteins, such that the multivalent glycopolymers were inhibiting multiple PNA 
proteins simultaneously. Glycopolymers also offer opportunities for therapeutic and other 
biomedical applications. They have been used for  drug release,
67,68
 scaffolds for tissue 
engineering,
69–71
 and, as inhibitors to block immune response during surgery.
72
 Notably, they 
are ideal candidates for the development of anti-adhesion thereapeutics. Haddleton and co-
workers used mannosylated glycopolymers to inhibit dendritic cell specific ICAM-3 grabbing 
non-integrin (DC-SIGN), a lectin present on immune response cells that contributes to the 
infectivity of HIV-1.
66
 By increasing the density of mannose on the glycopolymer from 20 to 
90 sugar moieties,
73
 a decrease in the concentration required for 50% inhibition (IC50) from 
1453 to 37 nM was observed. In order to side-step the difficulties in attempting to rationally 
design multivalent ligands, Fulton et al. have used polymer scaffolded dynamic 
combinatorial libraries (PS-DCL’S)74,75 to generate high affinity heterogeneous 
glycopolymers through templating with lectins. By templating heterogeneous galactose and 
mannose polymers against Concanavalin A (Con A) and E.Coli heat labile toxin (LTB), they 
saw an increase in the free energy of binding of 5.2-8.8 kJ mol
-1
.
76
 This method provides a 
way to ‘screen’ for anti-adhesion leads as well as probe the nature of carbohydrate binding in 
a high-throughput manner.  
This highlights the potential of glycopolymers and multivalent glycosylated structures in 
general, for both fundamental studies of carbohydrate binding, as well as for medical 
applications. Another method of preparing multivalent glycoassemblies are nanoparticles, 
that offer their own advantages and disadvantages in probing carbohydrate binding.  
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1.6. Glyco-nanoparticles  
Nanoparticles are easy to synthesise in a manner which is simple to scale up.
77–79
 They offer 
the possibility of multi-functionality such that the same particle might act in both a diagnostic 
and therapeutic manner (so called “theranostics”).80 While tuning the carbohydrate coating of 
nanoparticles allows probing of biological interactions, changing the nanoparticle core used 
offers a wide variety of tools for use in both a research and medical setting. The use of optical 
tags, magnetic particles and/or radionuclei allows nanoparticles to be used as biosensors,
80
 
therapeutics,
81–83
 in optical imaging,
84–88
 magnetic resonance imaging (MRI),
89–91
 positron 
emission tomography imaging (PET),
92–94
 and, x-ray computed tomography (CT).
95–97
  
1.6.1. Gold nanoparticles 
Gold nanoparticles (AuNPs) in particular offer some unique properties that have seen then 
widely employed for the design of biosensors and elsewhere.
77,78,98–101
 They are easy to 
synthesise and receptive to surface functionalisation, they have highly tuneable optical 
properties and are biocompatible for both ex and in vivo applications. Monodisperse solutions 
of gold nanoparticles are highly coloured. The electromagnetic field of incident light induces 
an oscillation of the free electrons in the conduction band of the metal. This oscillation 
induces a dipole in the particles with respect to the ionic lattice of the gold atoms along the 
plane of the electric field of light. The maximum amplitude of this oscillation occurs at a 
particular frequency, known as the surface plasmon resonance (SPR).
102–105
 For gold the SPR 
wavelength occurs around 520nm.
106
 The SPR wavelength and the intensity of the absorption 
depends on factors that affect the charge density at the surface of the particle, including the 
size of the particles. Importantly, as the particle separation distance is reduced to less than the 
diameter of a single particle, dipole-dipole coupling causes a red shift and broadening of the 
absorption spectrum which can be detected through UV-Vis spectroscopy.
77
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The first use of gold nanoparticles in this manner was by Mirkin et al. for the colourimetric 
detection of bacterial DNA
107
  (based on work by Leuvering et al. that proposed a gold 
nanoparticle based immunoassay, but did not utilise a colourimetric detection method
108
). 
Since then this method has been used to probe proteins,
109,110
 peptides,
111
 antibodies
112–116
 and 
DNA
117,118
 in a label free manner. More recently work by Richards et al. has used 
glycosylated gold nanoparticles to probe carbohydrate-lectin interactions.
119–124
  
Glycosylated nanoparticle surfaces effectively mimic the cell glycocalyx and so are ideal for 
studying or interrupting biological interactions, while allowing label free monitoring. By 
functionalising AuNPs with a mixture of galactose and mannose sugars Gibson and co-
workers started to mimic the natural heterogeneity of the cell for identification and 
concentration of unknown lectins.
122
 This highlights the power of gold nanoparticles as a 
label free system that can be utilised in a high throughput manner cheaply and easily when 
compared to other techniques such as glyco-arrays, which often require more extensive 
synthesis. 
125,126
  
1.7. Imaging the glycocalyx 
While it is important to develop methods for investigating carbohydrate binding interactions 
in a separate and controlled environment, it is also vital to develop tools for probing the 
glycocalyx of a cell directly. Tools for probing in vivo protein interactions have been in use 
for a number of years, largely by utilising genetic modification to generate fluorescent 
mutants that are easily visualised.
127
 However as glycans are dynamic biomolecules that are 
not directly encoded by DNA,
128
 glycans are resistant to imaging in this manner.   Work has 
been made to utilise lectin binding to visualise cell surface glycans,
129,130
 but lectins are 
unsuited for in vivo work due to their inability to cross cell membranes, as well as their 
potential toxicity.
131,132
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1.7.1. Metabolic labelling 
To circumvent this issue this issue Bertozzi and co-workers have developed a method of 
metabolic glycan labelling for direct imaging of the glycome (the complete glycan profile 
produced by a cell). This is achieved via the incorporation of unnatural sugars bearing a 
reactive tag functionality, typically an azide, however many others have been reported.
16,133–
140
 Various bio-synthetic pathways have been utilised for the labelling of glycans through this 
method: sialic acid biosynthesis,
135,140
 O-linked
141
 and N-linked glycosylation,
142
 
fucosylation
137
 and glycolipids
143
 have all been accessed. Even more impressively this 
technique has been used to directly observe the development of glycosylation in developing 
zebrafish embryos.
144–147
  
To achieve the biocompatibility necessary perform these labelling experiments in vivo with 
no detrimental effects requires the use of “bio-orthogonal reagents” as proposed by 
Bertozzi.
133
 These reagents are an extension of the principles of “click” chemistry and must 
fulfil the requirement of being small enough to be tolerated by the cells native enzymatic 
pathways, and chemically inert towards the chemical functionality of the cell.
148
 In order to 
further extend this methodology to labelling of multiple biosynthetic pathways, new 
chemistries and strategies must be produced.  
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1.8. Summary  
It is obvious that the development of tools to better investigate the glycome are vitally 
important. The staggering complexity presented by carbohydrate chemistry has allowed 
nature to develop glycosylation as an information dense mediator for a huge range of 
biological processes. Furthermore, the glycosylation of cells is not dependant on direct 
genetic encoding and is instead a function of a cell’s genome, transcriptome, proteome, and 
its extra cellular environment and varies with access to nutrients. This dependency on such a 
wide array of cellular processes means that analysis of a cell’s glycome is intrinsically linked 
to its physiological state, and will vary with the progression of disease. Changes in the 
glycome are linked to cancer,
26,132,149–151
 Alzheimer’s disease,142,152,153 and malaria. 154,155  
Meanwhile, cell surface glycans are the primary attack vectors for infectious diseases and 
some toxic plant proteins. Cellular adhesion of bacteria greatly increases the ability of 
bacteria to survive, while bacterial toxins weaken the host and reduce its ability to effectively 
combat the infection. A greater understanding of the dynamics of these multivalent 
interactions within a heterogeneous environment is vital to make progress towards effectively 
combating these diseases with alternative therapies such as by preventing adhesion.  
Finally, the ability to easily and at scale, investigate carbohydrate binding events is vital for 
the discovery of lead compounds, as well as providing a platform from which to effectively 
screen environmental and biological samples for the identification of unknown pathogens.  
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1.9. Aims  
Considering the above, this thesis aims to investigate three aspects of carbohydrate 
interactions. In Chapter Two, a panel of homo and heterogeneous glycopolymers are 
synthesised via a sequential three step procedure to generate a glycopolymer library. The 
binding properties of these polymers are then investigated against the biologically relevant 
toxins 26omofun communis agglutinin 120 (RCA`120) and toxin secreted by Vibrio cholerae 
(CtxB) using both a competitive binding assay to assess the inhibitory potential of the 
glycopolymers and a biolayer interferometer (BLI) to investigate the effect on the binding 
kinetics.  In Chapter Three, we propose a method for the generation of a high throughput, 
heterogeneous, glycosylated gold nanoparticle library that is synthetically simple and widely 
applicable. The limit of detection for assays of this type is investigated, and the gold 
nanoparticle library is screened against five lectins.  In Chapter Four, acetylated 
azidogalactose is used to metabolically label human carcinoma cells (A459), which are then 
labelled using fluorescent polymers. It is then demonstrated that the labelling of the cell 
surface with polymers doesn’t inhibit the viability of the cell surface.  
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Chapter Two 
Heterogeneous Glycopolymers to Target Bacterial 
Toxins 
Declarations 
The work submitted in this chapter was performed by myself, except for NMR DOSY 
experiments which were performed by Dr. Ivan Prokes 
2.1. Abstract  
The incorporation of ‘non-binding’ sugars into low density glycopolymers is found to 
enhance both avidity and inhibitory activity against toxins, despite seeming counter-intuitive. 
A library of homogenous and heterogeneous glycopolymers were synthesised by a three-step 
post-polymerisation modification process, with a final copper-free ‘click’ conjugation. 
Inhibitory assays showed it was possible to inhibit ricin over cholera toxin. Detailed analysis 
using biolayer interferometry assessed avidity and also rates of binding. This demonstrated 
binding towards cholera toxin did infact occur and highlighted the need for multiple 
analytical techniques when investigating multivalent binding. The findings demonstrate that 
mimicking the natural display of heterogeneous, or branched, glycans is a powerful, yet 
simple, tool to improve the function of glycomimetics. 
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2.2. Introduction 
Many pathogenic bacteria secrete toxins as their primary mode of pathogenicity, including E. 
coli O-157 shiga toxins (the cause of food poisoning) and the toxin from Vibrio cholerae 
(cholera).
1–4
 Plant toxins can also cause significant harm, such as Ricin (from Ricinus 
communis) which has a lethal dose of ~ 20 μg.Kg-1 and is more toxic than cyanide.5  A 
common feature is that these proteins contain a carbohydrate binding domain to hijack host 
cell-surface glycans and gain entry. Carbohydrate-protein interactions mediate a huge range 
of recognition/signalling events including inflammation
6
, immune-responses
7
 and cell-cell 
signalling.
8
 The ‘reader’ proteins that mediate these interactions are known as lectins, which 
typically have very weak binding affinities (mM).
9
 Nature therefore presents multiple copies 
of each glycan, giving a non-linear increase in affinity, known as “the cluster glycoside 
effect”.10,11 This has inspired the use of glyco-materials, such as polymers or particles, which 
use polyvalent presentation of carbohydrates to enhance affinity.
12,13
 This enhanced affinity 
offers a route to prophylactic anti-adhesion therapies against pathogens/toxins as an 
alternative to traditional antibiotics or small molecule drugs.
14
 ‘Starfish’ glyco-dendrimers 
have 10
6
 fold enhanced activity against shiga toxins compared to the free glycan,
15
 linear 
poly(mannose) is a nM inhibitor of DC-Sign/GP120 interactions,
16
 and inhibition of the 
Ebola virus by a 120-valent mannose glycofullerene cluster has been observed.
17
 High 
affinity sialic acid glycopolymer arrays have been used by Godula and coworkers to dissect 
how influenza engages with its host.
18
  Whilst these multivalent systems all show high 
avidity, they typically present monosaccharides and hence do not have high specificity. 
Glycopolymers have been developed by Kiick et al., and Gibson et al., with high avidity for 
the cholera toxin by modulation of the linker length to match  the binding pocket depth, 
increasing avidity without additional synthetic complexity.
19,20
 In addition to the chemical 
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complexity of oligosaccharides, cell surfaces are heterogeneous and dynamically display 
many different glycans.
21
 Evidence is emerging that these ‘non-binding’ glycans play a key 
role in the overall avidity, and that reproduction of this heterogeneity in glycomaterials can 
enhance avidity towards inhibitory targets.
22
 Percec et al. have introduced non-binding units 
into amphiphilic Janus-glycodendrimers resulting in a 12-fold increase in agglutination 
activity for the particles.
23
 Wu et al. reported that cholera toxin has increased binding 
capacity towards heterogeneous mixtures of GM-2 and fucosyl-GM-1, despite homogenous 
GM-2 having far lower binding affinity compared to homogenous fucosyl GM-1. 
This was reported to be due to an increased cooperativity of the system. The fucosyl GM-1 
activates the CtxB protein towards binding GM-2, which alone effectively does not bind. 
Fucosyl-GM-1 caused less cooperativity compared to the native GM-1 ligand, however this 
counter intuitively lead to a higher binding capacity 
24
 Multivalency is also observed to result 
in changed binding affinities compared to monovalent systems. Richards et al. have reported 
that mannosylated gold nanoparticles have affinity towards communis agglutinin 120 
(RCA120),a non-toxic derivative of ricin, despite the monosaccharides having little or no 
affinity.
25
  
The extreme variation observed in glycan binding is a direct result of the variation in the 
modes of multivalent binding to varied receptors. Multivalent ligands bind to receptors in 
multiple ways that do not apply to monovalent binders. Figure 2.1 shows the different modes 
of binding that apply to multivalent binding.  
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From L. L Kiessling, J. E. Gestwicki, L.E. Strong, Angew. Chem. Int. Ed., 2006, 4, 2348-68. Reprinted with 
permission from John Wiley and sons.  
Figure 2.1: Receptor binding mechanisms that are unique to multivalent ligands. (A) The 
chelation of a multi-dentate ligand to two equal and independent receptor sites. (B) Subsite 
binding whereby either a secondary binding ligand or a part of the multivalent scaffold can 
reach a secondary binding domain that would be impossible for a monovalent ligand to reach. 
(C) The clustering of receptors by binding to multiple independent and equal receptors 
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simultaneously. (D) The statistical rebinding of a multivalent ligand with a single receptor 
due to increased proximity to the binding domain and a neutral entropic penalty.
26,27
   
The variety of interactions possible between multivalent ligands and their receptors therefore 
complicates the process of accurately describing and quantifying the strength of the 
interactions. It has become commonly accepted that the strength of the interaction between a 
single ligand and receptor is known as the affinity, while the overall strength of the 
interaction between a multivalent ligand and receptor is the avidity. Both affinity and avidity 
are described by the association constant Ka or, more commonly the dissociation constant Kd 
(equal to Ka
-1
).   While end-point assays are typically employed to determine the dissociation 
constant, a truer picture of the nature of binding can be obtained, by measuring both the rates 
of association and dissociation of the ligand-receptor complex.  One method of directly 
measuring these quantities is biolayer interferometry (BLI).  
Biolayer interferometry is a technique analogous to surface plasmon resonance (SPR) assays 
that allows for the direct observation of both the association and dissociation rate constants 
for binding events. It works by shining white light down a glass tip with a partially reflective 
surface at the end, Figure 2.2A, any change to the optical thickness of the bound layer at the 
tips surface will result in a shift in the interference pattern observed between the two reflected 
light sources, Figure 2.2B.  
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Figure 2.2: (A) Diagram representing a BLI sensor, showing the light source reflected from 
the partially relflective tip end (blue) and the bound layer (orange) (B) Graph showing the 
shift in wavelength (Δλ) between the two reflected sources.  
Δλ can therefore be directly linked to amount of bound analyte to the tip surface. By utilising 
chemically reactive tips for the immobilisation of proteins onto the tip surface, protein 
binding interactions can be directly observed.  By plotting the size of the bound layer with 
time, values for the rate constants can be extracted. This is discussed in more detail later. BLI 
has several advantages as a technique; it allows real-time, label-free detection in a high 
throughput manner and is relatively insensitive to pH, solvent, and any changes to the 
refractive index of the sample.  
Considering the above, the aim of this work was to probe the effect of mixing ‘non-binding’ 
with ‘binding’ carbohydrates on a single multivalent scaffold using both an assay to screen 
for inhibition, and BLI to investigate the binding affinity, to screen for the next generation of 
glycomaterials.   
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2.3. Results and Discussion 
2.3.1. Synthesis of Glycopolymers  
To access heterogeneous glycopolymers, a three step sequential post-polymerization 
modification strategy was developed, Scheme 2.1.  
 
Scheme 2.1: Synthesis of heterogeneous glycopolymers. (i) DBCO (0.3 eq, Dioxane, 16 
hours 50°C) (ii) Ethanolamine (3 eq, dioxane,16 hours 50°C); (iii) Sugar-N3 (2.5 eq, DMF, 
16 hours, room temperature).  
The method ensured that only a single reactive monomer (pentafluorophenyl methacrylate, 
PFMA)
20
 needs to be polymerised, and avoids the issue of copolymer reactivity ratios. PFMA 
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was synthesised using a previously reported protocol
28
, through the reaction of PFP with 
methacroyl chloride, Scheme 2.2.  
 
Scheme 2.2: Synthesis of PFPMA.  
PFPMA was characterised by 
1
H and 
13
C NMR, IR spectroscopies and mass spectrometry, 
before being polymerised using 4,4′-azobis(4-cyanovaleric acid) (AVCA) as the initiator and  
2-cyano-2-propyl benzodithioate as the RAFT agent. 2-Cyano-2-propyl benzodithioate gives 
reasonable control over methacrylates. A poly(pentafluorophenol methacrylate) master 
polymer with Mn=8900 was obtained. Figure 2.3. 
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Figure 2.3: SEC trace of master PPFMA polymer. 
The dispersity was higher than expected due to the elution behaviour of the PPFMA in SEC, 
but the use of a ‘master batch’ means the actual dispersity is not crucial here as all further 
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polymers synthesised will be equivalent.
29
 
19
F NMR and IR spectroscopy confirmed that the 
PFP group was retained during polymerisation, Figure 2.4.  
 
Figure 2.4: (A) IR of P(PFPMA) showing C-F halide bond 950 cm
-1
 (B) 
19
F
 
NMR spectrum. 
The PFP group was displaced by addition of 30 mol % of dibenzocyclooctyne-amine 
(DBCO) followed by excess ethanolamine to generate a water soluble, copper-free ‘clickable’ 
template polymer.
30
 DBCO incorporation was confirmed by observing the changes to the 
19
F 
NMR spectrum, Figure 2.5A. The integral ratios of free PFP to polymer conjugated PFP in 
the crude reaction mixture (Red) showed 30% displacement, while after addition of 
ethanolamine 100% displacement was observed (Green). Inclusion of DBCO was also 
confirmed via diffusion ordered spectroscopy (DOSY) NMR spectroscopy, Figure 2.5B, and 
Raman spectroscopy 2.5C.  
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Figure 2.5: (A) 
19
F NMR showing two step reaction of PPPFMA (blue), DBCO 
functionalisation to 30 % (red) then following quenching with ethanolamine (green). (B)  
DOSY NMR, showing aromatic peaks (7.5ppm) at the same diffusional co-efficient of -9.25 
log(m
2
s
-1
), as polymer backbone peaks, marked by red line.  (C) Raman spectra showing 
aromatic C-C and alkyne peaks.  
  
A 
C B 
Polymer backbone 
Solvent Peaks 
DBCO Aromatics 
P(PFPMA) 
P(PFPMA)7(DBCO)3 and PFPOH 
P(HEMA)7(DBCO)3 and PFPOH 
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With this reactive precursor to hand, 1-azido-1-deoxy-β-D-galactose (GalN3) and 1-azido-1-
deoxy--D-mannose (ManN3) were synthesised using 2-chloro-1,3-dimethylimidazolinium 
chloride to activate the anomeric position towards nucleophilic attack from the azide anion, 
as per a previously reported procedure, Scheme 2.3
31
  
 
Scheme 2.3: Synthesis and mechanism of 1-azido-1-deoxy hexoses 
The resulting 1-azido-1-deoxy hexoses were characterised by 
1
H and 
13
C NMR spectroscopy, 
mass spectrometry, and the inclusion of the azide group was confirmed by infrared 
spectroscopy, Figure 2.7. To obtain heterogeneous, galactose-rich polymers, GalN3 and 
ManN3 were mixed in the indicated ratios and then applied to the ‘clickable’ polymer such 
that the overall ratio [alkyne]:[N3] was 1:2.5, Table 2.1. 
Table 2.1. Polymers synthesised. 
Polymer Conversion(%)
(a) 
Mtheoretical Mn 
(g.mol
-1
) 
Mw / Mn 
(a)
  Gal 
(%) 
Gal
(c)
 Man
(c)
 
PPFPMA 62 11600 8900
(a)
 1.7 - - - 
PG25M75 - 12900 12900
(b)
 - 25 4 11 
PG50M50 - 12900 12900
(b)
 - 50 7.5 7.5 
PG75M25 - 12900 12900
(b)
 - 75 11 4 
PG100 - 12900 12900
(b)
 - 100 15 0 
(a) Determined by NMR relative to mesitylene reference (b) Determined by SEC (DMF);(c) 
From feed ratio of glycosyl azides; (d) sugars/chain. 
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A mannose-negative control was also synthesised to ensure that any binding effects observed 
were not simply due to density effects of galactose on the polymer chains. To generate an 
analogous homogenous polymer library, another master PPFMA polymer was synthesised 
with the same degree of polymerisation and molecular weight, confirmed by SEC. Three 
polymers were then synthesised targeting 7.5%, 15%, 22.5% displacement of PFP with 
DBCO-amine to obtain polymers with 4, 8, and, 12 cyclooctyne moieties and subsequently 
quenched with ethanolamine. Integrating the relative peaks of pentafluorophenol ester and 
free pentafluorophenol as before gives the percentage DBCO-amine substitution. A fourth 
polymer was substituted only with ethanolamine to give poly(hydroxyethyl methacrylamide) 
with identical molecular weight and dispersity as the glycopolymers, Figure 2.6.  The results 
are summarised in Table 2.2   
 
Figure 2.6: 
19
F NMR of PG75 (red) PG50 (grey) PG25 (green) and HEMA (blue) post addition 
of DBCO (or ethanolamine for HEMA control). Peaks A, B, C, and D relate to fluorine atoms 
in the polymer repeat unit while peaks E, F and G relate to fluorine atoms in solvated 
pentafluorophenol. 
  
A 
C 
B 
D 
E F 
G 
51 
 
Table 2.2: Summary of the DBCO-substitution of P(PFPMA). 
(a) Determined by SEC (DMF); (b) sugars/chain. 
The inclusion of the azido-sugars was confirmed via infra-red spectroscopy using the 
disappearance of the azide associated peak in the purified glyco-polymers, Figure 2.7. Raman 
spectroscopy also indicated the lack of alkyne peak in the purified polymer. 
Polymer Target Alkyne 
Substitution 
Calculated Alkyne  
Substitution 
Mn 
(g.mol
-1
) 
Mw/Mn
(a)
 
(-) 
Gal
(b)
 
(-) 
P(HEMA) 100% 100% 8700 1.6 0 
PG25 7.5% 9.7% 8700  4.85 
PG50 15% 16% 8700  8 
PG75  22.5% 21.42% 8700  10.71 
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Figure 2.7: Infrared spectrum of 1-azido-1-deoxy galactose (black), P(DBCO)15(HEMA)35 
(red) and PGal100 (blue) showing the disappearance of the azide stretch at 2100cm
-1
.  
2.3.2. Competitive binding assay to determine inhibition  
This panel of low density, heterogeneous and homogenous, glycopolymers were subsequently 
screened for inhibitory activity against cholera toxin B-subunit (CTxB) and Ricinus 
communis agglutinin 120 (RCA120), a substitute for the biological warfare agent Ricin.  CTxB 
is the pentameric subunit responsible for cell surface binding and subsequent internalisation, 
Figure 2.8A. The diameter of CTxB is approximately 60 Å
32
 with approximately 30 Å 
between binding domains (measured with Jmol using the protein data bank file (PDB) 1JR0). 
RCA120 has two identical binding sites
33
 that are 110 Å apart, Figure 2.8B.  
34,35
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Figure 2.8: (A) The CtxB pentamer from PDB file 1JR0
36
 (B) RCA120 lectin from PDB file 
1RZO.
37
  
By assuming a carbon-carbon bond length of 1.54 Å and a dihedral bond angle of 109.5° we 
can calculate an estimate for the maximum chain length of our DP50 polymers as 125.75 Å 
and therefore the average galactose spacing for each polymer is shown in Table 2.3.  
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Table 2.3: Table showing average galactose spacing for each polymer. 
Polymer Average Spacing 
between Galactose (Å) 
Average Spacing between Sugars 
(Å)  
P(HEMA) N/A N/A 
PG25 31.4 31.4 
PG50 15.7 15.7 
PG75  10.5 10.5 
PG25M75 31.4 8.4 
PG50M50 15.7 8.4 
PG75M25 10.5 8.4 
PG100 8.4 8.4 
 
These estimates for the average sugar spacing will not be representative of the conformation 
of the polymers in solution. They do, however, provide us with estimation for the physical 
spacing of the sugars, and even at the lowest density of galactose, the average spacing 
between sugars is sufficient to bridge the gap between binding sites for CTxB. However for 
RCA120 the average spacing of the galactose moieties are far too small to bridge the distance 
between RCA120 binding sites (110Å 
35
). While the entire polymer is large enough that sugars 
at either end of the polymer chain have the potential to span the binding sites; it is more likely 
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that we will be operating in a statistical rebinding regime with only one polymeric ligand per 
lectin binding site.  
To generate a ‘competitive’ surface to perform the assay with, lipid coated “high-bind” 384-
well plates were incubated for 16 hours with 1 mg.mL
-1
 of the galactose rich GM-1 
ganglioside, the native ligand for CTxB, Figure 2.9. This allowed the GM-1 ganglioside to 
undergo lipid insertion and become bound to the 384-well surface.  
 
 
 
Figure 2.9: The GM-1 ligand, D-galactose-β(1-3)-N-acetyl-D-galactosamine-β(1-4)-D-
galactose- (α(2-3)-neuraminic acid)-β(1-4)-D-glucose-β(1-1)- ceramide. 
To perform the competitive binding assays, lectin binding assays were first performed to find 
the optimal lectin concentration. Serial dilutions of FITC-labelled RCA120 and FITC-labelled 
CTxB were incubated with the GM-1 coated plates for 30 minutes at 37.5 °C. The middle of 
the dose-dependant binding curves were chosen, which gave concentrations of 0.13 mg.mL
-1 
and 0.05 mg.mL
-1
 for RCA120 and CTxB respectively. The fluorescently labelled lectins were 
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then incubated with each polymer, before being applied to the (GM-1) microtitre (384 well) 
plate using an automated pipetting robot to increase throughput. After incubation and 
washing the total fluorescence was measured, Figure 2.10. 
 
 
 
Figure 2.10: Schematic of inhibitory assay demonstrating the inverse relationship between 
inhibitory activity and fluorescence readout. In (A), glycopolymer binding out competes 
binding of the lectin to the GM-1 surface, leading to the formation of lectin-polymer complex 
that is then removed by washing, resulting in no fluorescence reading. In (B) the GM-1 
surface out competes binding with the glycopolymer, which is then removed by washing, 
leaving only fluorescently labelled lectin bound to the surface. 
 
In this assay, less fluorescence corresponds to more inhibition. As none of the polymer 
concentrations tested result in 100% inhibition and this assay lacks a positive control, the 
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results are reported as the relative IC50. We have defined the relative IC50 as the mid-point 
between the estimates for the upper and lower plateaus, rather than the more often used 
absolute IC50 which defines the point at which 50% inhibition has been achieved.
38
 While the 
relative IC50 value is less preferable to the absolute, it still allowed us to evaluate the trends in 
inhibition and what effect, if any, the heterogeneity had upon the inhibition. The results of the 
assay against RCA120 and CTxB are shown in Figure 2.11.  
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Figure 2.11:  Fluorescence linked inhibitory assay results. (A) Heterogeneous polymers vs 
RCA120 inhibition, n=18 (B) Heterogeneous polymers vs CTxB inhibition n=3 (C) 
Homogeneous polymers vs RCA120, n= 6 (D) Homogenous polymers vs CTxB, n=6. Error 
bars are one standard deviation.  
The heterogeneous polymers demonstrate inhibitory activity towards RCA120, however, 
against CTxB no inhibition was observed, which was surprising as there are several reports of 
galactose rich polymers which inhibit CTxB. Meanwhile the homogenous polymers display 
only weak inhibitory activity against RCA120 and negligible activity towards CTxB.  
  
A B 
C D 
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2.3.2.1 Inhibition of RCA120 Discussion 
To determine the percentage inhibition, the fluorescence value at zero polymer concentration 
(Y0) is taken to be the total possible binding. The percentage inhibition is therefore given by 
Equation 2.1:  
 
𝜃 =
(𝑌0 − 𝑌)
𝑌0
 
2.1 
 
Plotting the maximum inhibition obtained for each polymer shows that the heterogeneous 
polymers achieve much higher inhibition than the homogenous, 20 percentage points more 
than PG100 and by 50 percentage points more than PG25-75, which achieve only a similar level 
of inhibition as the non-glycosylated pHEMA negative control, Figure 2.12.  
 
 
Figure 2.12: Maximum inhibition achieved by heterogeneous (black) and homogenous (red) 
polymer libraries. 
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The binding curves were then plotted individually and fit with a logistic curve fit to 
determine the mid-point and relative IC50 value, Figure 2.13. As the entire binding curve for 
PG100 was not obtained within the concentration range tested, the relative IC50 could only be 
determined to be greater than the maximum concentration tested. 
To enable comparison of any avidity enhancement due to multivalency, the relative IC50 
values were also calculated in galactose concentration, by correcting for the valency of each 
polymer and plotting the curves against the total galactose concentration, see Appendix 1. 
This is assuming the observed binding was due to the galactose units alone. The relative IC50 
values determined for both polymer concentration (mg.mL
-1
) and galactose concentration (M) 
are shown in Table 2.4.  
Table 2.4: Summary of relative IC50 values obtained. 
Polymer IC50 (mg.mL
-1
) Error IC50 Gal (M)
 
Error 
PG100 >0.54 N/A >632.64 x10
-6
 N/A 
PG75M25 59.96x10
-3 2.25x10-3 55.77x10-6 2.09x10-6 
PG75 17.46x10
-3
 4.56x10-3 21.99x10-6 5.75x10-6 
PG50M50 122.25x10
-3
 5.08x10-3 75.81x10-6 3.14x10-6 
PG50 20.25x10
-3
 3.44x10-3 19.06 x10-6 3.24x10-6 
PG25M75  105.26x10
-3 4.32x10-3 34.06 10-6 1.39x10-6 
PG25 21.18x10
-3
 5.76x10-3 12.09x10-6 3.28x10-6 
PHEMA 25.08x10
-3
 6.73x10-3 N/A N/A 
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Figure 2.13: Fitted curves of heterogeneous (A-D) and homogeneous libraries (E-H) binding 
with RCA120.  
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All heterogeneous polymers were potent inhibitors of RCA120 compared to galactose 
monosaccharide alone (no inhibition observable) with IC50 values in the μM range. 
Interestingly, going from 100% to 75% gal, 50% gal, and 25% gal, (15 to 12, 8 and 4 Gal per 
chain) gave an 11, 8, and 18-fold enhancement in activity per galactose respectively. This 
revealed that simply increasing the density of homo-multivalent polymers will not are not 
necessarily lead to the best inhibitors. On a polymer basis the lowest IC50 was PG75M25, 
however, when valency corrected the lowest IC50 was PG25M75, demonstrating an increased 
inhibitory effect per galactose in the presence of mannose.  Comparing this result with the 
homogenous polymers to determine if this decrease in IC50 is due to the mannose or simply a 
density effect gave some surprising results.  
 
Despite the lower maximum inhibitory activity observed (as discussed earlier), when 
compared only by the relative IC50 values, the homogeneous polymers appear to be better 
inhibitors of RCA120, than the heterogeneous polymers. Unexpectedly, when measured in 
polymer concentration, the IC50 stays relatively constant (within error) as galactose density 
changes. However, on a valency corrected basis the IC50 increases as galactose density 
decreases, such that PG25 has the lowest IC50 value. Figure 2.14. This implies that the lower 
sugar density overall and lower galactose density in particular is having a contribution 
towards the decreased IC50 values observed, but the presence of mannose is resulting in an 
increased inhibitory activity of the polymer.  
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Figure 2.14: Relative IC50 values in (A) polymer concentration and (B) galactose 
concentration. 
To determine if there are any differences in the cooperativity of the binding between the 
heterogeneous and homogeneous libraries the Hill binding coefficients were extracted from 
plots of: the percentage of specific binding (binding between polymer and RCA120) against 
the polymer concentration, Appendix Figure S3.  These curves can be fit with the Hill-Waud 
Equation: 
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𝜃 =
𝐼𝑀𝑎𝑥[𝑃]
𝑛
𝑘ℎ
𝑛 + [𝑃]𝑛
 
2.2 
 
Where θ = Specific binding, i.e. the percentage inhibition, [P] = Polymer concentration, kh = 
the ligand concentration that results in half occupation, Imax = maximum inhibition and n = 
Hill cooperativity constant. The results of which are shown in Table 2.5.  
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Table 2.5: Hill Cooperativity Coefficients.  
Polymer n Error 
PG75M25 1.69 0.10 
PG75 1.87 0.83 
PG50M50 2.13 0.31 
PG50 1.88 0.55 
PG25M75 1.98 0.13 
PG25 1.41 0.26 
 
The Hill Cooperativity Coefficient is a measure of the cooperativity of the system, i.e. the 
extent to which initial binding is either synergistic (resulting in a value of n>1), antagonistic 
(n<1) or additive (n=1) towards further binding events. All the polymers show positive 
cooperativity (n>1) toward RCA120. This is in contrast to previous reports that have seen 
negative cooperativity of multivalent binders and lectins.
24,40
 With the exception of PG75M25 
the heterogeneous polymers display greater cooperativity than the homogenous polymers, but 
the difference is much smaller than might be expected from the relative steepness of the 
binding curves.  
Contrasting this increased inhibitory activity for the heterogeneous polymers with the 
apparent lower relative IC50 values of the homogenous polymers shows the importance of the 
roles of the relative rates of association and dissociation occurring within the assay. The 
65 
 
percentage inhibition achieved at any concentration is due to the formation of protein-
polymer complexes in solution. It is therefore a function of the forward and backward rate 
constants for the formation and dissociation of the protein-polymer complex during the initial 
incubation period, and for the formation and dissociation of the protein-competitor (GM-1) 
complex in the second incubation period.   
The results of this assay imply that the interplay between the rates for the competing 
reactions result in the homogenous polymers forming a higher concentration of protein-
polymer complex at lower concentrations, relative to the heterogeneous polymers. However 
the formation of protein-polymer complex plateaus quickly for the homogenous polymers, 
resulting in a lower maximum inhibition. Therefore in the case of RCA120 it appears that the 
inclusion of low-affinity secondary sugars actually enhances inhibitory activity.  
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2.3.2.2. Inhibition of CTxB  
In contrast to RCA120, against CTxB both sets of glycopolymers showed very weak inhibitory 
activity, Figure 2.15. 
 
 
Figure 2.15:  Results of the inhibitory assay against CTxB for (A) Heterogenous polymers 
(B) Homogenous polymers.  
 
We attribute this to the nature of the CTxB binding pocket(s).  CTxB binding of GM-1 
involves the interaction of two binding domains: a deep binding domain interacts with a 
galactose and a shallower secondary domain that interacts with a neuramic acid.  These two 
interactions have intrinsic dissociation constants of Kd= ~50 mM and 210 mM respectively
41
. 
The other carbohydrates of the GM-1 pentasaccharide restrict the conformations possible, to 
the extent that the CTxB-GM-1 complex has one of the highest affinities known for a protein-
carbohydrate interaction
42
; 1.9x10
-10
 M (±0.9 x10
-10
).
43
  Experiments have shown the 
importance of the role of the linker and 3 dimensional arrangement.
20,44
 We therefore 
attribute the lack of CTxB inhibition observed to be a result of the conjugation chemistry 
resulting in a relatively inaccessible galactose (for the deep CTxB binding pocket), as well as 
being out-competed by the GM-1 carbohydrate. This means that lack of inhibition does not 
mean lack of binding. Further binding analysis is included later in this chapter. 
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2.3.3. Biolayer interferometry analysis of glycopolymer binding  
The observations that the incorporation of a low-affinity sugar enhanced the inhibitory 
activity against RCA120 is initially counter intuitive. However, in nature, native glycan 
ligands are often branched carbohydrates enabling presentation of multiple monosaccharides 
which undergo separate (or allosteric) interactions.
24
 To probe in detail the molecular basis 
for these observations, biolayer interferometry (BLI) was employed.
45
 First, the optimal 
loading conditions for each protein were established by testing the loading density of each 
protein at pH4, 5, and 6 HEPES at 25 and 50 µg.mL
-1
. It was determined that 25 µg.mL
-1
 at 
pH 5 gave the best loading density for both polymers. CTxB and RCA120 were then 
immobilised in situ and exposed to the glycopolymers. An example of the binding curves 
obtained for PG100 vs RCA120 is shown in Figure 2.16 with the characteristic association and 
dissociation phases.  
  
68 
 
 
Figure 2.16: BLI response of PG100 showing the characteristic association phase, followed by 
the dissociation phase starting at t ≈4250s. 
 
During the association phase we observe the binding that results from the equilibrium 
between association (kon) and dissociation (koff), while in the dissociation phase we only 
observe the loss of binding resulting from dissociation. This is because the BLI technique 
utilises low concentrations and high levels of mixing to ensure that re-association cannot 
occur during the dissociation phase.  By fitting the association and dissociation curves we can 
obtain values for the observed rate during the association phase (kobs) and a value for koff 
from the dissociation phase. The observed rate kobs is related to kon and koff by Equation 2.3:  
 
 𝑘𝑜𝑏𝑠 = (𝑘𝑜𝑛+𝑘𝑜𝑓𝑓)[𝐿𝑖𝑔𝑎𝑛𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛] 2.3 
 
Therefore by extracting kobs and koff from the binding curves, a value for kon can be calculated 
and therefore, from the ratio between koff/kon, the dissociation constant Kd.  
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Choosing which fitting model to apply can therefore have a huge impact on the outcome. In 
this instance RCA120 and CTxB are multivalent receptors, bivalent and pentavalent 
respectively, interacting with the disperse multivalent glycopolymers. This is a highly 
complex system that is impossible to model with complete accuracy, and so some 
simplifications must be made. The heterogeneous binding model treats the binding curve as 
resulting from the simultaneous competition of two binders, which in this system are 
galactose and mannose, Figure 2.17.  
 
 
 
Figure 2.17: The heterogeneous binding model. 
However, as previously mentioned this system is complicated by the presence of multiple 
protein binding sites and dispersity in the polymer. For RCA120 a more realistic list of the 
interactions taking place is shown in Figure 2.18. 
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Figure 2.18: A more realistic depiction of the interactions taking place between bivalent 
RCA120 and the glycopolymers. Pentameric CTxB will have an associated increase in 
complexity. Furthermore, there will also be polymer-polymer interactions in solution and 
polymer backbone – protein interactions; however, as these should be essentially equal for 
each polymer they can be discounted.  
 
This means that the two Kds calculated by this model will be amalgamations of the galactose 
and mannose binding rates and primary and secondary binding events. An alternative method 
of analysis will be to generalise these interactions as shown in Figure 2.19.  
 
Figure 2.19: Where the ratio of (x1):(x2) varies as the heterogeneity of the polymers change. 
As the BLI method measures the size of the bound layer onto the tip, we can gain a value for 
the Kd of the formation of all the protein-polymer complexes by plotting the end points of the 
dissociation curves vs polymer concentration. 
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2.3.3.1. Biolayer interferometry of RCA120 
The Kds, on rates (kon), and, off rates (koff) are summarised in Table 2.6 and shown in Figure 
2.20 below. All rate constants are expressed in molar concentration of polymer. As the rate 
constants are functions of both galactose and mannose binding, it does not make sense to 
valency correct these rates constants and would bias the data. 
Table 2.6: Summary of rate constants and R
2
 and χ2 values associated with the fitting.  
(a) Values closer to 1 indicate a better fit, values greater than 0.80 are considered acceptable 
(b) Values closer to 0 indicate a better fit, values less than 3 are considered acceptable.  
  
Polymer  Kd1 
(M) 
Kd2 
(M) 
Kon1 
(M
-1
S
-1
) 
Kon2 
(M
-1
S
-1
) 
Koff1 
(S
-1
) 
Koff2 
(S
-1
) 
R
2 (a)
 χ2 (b) 
PG100 1.8x10
-6
 <1.0x10
-12
 980 30 1.8x10
-3
 <1.0 x10
-7
 0.99 0.32 
PG75M25 1.0x10
-4
 3.9x10
-6
 19 2400 1.9x10
-3
 <1.0x10
-7
 0.99 3.70 
PG50M50 1.9x10
-8
 1.9x10
-8
 78 78 1.5x10
-6
 1.5x10
-6
 0.86 9.42 
PG25M75 3.3x10
-5
 <1.0x10
-12
 70 11000 2.3x10
-3
 <1.0x10
-7
 0.99 0.73 
PG75 3.2x10
-7
 <1.0 x10
-12
 8900 220 2.9x10
-3
 <1.0x10
-7
 0.81 2.83 
PG50 2.8x10
-7
 <1.0x10
-12
 15000 230 4.1x10
-3
 <1.0x10
-7
 0.97 0.90 
PG25 4.1x10
-7
 <1.0x10
-12
 9700 85 4.0x10
-3
 <1.0x10
-7
 0.99 1.68 
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 Figure 2.20: Calculated values of (A) Kd, (B) kon, and (C) koff, as determined by the 
heterogeneous fitting model applied to BLI binding curves.  
 
As may be predicted for a bivalent protein and multivalent binder, one Kd is considerably 
smaller than the other in most cases, reflecting the increased affinity resulting from the 
chelate effect. Interestingly for PG50M50, the rate constants are identical for Kd, kon and koff. 
This is likely an artefact of the fitting; the relative concentrations of galactose and mannose 
are the same, therefore both galactose and mannose binding contribute equally to the 
competing rates and are modelled as the same value. However, care must be taken as the 
fitting model was poor, R
2
 = 0.86 and χ2 = 9.42.  
 
  
A B 
C 
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The first thing to note is that the heterogeneous polymers PG25M75 and PG75M25 have a Kd 
value considerably higher than the other polymers tested and that the Kd values do not follow 
the trends for relative IC50 nor the percentage inhibition observed from the inhibition assays. 
It is important to remember that in a multivalent or competitive binding scenario, of which 
both are true here, the Kd does not relate to the concentration that produces 50% inhibition 
and is only the ratio of the forward and backward reaction rate constants. All the 
homogeneous polymers (excluding PG100), have similar Kd’s, correlating with the similar 
relative IC50 and inhibition values, but drastically different on and off rates. 
 
While we cannot assign individual interactions to the rate constants calculated, we can make 
generalisations about the binding events taking place. The difference in the Kd1 values of 
PG75M25 and PG25M75 are due to the kon1 rate only. The two polymers have almost identical 
koff1 rates, but PG25M75 has a kon1 rate 3.6x faster, resulting in a Kd1 value a factor of ten 
smaller. For the homogeneous polymers, the kon1 rate does increase with decreasing galactose 
valency (up to a point, at PG25 the rate decreases again); however, we also see the trend is 
mirrored in the koff rates, see Figure 2.21B and C. This symmetry in the on and off rates is not 
present in the heterogeneous polymers. For PG25M75 and PG75M25, the binding event with the 
fastest on rate has the slowest off rate and vice versa, see Figure 2.22B and C. The highest 
affinity Kd (Kd2) for both PG75M25 and PG25M75 are the same (<1x10
-12
), which we can 
assume to be the secondary binding event. Therefore we would expect the inhibition to be 
determined by the lower affinity Kd. However, looking at the Kd1s alone, it would be 
expected that PG25M75 would be the better inhibitor of the two. PG25M75 does achieve a lower 
IC50, when measured in galactose concentration, however, it is PG75M25 that has a lower 
relative IC50 value when measured by concentration of polymer. Both polymers achieve 
similar inhibition of 77% and 72%. The koff1 for both of these polymers are essentially the 
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same (1.92x10
-3
 and 2.32x10
-3
 respectively) so the difference in the inhibition activity of 
these polymers must be determined by the difference in the kon1 rate constant, which for 
PG25M75 is 3.6x larger than PG75M25. 
Therefore it seems that the addition of mannose to the polymers results in an increased kon 
rate, and therefore an increased relative IC50 per galactose. However this is clearly offset by 
other factors as the galactose density increases, to give similar overall inhibition.  
It is apparent therefore that the galactose density and orientation is playing a role in the 
binding rates of the polymers. For both homogeneous and heterogeneous polymers higher 
density multivalent glycopolymers are not necessarily better inhibitors, and that in 
heterogeneous multivalent systems, calculation of Kd alone may not be an indicator for a 
good inhibitor or not.  
 
 
Figure 2.21: Homogeneous polymers: (A) Kd (B)kon (C)koff.  
 
A B 
C 
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Figure 2.22: Heterogeneous polymers: (A) Kd (B)kon (C)koff.  
An alternative method to extract an overall Kd for the process is to perform an end point 
analysis of the BLI binding curves. As the curves decay quickly and plateau the binding mass 
of the curves can be directly related to the formation of polymer-protein complex on the 
surface of the BLI sensor. By fitting just the dissociation curve for the end point and plotting 
the end points against polymer concentration, a value for the steady state Kd can be obtained, 
an example of which is shown in Figure 2.23. All the other curves are in the Appendix. 
  
A B 
C 
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Figure 2.23: For PG25M75: (A) Fitting of the dissociation phase to extract the end point (B) 
End point vs Concentration fit to extract an overall Kd.  
 
The results of this method are summarised in Table 2.7. However when this method was used 
to analyse the binding of the homogeneous curves, the fitting was very poor, and for 
PG75M25, no fit could be obtained, Figure 2.24.   
A B 
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Figure 2.24: Attempted fits of homogeneous polymers steady state Kd.  
Table 2.7: Steady state Kd against RCA120 in polymer concentration (M). 
 
 
 
 
 
 
 
(a) Obtained from fit with R
2
 = 0.6 (b) Obtained from fit with R
2
=0.8  
Polymer Kd [Polymer] (M) Kd Error Kd [Galactose] (M) Kd err 
PG25M75 1.38x10
-5
 7.27x10-7 5.52x10-5 2.90x10-6 
PG50M50 2.18x10
-5
 6.23x10-8 1.52x10-4 4.36x10-7 
PG75M25 5.95x10
-6
 5.22x10-6 6.54x10-5 5.74x10-5 
PG100 2.19x10
-5
 1.01x10-7 3.29x10-4 1.51x10-6 
PG25
(a) 1.06x10-5 6.10x10-6 4.79x10-5  2.75x10-5 
PG50
(b) 1.93x10-11 1.20x10-7 1.54x10-10 9.63x10-7 
PG75 Could not fit Could not fit Could not fit Could not fit 
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The Kds obtained in this way match the trend observed with the relative IC50 values obtained 
via the competitive binding assay performed in section 2.2. Figure 2.25.  This further points 
to the inclusion of mannose resulting in an effective increased affinity per galactose due to 
the heterocluster effect.  
 
Figure 2.25: Steady State Kd for RCA120. 
2.3.3.2. Biolayer interferometry of CTxB 
BLI analysis of the polymer series PG25M75 – PG100 showed that despite any evidence of 
inhibition from the competitive binding assay, binding to CTxB was occurring, and for all 
heterogenous polymers a BLI response was observed. BLI of the homogeneous library 
against CTxB was not performed. The resulting association and dissociation curves were fit 
to the heterogeneous binding model as described in section 2.2.3. and the results  are 
summarised in Table 2.8.  One of the first things to note is that the heterogeneous binding 
model fits to the CTxB data with a higher confidence, with R
2=0.99 and χ2 <3 in all cases. 
The reason for this increased accuracy in fitting the CTxB binding data (with its five binding 
sites and associated increase in complexity) over the RCA120 binding is unknown.  
79 
 
 
Table 2.8: Summary of BLI derived rate constants against CTxB. 
(a) Values closer to 1 indicate a better fit, values greater than 0.80 are considered acceptable 
(b) Values closer to 0 indicate a better fit, values less than 3 are considered acceptable.  
 
As seen against RCA120, the two binding events probed by the hetereogenous binding model 
will in this case be an accumulation of galactose vs mannose binding and primary vs 
secondary binding events.  However, we can make some general observations. It appears that 
there is a lower avidity event (Kd 1) and a higher avidity one (Kd 2). The low avidity event is 
most likely is mostly due to the primary binding event. As the mannose density increases the 
avidity increases, due to a 39-fold increase in kon 1 while koff 1 only sees a ~6.5 fold increase. 
This increase plateaus at PG50M50 (8 Mannose per chain) and PG25M75 (4 Mannose per 
chain), Figure 2.26.  
 
Polymer Kd1 
(M) 
Kd2 
(M) 
Kon1 
(M
-1
S
-1
) 
Kon2 
(M
-1
S
-1
) 
Koff1 
(S
-1
) 
Koff2 
(S
-1
) 
R
2 (a)
 χ2 (b) 
PG100 
6.67x10
-5
 <1x10
-12
 44.8 183 2.99x10
-3 
<1x10
-7
 
0.99 0.10 
PG75M25 
4.9x10
-5
 3.05x10
-6
 603 59.2 29.5x10
-3
 1.8x10
-4
 
0.99 0.03 
PG50M50 
1.07x10
-5
 2.64x10
-6
 1760 71.9 18.9x10
-3
 1.9x10
-4
 
0.99 0.04 
PG25M75 
1.13x10
-5
 3.52x10
-6
 1760 72.8 19.8x10
-3
 2.56x10
-4
 
0.99 0.02 
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Figure 2.26: For the binding of heterogenous polymers with CTxB  (A) Dissociation 
constants (Kd) (B) Association rate constants (kon) (C) Dissociation rate constants (koff)  
This demonstrates that despite showing no activity in the inhibitory assay, the heterogenous 
polymers do display affinities against CtxB in the tens of μM range, which could not out-
compete the CTxB-GM-1 interaction (Kd = 1.9x10
-10
 M)
43
 in the inhibitory test. We also see 
further evidence that an increased density of mannose results in faster rates of both 
association and dissociation; however the increase in association outcompetes the increase in 
dissociation to provide an overall lower avidity.    
The same end point analysis of the dissociation curves was also performed as before, see 
Appendix, and the results are shown in Table 2.9.  
  
A B 
C 
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Table 2.9: Steady state Kd against CTxB in polymer concentration 
Polymer Kd [Polymer] (M) Kd Error Kd [Galactose] (M) Kd Error 
PG25M75 1.19x10
-5
 2.49x10-6 4.76x10-5 9.97x10-6 
PG50M50 8.75x10
-6
 4.63x10-6 6.12x10-5 3.24x10-5 
PG75M25 3.76x10
-5
 4.75x10-6 4.14x10-4 5.23x10-5 
PG100 2.45x10
-5
 1.83x10-6 3.67x10-4 3.37x10-5 
 
The values obtained from the end point analysis are in good agreement with the values 
obtained via BLI, with the exception of PG75M25, somewhat validating the method, Figure 
2.27.  
 
Figure 2.27: Comparison of Kd’s obtained from either the BLI method or end point analysis 
method.  
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2.4. Conclusions and further work 
In conclusion we have shown that increasing glyco-conjugate density does not necessarily 
correlate with increased affinity, or increased inhibition. The inclusion of the nominally non-
binding mannose, appears to result in a decrease in avidity, but an increase in the inhibition of 
RCA120 compared to the isovalent homogenous polymers. There was not a linear relationship 
between the mannose density and inhibition or avidity observed for RCA120 binding, with the 
highest affinity per galactose being PG25M75, the lowest galactose density polymer tested. 
This was attributed to the increased association rate, while the dissociation rate stayed 
constant. This fits with a mechanism of binding whereby the weaker binding sugar does not 
pay as large an entropic penalty for binding due to its increased degrees of freedom relative to 
a more specific interaction. Once bound the entropic penalty for binding of the polymer as a 
whole has largely been paid and the bind and slide mechanism results in increased re-binding 
and movement of the polymer to find the optimal binding configuration. However it should 
be stressed that sufficient evidence for this mechanism is not presented here and further work 
is required.  However this does highlight the need to consider every aspect of the system 
under investigation.  
Meanwhile for CtxB, no inhibitory activity was detected at all. We attribute this to the 
inability of the glycosylated polymers to outcompete the very strong GM-1 interaction. BLI 
analysis revealed that the polymers do bind to CTxB with tens of μM avidity. The observed 
avidity decreased with increasing mannose density up to a plateau at PG50M50 (8 Gal and 8 
Man per chain).  Again this was due to an increased rate of association with increased 
mannose density, while the rate of disassociation did not increase to the same extent and fits 
with the proposed model for RCA120 and previous observations of the heterocluster effect.  
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The use of asialoganglioside GM1, a GM-1 isomer that does not contain the neuraminic acid 
used by CTxB as a secondary binding site as an alternative competitive binder for inhibitory 
assays may allow access to competitive binding behaviour for CTxB, however, any IC50 or 
inhibitory data for assays of this type are highly dependent upon the system and so would 
have to be considered separately to the already obtained data here for RCA120.  
To extend this work further the use of further parameterized fitting model to better fit the BLI 
kinetic data could allow for the extraction of rate constants that relate directly to the 
interactions resulting from galactose or mannose binding, as well as the primary and 
secondary binding states of RCA120. Furthermore the use of isothermal titration 
microcalorimetry (ITC) would allow for the determination of the thermodynamic parameters 
associated with the binding. However this is ultimately beyond the scope of what was 
achievable within the timeframe of this work.  
  
 
  
84 
 
2.5. Experimental 
2.5.2. Materials 
2-Chloro-1,3-dimethylimidazolinium chloride, and GM-1 Ganglioside was purchased from 
Carbosynth. D-(+)-galactose was purchased from MP Biomedicals. D-(+)-Mannose, 
trimethylamine, sodium azide, pentafluorophenol, methacroyl chloride, 2-cyano-2-propyl 
benzodithioate, 4,4′-azobis(4-cyanovaleric acid), 1,4-dioxane, dichloromethane, DBCO-
amine, DMF, 2-aminoethan-1-ol, Greiner 384-well “high-binding” microtitre plates, PBS, 
HEPES (10 mM HEPES (0.48 g), 0.15 M NaCl (1.75 g), 0.1 mM CaCl2 (2 mg), 0.01 mM 
MnCl2 (0.2 mg) in 200mL DI water), FITC-labelled CtxB, and unlabelled CTxB,  were 
purchased from Sigma-Aldrich. 2,6-lutidine 99% was purchased from Acros Organics. FITC-
labelled RCA120 and RCA120 was purchased from Vector labs. Amine reactive 2
nd
 Generation 
BLI sensors, EDC, NHS, from Bioforte. Ultrapure milli Q water was obtained from a Merk 
Milli-Q water purifier at 18.2 MΩ.cm resistivity at 25 °C.  3500 MWCO ‘snakeskin’ dialysis 
tubing was purchased from Thermofisher (UK). 
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2.5.2. Analytical methods 
1
H, 
13
C NMR, and 
19
F spectra were recorded on Bruker HD-300, HD-400, and AV-500 
spectrometers using deuterated solvents purchased from Sigma-Aldrich. Chemical shifts are 
reported relative to residual non-deuterated solvent. Mass spectrometry was performed on an 
Agilent 6130B single Quad (ESI). FTIR spectra were acquired using a Bruker Vector 22 
FTIR spectrometer with a Golden Gate diamond attenuated total reflection cell. Raman 
spectra were collected on a Reinshaw inVia Reflex Raman using a 442 nm HeCd laser. 
Liquid handling was performed by Gilson Pipette Max. 96-well plates were read using a 
Bioteck Synergy plate reader set at 25 °C. UV-Vis spectra were obtained an Agilent Cary 
spectrometer. Biolayer interferometry was performed using a ForteBio Octet 96 RED 
interferometer, with the indicated probes.  DMF SEC was performed on a varian 390-LC 
MDS system equipped with a PL-AS RT/MT autosampler, a PL-gel 3 μm (50 x 7.5 mm) 
guard column, two PL-gel 5 μm (300 x 7.5 mm) mixed-D columns using DMF with 5 mM 
NH4BF4 at 50 °C as eluent at a flow rate of 1.0 mL.min
-1
. The SEC system was equipped 
with ultraviolet (UV)/visible (set at 280 and 461 nm) and differential refractive index (DRI) 
detectors. Narrow molecular weight PMMA standard (200 – 1.0 x 106 g.mol-1) were used for 
calibration using a second order polynomial fit.  
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Bilayer Interferometry  
Amine reactive 2
nd
 Generation BLI sensors from ForteBio were pre-soaked for 10 minutes in 
MilliQ  water before activation with an EDC/NHS solution. After 10 minutes the sensors 
were moved to a solution containing the lectin at 25 µg.mL
-1
 in pH 5 HEPES. After 10 
minutes the sensors were quenched with ethanolamine, placed in HEPES buffer at the 
corresponding pH to baseline for 10 minutes, and tested against 5 serial dilutions of polymer 
solution for 30 minutes. The sensors were then placed into HEPES buffer for 10 minutes to 
measure dissociation.  The raw data was processed using ForteBio analysis software 
heterogenous ligand model. To measure the pseudo steady state Kd’s the dissociation steps 
only where plotted and fit with an exponential decay in Origin to extract the end point 
deflection. The end points were then plotted vs both polymer and galactose concentration and 
fit with logistic curves to extract a midpoint value.  
Competitive Binding Assays 
384-well high-binding microtitre plates were incubated for 16 hours with  50 μL of  
1 mg.mL
-1
 GM-1 Ganglioside dissolved in phosphate buffered saline solution, per well. 
Unattached GM-1 was removed by washing extensively with PBS buffer.  
Due to the relatively low solubility of the polymers, polymers were dissolved in HEPES 
buffered saline, and any undissolved material removed by centrifugation. Exact 
concentrations were determined by the DBCO absorbance at 292 nm, using a calculated value 
for the extinction co-efficient ε as 2.00628 mL.mg-1 cm-1.  
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Table S1: Glycopolymer Concentrations used for serial dilutions 
Polymer Concentration  
(mg.mL
-1
) 
PG100 0.90 
PG75M25 0.93 
PG50M50 0.96 
PG25M75 0.97 
 
To perform the competitive binding assays, lectin binding assays were first performed to find 
the optimal concentration. Serial dilutions of FITC-labelled RCA and FITC-labelled CTx in 
HEPES buffered saline were made and incubated in a GM-1 coated 384 well plate for 30 
minutes at 37 °C. After this time, the plates where washed extensively with buffer to remove 
unbound lectin and the fluorescence. The middle of the dose-dependent binding curves were 
chosen, which gave concentrations of 0.13 mg.mL
-1 
and 0.05 mg.mL
-1
 for RCA120 and CTx 
respectively. 
Polymer solutions were made up as serial dilutions in HEPES from saturated stock solutions 
to give a volume of 180 μL in each well. 120 μL FITC labelled lectin in HEPES was added to 
180 μL of each polymer solution and incubated for 30 minutes at 37 °C. 45 μL of the polymer 
FITC-labelled lectin solutions were then added to the GM-1 surfaces and incubated at 37 °C 
for 30 mins. Fluorescence was then measured at excitation/emission wavelengths of 485/528 
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nm. All RCA experiments were carried out 18 times, CTx B experiments were carried out in 
triplicate. MIC50 values were calculated using logistic fitting in Origin. 
 
2.5.3. Synthetic Procedures 
Synthesis of Azido-Monosaccharides 
2-Chloro-1,3-dimethylimidazolinium chloride (2.82 g, 16.7 mmol) was added to a solution of 
galactose/mannose (1.00 g, 5.6 mmol), trimethylamine (7.7 mL, 55 mmol) and sodium azide 
(3.61 g, 55.5 mmol) dissolved in ultrapure milli Q water (20 mL), sitting on ice. The solution 
was stirred for 40 minutes on ice before removing the solvent in vacuo.  Ethanol (40 mL) was 
added to precipitate NaN3, filtered, and the solvent removed (repeat to ensure complete 
removal of NaN3). The resulting solid was then dissolved in ultrapure milli Q water (10 mL) 
and washed three times with dichloromethane. The water layer was freeze dried to give a 
yellow solid. The product was then purified on a silica column using 5:1 chloroform: 
methanol (Rf = 0.3) to give an off-white product. Yield: 0.98 g 86% 
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1-Azido-1-deoxy-galactose 
1
H NMR (D2O) 400MHz, ppm: 5.57 (1H, d, J1-2= 4.40Hz, H1, α anomer 23.7%), 4.67 (1H, d, 
J1-2=8.68Hz, H1, β anomer 76.3%), 3.96 (1H, d, J1-2 = 3.30Hz, H5), 3.79-3.78 (1H, m, H4), 
3.77-3.75 (2H, m, H6), 3.70 (1H, dd J1-2 = 3.42, J3-4 = 9.78Hz, H3) 3.53 (1H, t, J1-2 = 9.78, 
H2) 
13
C NMR (D2O) 75MHz, ppm: 90.55 (β C1), 89.44 (α C1) 77.21 (β C4), 75.88, 75.13, 74.23, 
73.06, 72.64 (β C3), 71.20 70.32 (β C2), 69.19, 68.51(β C5), 68.20, 64.20, 63.46, 61.17, 
60.94 (β C6)  
MS (ESI +): Observed: 228.00 Expected: 228.17 [M+Na]
+
 
IR: 2107cm
-1 
(-N3) 
1-Azido-1-deoxy-mannose 
1
H NMR (D2O) 400MHz, ppm: 5.46 (1H, d, J1-2 = 1.71 Hz, alpha 100%) 3.92 (1H, d, J=10.27 
Hz) 3.86 (1H, dd, J1-2 = 1.96, J3-4 = 3.18 Hz, H
2
) 3.78, (2H, m) 3.75-3.72 (2H, m), 3.64 (1H, t, 
J1-2 = 9.54Hz)    
13
C NMR (D2O) 75MHz, ppm: Major Anomer (100%): 90.57 (C1), 78.47 (C5), 70.36 (C2), 
70.37 (C3), 66.60 (C4), 61.10(C6) 
Mass Spec:  Observed: 228.00 Expected: 228.17 [M+Na]
+
 
IR: 2107cm
-1
 (-N3) 
  
90 
 
Synthesis of Pentafluorophenyl Methacrylate  
Pentafluorophenol (5.4 g, 29.3 mmol) and lutidine (3.5 ml, 30.0 mmol) were added to a round 
bottom flask of dichloromethane (50 mL) on ice. Methacroyl chloride (3.0 mL, 31.0 mmol) 
was slowly added. The reaction was stirred for 3 hours on ice, before leaving at room 
temperature overnight. The lutidine HCl precipitate was filtered and the filtrate was washed 
twice with water (30 mL), dried with MgSO4, and the solvent removed in vacuo. The product 
was then passed through a silica column in petroleum ether 40-60 (Rf = 0.3) to give a 
colourless liquid, Yield 4.7 g.  
1
H NMR (CDCl3) 400MHz, ppm: 6.37 (1H, s), 5.83 (1H, s), 2.01 (3H, s) 
19
F NMR (CDCl3) 376MHz, ppm: -152.89 (2F, dd, J1-2 = 16.35 Hz, J3-4 = 6.81 Hz) -158.34 
(1F, td, J1-2 = 21.80, J3-4 = 9.53 Hz) -162.63 (2F, m)  
13
C NMR (CDCl3) 100MHz, ppm: 163.04 (C4, C=O), 142.52, 140.67, 140.14, 139.14, 138.16 
(C5-10, Aromatics), 133.68 (C3, Me-C(=CH2)-CO)), 129.91(C2, =CH2) 18.18 (C1, -Me)  
Mass Spec: Observed: 253.1 Expected 253.1  [M+H]
+
  
IR: 1760 cm
-1
 (ester), 1517 cm
-1
 (unsaturated C=C), 1086 cm
-1
 (C-O), 994 cm
-1
 (C-F) 
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Synthesis of Poly(Pentafluorophenol Methacrylate)  
PFMA (4.7 g, 18.6 mmol), 2-Cyano-2-propyl benzodithioate (55.3 mg, 0.25 mmol) and 4,4′-
Azobis(4-cyanovaleric acid) (35.0 mg, 0.12 mmol) were dissolved in dioxane (9 mL). A 
sample was removed for NMR analysis. The solution was degassed with N2 for 30 minutes. 
The reaction was then heated to 90 °C and left for 90 minutes. The polymerisation was 
quenched in liquid nitrogen and precipitated three times from pentane into THF to give a pink 
solid, 2.3 g 50% yield.  62% Conversion by NMR. SEC (THF): Mw = 15250 Ð = 1.7.  
1
H NMR (CDCl3) 400MHz, ppm: 2.42 (2H, br, CH2) 1.72 (NC-C(CH3)2-) 1.54 (3H, br, CH3)  
19
F NMR (CDCl3) 376MHz, ppm: -150.35 (1F,br s), -151.44 (1F, br s), -156.97 (1F, br s), -
162.11 (1F, br s) 
IR (cm
-1
): 950
 
(C-F) 1050 (C-O) 1600 (C=O)  1700  (C=C) 
Post-polymerisation modification of Poly(Pentafluorophenol Methacrylate)  
For the synthesis of PG25M75, PG50M50, PG75M25, PG100. 
P(PFPMA) (0.260 g, 0.12 mmol) and DBCO-amine (72 mg, 0.26 mmol) were dissolved in 3 
mL DMF and left at 50°C overnight under N2. Reaction completion was confirmed via 
fluorine NMR, ratio of pentafluorophenol peaks to polymeric pentafluorophenol ester peaks 
was 33%. Without further workup, a large excess of 2-aminoethan-1-ol (0.5 mL, 8.3 mmol) 
was added, and left for a further 16 hours at 50 °C.  Reaction completion was again 
confirmed via fluorine NMR observation of only pentafluorophenol peaks. The reaction was 
then diluted into ultrapure milli Q water and dialysed for 3 days. 0.10 g of white polymer was 
isolated. No fluorine was observed in the NMR of the final product. DOSEY was carried out 
to further confirm the conjugation of the DBCO unit to the polymer.  
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1
H NMR (MeOD) 500MHz, ppm: 7.5-7.0 (br, Benzyl) 4.42 (br, cyclooctyne ring CH2) 3.65 
(br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2) 1.5-1.0 (br, 
backbone Me) 
DOSEY NMR (MeOD) 500MHz, log(m
2
s
-1
) = -9.25, ppm: 7.5-7.0, (Benzyl) 4.42 (br, 
cyclooctyne ring CH2) 3.65 (br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, 
Backbone CH2) 1.5-1.0(br, backbone Me) 
13
C NMR (MeOD) 500MHz: 179.42 (br, C=O) 141.16 (Benzyl No H), 136.93 (Benzyl No 
H), 132-128 (benzyl H), 63.02, 61.31 (NH-CH2-CH2-OH), 61.08 (NH-CH2-CH2-OH), 60.09, 
59.61, 56.93, 52.49 (Cyclooctyne Ring CH2), 46.95 (NH-CH2-CH2-C(=O)-DBCO), 46.56 
(NH-CH2-CH2-C(=O)-DBCO), 43.77 (Backbone CH2), 43.14 (Backbone CH2) 30.93 
(backbone CH3)   
Raman (cm
-1
): 1614 (Aromatic C-C) 2159 (Alkyne) 
For the synthesis of PG25, PG50, and PG75 
The same synthetic procedure as above, but with the number of equivalents of DBCO 
adjusted to give target substitutions of 7.5%, 15% and 22.5%.  
1
H NMR (MeOD) 500MHz, ppm: 7.5-7.0 (br, Benzyl) 4.42 (br, cyclooctyne ring CH2) 3.65 
(br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2) 1.5-1.0 (br, 
backbone Me) 
13
C NMR (MeOD) 500MHz: 179.42 (br, C=O) 141.16 (Benzyl No H), 136.93 (Benzyl No 
H), 132-128 (benzyl H), 63.02, 61.31 (NH-CH2-CH2-OH), 61.08 (NH-CH2-CH2-OH), 60.09, 
59.61, 56.93, 52.49 (Cyclooctyne Ring CH2), 46.95 (NH-CH2-CH2-C(=O)-DBCO), 46.56 
(NH-CH2-CH2-C(=O)-DBCO), 43.77 (Backbone CH2), 43.14 (Backbone CH2) 30.93 
(backbone CH3)   
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Raman (cm
-1
): 1614 (Aromatic C-C) 2159 (Alkyne) 
Synthesis of Glycopolymers PG25M75, PG50M50, PG75M25, PG100 
Using stock solutions of 1 mg.mL
-1
 sugar azide (4.87x10
-3
 mL
-1
), 2.75 ml of each of; 
[Gal]:[Man],100:0, 75:25, 50:50 and 25:75 (V:V) solutions were prepared. For each 
glycopolymer, 2.75 mL of the corresponding azido-sugar solution was added to 
p(DBCO)15(HEMA)35 (5 mg, 357 nmol) in a vial. The reaction was left at room temperature 
overnight. To remove excess sugar the solutions were passed through a 1000MWCO 
centrifugal filter and re-suspended in water three times. The resulting solution was then 
freeze dried. IR and Raman of final polymers showed no presence of alkyne or azide peak.  
N.B. To give a 2.5x excess of sugar-azide to polymer-alkyne, the number of moles of 
polymer was multiplied by 15 (for each alkyne unit) and 2.5 (to give an excess of sugar) 
Synthesis of Glycopolymers PG25, PG50, and PG75 
To  50mg of p(DBCO)4.85(HEMA)45.15, p(DBCO)8(HEMA)42 and p(DBCO)10.71(HEMA)39.29  
each, was added 1-azido-1-deoxy galactose, (7.5mg, 12mg and 15mg respectively) and 
2.75mL of DI water added. The reaction was left at room temperature overnight. To remove 
excess sugar the solutions were passed through a 1000MWCO centrifugal filter and re-
suspended in water three times. The resulting solution was then freeze dried. Raman of final 
polymers showed no presence of Alkyne peak.  
1
H NMR (MeOD) (500MHz): 7.5-7.0 (br, Benzyl) 4.59, 4.59 (br, cyclooctyne ring CH2) 3.65 
(br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2) 1.5-1.0 (br, 
backbone Me) 
13
C NMR (MeOD) 500MHz: 179.42 (br, C=O) 141.16 (Benzyl No H), 136.93 (Benzyl No 
H), 132-128 (benzyl H), 63.02, 61.31 (NH-CH2-CH2-OH), 61.08 (NH-CH2-CH2-OH), 60.09, 
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59.61, 56.93, 52.49 (Cyclooctyne Ring CH2), 46.95 (NH-CH2-CH2-C(=O)-DBCO), 46.56 
(NH-CH2-CH2-C(=O)-DBCO), 43.77 (Backbone CH2), 43.14 (Backbone CH2) 30.93 
(backbone CH3)   
DOSEY NMR (MeOD) 500MHz, log(m
2
s
-1
) = -4.8, 7.5-7.0, (Benzyl) 4.42 (br, cyclooctyne 
ring CH2) 3.65 (br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2) 
1.5-1.0(br, backbone Me) 
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Chapter Three 
Semi-Automated Assembly of Heterogeneous 
Glycosylated Gold Nanoparticles for High-
Throughput Screening 
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3.1. Abstract 
Carbohydrate binding proteins, which include lectins, play a vital role in many biological 
processes including pathogen binding at the initial stages of infection. Tools which can detect 
pathogenic lectins may enable the development of point-of-care diagnostics to help prevent 
the spread of diseases, detecting biological warfare agents and also to enable fundamental 
glycobiology studies as mimics of complex cell surfaces. Further to this, a greater 
understanding of lectin interactions may play a role in developing anti-adhesion therapies as 
alternatives to traditional antibiotics. This chapters introduces the development of scalable 
methods for assembling glycosylated nanoparticle libraries containing both homogenous and 
heterogeneous glycan coatings that is simple, compatible with automated liquid handling 
robots and generates a binding signal without additional labels, allowing native (unlabelled) 
lectins to be studied. Figure 3.1.   
 
 
 
Figure 3.1: Overall schematic for the robotic assembly and label-free detection of lectins. A. 
Formation of a azide reactive polymer coated gold nanoparticle precursor  B and C. Homo 
and heterogeneous functionalisation of the nanoparticle with azide-modified sugars in a 
statistical manner. D. Lectin induced aggregation results in a reduced gold nanoparticle 
separation distance and produces a blue colour.  
A B C D 
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3.2. Introduction 
Carbohydrates play a key role in the adhesion of pathogenic species
1–4
, cancer progression
2,5–
7
, inflammation
1,8
 and a host of other processes
1
. It is estimated that up to 50% of proteins in 
the human body are glycosylated
9
 and the mapping of this ‘glycome’ remains a huge 
challenge. The proteins that decipher this glycan-information are termed lectins. Lectins non-
covalently bind to their specified carbohydrate targets dependant on the carbohydrate 
stereochemistry, branching pattern and functional isomerism. Individual protein-
monosaccharide interactions are usually very weak; however, the interaction with multiple 
clustered saccharides is much greater than the sum of the individual affinities. This 
multivalent effect is termed “the cluster glycoside effect”.10,11  This effect is well 
documented, with a wide number of lectins and carbohydrate ligands studied; a prime 
example is the use of rational design to create a sub-nanomolar inhibitor of shiga toxins I and 
II by Kitov et al. Shiga toxins are AB5 toxins consisting of an A domain that gains entry to 
mammalian cells after the adhesion of the homopentameric B subdomain. By synthesising a 
pentameric multivalent carbohydrate ligand (named STARFISH), inhibition of shiga toxins I 
and II was increased by more than 1 million fold over the carbohydrate ligand alone.
12
 
However, most studies using multivalent scaffolds have focused on homogenous structures – 
i.e. using a single glycan. Cell surfaces, however, present a heterogeneous array of glycans 
and lectins themselves are often termed pattern recognition domains.
13
 Therefore, any 
synergistic or antagonistic effects that may arise within such a heterogeneous environment, 
that would help to understand affinity in vivo, may be missed. Work by Hartmann and co-
workers investigated the effects of heterogeneity in glyco oligomers. It was shown that for 
the Mannose binding lectin Con A, a glucose-mannose-glucose trimer had twice the 
inhibitory activity (0.4μM), compared to the mannose only trimer (0.8μM), while the 
galactose-mannose-galactose trimer had comparable activity (1.0μM).14  This is despite Con 
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A having an affinity 4 times greater for mannose than glucose, and no affinity for galactose. 
They found that the galactose residues in this instance do not participate in the binding to Con 
A, but they promote steric shielding giving an increase in affinity. This highlights the 
complexity in understanding multivalent modes of binding the difficulty in rationally 
designing inhibitors.  
Therefore it is important to develop widely applicable, robust, easily synthesised screening 
techniques to probe lectin binding in heterogeneous environments.  
One of the difficulties in synthesising heterogeneous multivalent glyco-libraries is 
maintaining control over the positioning of the two (or more) sugars relative to each other in 
the heterogeneous assembly. There have been two main approaches to this problem: (1) Low 
density glyco-clusters utilizing multiple protecting group and/or orthogonal chemical 
strategies to develop well defined glyco-environments at a cost of greater synthetic 
complexity and the associated drawbacks or (2) High density glyco-clusters utilizing a 
statistical approach to lectin binding. 
To move towards ‘glycomics’ research in the same vain as proteomics, large scale robust 
screening libraries are required. To achieve this several aspects need to be addressed:  
 Straightforward, robust synthesis  
 Facile purification to allow large scale production 
 High throughput output  
 Straight forward analysis 
Gold nanoparticles offer a convenient route to a high through-put colourimetric assay. 
Monodisperse solutions of gold nanoparticles are highly coloured, this is due to the 
electromagnetic field of incident light inducing an oscillation of the free electrons in the 
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conduction band of the metal. This oscillation of electrons at the particles surface induces a 
dipole and the frequency at which this oscillation occurs is known as the surface plasmon 
resonance (SPR peak), which for gold occurs around 520 nm.
13
 The SPR causes a strong 
absorption of incident light, and the intensity and wavelength of the absorption is dependent 
on factors that affect the electron charge density at the surface of the particle. As such, 
changing the particles size changes the absorption of the SPR peak and so the colour of the 
nanoparticle solution. At smaller wavelengths the SPR peak absorbs in the blue-green portion 
of the spectrum and so the particles appear red. As the nanoparticle size increases, the SPR 
absorption is red shifted and so the solution takes on a blue hue. This makes gold 
nanoparticles ideal for a colorimetric assay based on aggregation of the gold nanoparticles 
that can be analysed using UV-Vis spectrometry.
15–21
   
On top of this, colourimetric assays of this type have potential applications in point of care 
diagnosis work.
20,22,23
 The thermal stability of gold nanoparticles allows easy transportation 
to areas of the world where refrigeration is difficult or not an option, and while UV-Vis 
spectrometry is a relatively cheap analysis technique (compared to other options such as SPR 
assays) efforts have been made to allow analysis of colourimetric assays using mobile 
phones.
24–26
 While this is outside the scope of this work, assays based on this technique have 
the ability to expand into practical diagnostic roles from the outset.  
To give gold nanoparticles the stability against salts required for protein buffers and 
biological conditions they must be stabilised with a steric coating.
23
 Polymers offer an easy 
method to provide this coating and provide chemical functionality. In particular polymers 
produced via reversible addition fragmentation chain transfer polymerisation (RAFT) are 
perfect as they contain a thiol end group that is reactive towards gold. RAFT polymerisation 
allows the synthesis of polymers with high control over the molecular weight and dispersity 
to ensure repeatability and control over the particle stability. Figure 3.2.  
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Figure 3.2: Assembly of functionalised gold nanoparticles using raft polymerisation, where 
X, Y and Z are potential chemical functionality that can be incorporated. This figure ignores 
co-polymer effects. 
To assemble our ‘modular’ nanoparticle we have chosen to use the strained cyclooctyne 
DBCO, Figure 3.3. This allows us to utilise the strain promoted alkyne azide cyclisation 
reaction, also known as copper-free click in reference to the well-known copper catalysed 
azide alkyne cycloaddition popularised by Sharpless. 
27
 
 
 
Figure 3.3: DBCO. 
 This reaction is fast and has 100% atom efficiency resulting in very little work up, making it 
ideal for large scale combinatorial chemistry. Further to this it introduces a large hydrophobic 
face close to the binding ligand which may help increase the rigidity of the system and reduce 
the entropic cost of binding. 
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All of these synthetic components together are compatible with large scale liquid handling 
robots and biological assay consumables such as 384-well plates, giving the assays built in 
scale-ability for high throughput processing.   
To test the effectiveness of the AuNP library, 5 lectins were screened against, Table 3.1.   
Table 3.1: Lectin and stated specificity. 
Lectin Stated Binding Ligand 
Dolichos biflorus agglutinin (DBA)  N-Acetyl galctosamine 
Peanut agglutinin (PNA) Galactose 
Soy bean agglutinin (SBA) N-Acetyl galctosamine 
Wheat germ agglutinin (WGA) N-Acetyl glucosamine 
Ricinus communis Agglutinin I (RCA120) Galactose 
 
Despite having similar stated binding specificities, in practise they have quite different 
binding behaviours. PNA is known to bind to lactose
28
. All five lectins are easy to work with 
and obtain.  
To this end, a gold nanoparticle based carbohydrate screening library was developed, which 
utilises the multivalency effect as a means of both interrogating lectin binding and as method 
for circumventing time consuming purification steps. This library is easily adapted to give 
any glyco-environment required; homo- or heterogeneous and is compatible with high 
throughput liquid handling and analytical techniques.  
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3.3. Results and discussion 
3.3.1. Polymerisation 
To generate the heterogeneous library the polymer coating must fulfil several criteria. It must 
be water soluble, sufficiently stabilise the gold particles against protein buffer solution, not 
stabilise the particles so much that the reaction times are prohibitively long and allow further 
functionalisation to generate the heterogeneous library.  In line with previous work by 
Richards et al, hydroxyethyl acrylamide (HEAA) was chosen as an appropriate stabiliser
29
. In 
order to maintain control over the polymer chain length and therefore have control over the 
assay reaction time, 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid 
pentafluorophenyl ester was synthesised using a modified method by Phillips et al, 
30
  
Scheme 3.1.   
19
F NMR confirmed the presence of the PFP group, and 
1
H NMR and Mass 
spec confirmed the structure in line with previous reports.  
 
Scheme 3.1:  Two step synthesis of 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid 
pentafluorophenyl ester. 
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A trithiocarbonate-based RAFT agent was chosen as they give good molecular weight control 
over acrylamide monomers and are convenient to synthesise. This allowed us to polymerise 
acrylamides with high molecular weight control and low dispersity, and to install the 
pentafluorophenol-ester at the alpha end of any generated polymer.  The raft agent was 
synthesised in a two-step procedure and the resulting yellow liquid characterised using 
1
H 
NMR spectroscopy, and used as a RAFT agent for the polymerisation of hydroxyethyl 
acrylamide. 
 
Scheme 3.2: Polymerisation of PFP-HEAA synthetic scheme. 
Hydroxyethyl acrylamide was prepared using RAFT polymerisation with a targeted degree of 
polymerisation of 25, 50, 75 and 100, Scheme 3.2.  PFP-DMP was used as the RAFT agent 
(CTA) as previously discussed, and 4,4′-azobis(4-cyanovaleric acid) (ACVA) was chosen as 
the radical initiator.  The polymer was isolated by precipitation.  The isolated yellow solids 
were characterised by 
1
H NMR, and size exclusion chromatography (SEC), Figure 3.4.  
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Figure 3.4: SEC trace of pHEAA-PFP at different degrees of polymerisation. 
The degree of polymerisation was calculated using 
1
H NMR spectroscopy by determining the 
relative monomer concentration before the reaction is initiated and after the reaction has been 
quenched, relative to an internal mesitylene standard.  
 
Table 3.2: Characterisation of p(hydroxyethyl acrylamide) pentafluorophenol ester. 
Polymer
(a)
 [HEAA]:[CTA] Conversion(%)
(b)
 Mn Theo Mn SEC Mw/Mn
(c)
 
pHEAA25-PFP 25:1 97 3300 6300 1.15 
pHEAA50-PFP 50:1 96 6100 12900 1.17 
pHEAA75-PFP 75:1 85 7900 19100 1.19 
pHEAA100-PFP 100:1 90 10900 22500 1.20 
a
PHEAA-PFP = p(hydroxyethyl acrylamide) pentafluorophenol ester;  
b
Determined by 
1
H 
NMR spectroscopy relative to an internal standard (mesitylene); 
c
 Determined by SEC 
(DMF) relative to PMMA standards. 
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After the polymerisation, the α-end group of PHEAA25-PFP was modified via nucleophilic 
addition of dibenzocyclooctyne-amine (DBCO-amine) to the pentafluorophenol ester, as 
shown in Scheme 3.3 PHEAA25-PFP was chosen for this step as this has previously been 
identified as an ideal chain length for stabilising 30-60nm gold nanoparticles while ensuring 
the agglutination assay still occurred rapidly.
29
   
 
Scheme 3.3:Nucleophilic addition of DBCO-amine to the amine reactive PFP-endgroup. 
The reaction was monitored using 
19
F NMR spectroscopy, and the presence of the DBCO 
alkyne was confirmed using Raman spectroscopy, showing the aromatic C-C and alkyne peak 
at 1600cm
-1
 and 2159 cm
-1 
respectively, Figure 3.5. 
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Figure 3.5: Solid phase Raman spectra of PHEAA25-DBCO.  
3.3.2. Synthesis of gold nanoparticles via one-pot citrate reduction 
The AuNPs were synthesised using the citrate reduction method,
31
 varying the ratio of 
HAuCl4 to citrate to allow control of the size.  Originally 60 nm gold particles were targeted, 
as this had previously been shown to give an effective response within a reasonable 
timeframe.
23
 However these particles where found to be unstable during a period of 24-48 
hours post coating with HEAA25-DBCO, which would make them non applicable for 
screening applications, where a stock of stable particles is essential. This can be explained if 
we assume that 60 nm gold and pHEAA with a degree of polymerisation of 25 is on the 
boundary of stability for the nanoparticles not providing a sufficient steric shield. Therefore, 
variations in the dispersity of either the gold nanoparticles or the polymer stabiliser will have 
an impact upon the stability of the system.  It was decided to use a smaller size of gold 
nanoparticle.  
A molar ratio of 1:3.5 gold:citrate gave nanoparticles with diameter 32 nm, as measured by 
the Haiss method
32
 with UV-Vis and by dynamic light scattering, Table 3.3. The resulting 
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particles were also characterised by transmission electron spectroscopy (TEM), the resulting 
images where processed in imageJ
33
 to obtain a histogram of nanoparticle size, Figure 3.6.   
The gold particles were then coated with the DBCO-pHEAA at a concentration of 1 mg/ml 
overnight, and excess polymer was removed by repeated centrifugation-resuspension cycles. 
UV-Vis and DLS characterisation are shown below, Figure 3.7 and summarised in Table 3.3.  
 
Figure 3.6: (A) Histogram of AuNP size,  n= 567, d=19.2±7.6 (B) Example TEM showing 
nanoparticle morphology. 
 
  
A B 
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Figure 3.7: (A) DLS trace of Citrate and PHEAA25-DBCO-stabilised polymers N.B. small 
intensity peak at very low size. (B) UV-Vis of Citrate and PHEAA25-DBCO-HEAA 
stabilised particles.  
Table 3.3 Summary of UV-Vis and DLS characterisation. 
Coating Size 
(a)
 (nm)  Size 
(b)
 (nm)  Size (nm) 
(c) 
Citrate 32 32 ±0.2 19.2 ±7.6 
DBCO-HEAA25 54 47 ±1.7 N/A 
(a) UV-Vis (b) Dynamic light scattering (c) TEM 
The DLS trace showed a small intensity peak ~3-5nm in size. This peak could be due to gold 
seed particles that did not grow during the synthesis. However, it is more likely that these are 
artefacts arising from glancing-angle light scattering causing a false peak.  
  
A B 
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3.3.3. Synthesis of azido-sugars and assembling a heterogeneous 
library  
 
Scheme 3.4: General synthesis for forming 1-azido-1-deoxy hexoses.  
In order to construct a heterogeneous library, 1-azido-1-deoxy galactose and 1-azido-1-deoxy 
mannose were synthesised, as shown in Scheme 3.4, using the synthetic scheme reported by 
Vinson  et al. 
34
 2-Chloro-1,3-dimethylimidazolinium chloride (DMC) which specifically 
activates the anomeric centre rather than the other hydroxyls, due to its lower pKa, enables 
nucleophilic attack by sodium azide without the use of protecting groups. IR and MS 
confirmed installation of the azide.  
Galactose was chosen as this is the stated primary binding partner for the lectins (PNA and 
RCA, while DBA and SBA bind N-Acetyl galactosamine, WGA binds N-Acetyl 
glucosamine) we intended to screen against, while mannose is a nominally non-binding 
sugar. However as shown in chapter two, there is evidence to suggest that mannose can act to 
improve the binding of nominally galactose binding lectins such as RCA120 by  acting as a 
weak but rapid binder to drive lectin association .  
In addition to this, 2-azido-2-deoxy glucose, 2-azido-2-deoxy galactose,  6-azido-6-deoxy 
glucose, and, 6-azido-6-deoxy galactose where also purchased from a commercial source 
(Carbosynth Ltd), while 1-(8-azidooctyl)-1-deoxy mannose (mannose-C8-azide), Scheme 
3.5, was obtained from Martina Lahmann at Bangor University, Wales to provide a glycan 
with a longer linker.  As the monosaccharides all have azido groups on them, they will 
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undergo spontaneous cycloaddition with the strained cyclooctyne at the polymer terminus, on 
the gold nanoparticle surface.  
 
 
Scheme 3.5 : The structure of 1-(8-azidooctyl)-1-deoxy mannose (mannose-C8-azide) 
To assemble the heterogeneous nanoparticle library, Scheme 3.6, solutions containing the 
molar percentage ratios of the intended final sugar concentration of each sugar combination 
to be tested were prepared in milliQ water and added to the alkyne-functional gold 
nanoparticles.  
 
Scheme 3.6: The strain promoted azide alkyne coupling reaction  
For example, to obtain a particle with an 80:20 ratio of 2-azido-2-deoxy galactose to 6-azido-
6-deoxy glucose, a solution containing an 8:2 molar ratio of 2-azido-2-deoxy galactose to 6-
azido-6-deoxy glucose was made. The total number of moles of both sugars was 2.5x the 
number of moles of polymer added to coat the particles. The particles were left overnight and 
purified by centrifugation at 3,000g for 30 minutes, three times. During these purification 
cycles it was noted that a large proportion of the gold nanoparticles formed aggregated 
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clusters that would not re-suspend without sonication, a step we were keen avoid due to 
potential damage to the polymer coating and a loss of material. The new concentration of 
gold was determined via UV-Vis to be 6.7x10
-11
 M, using the Beer Lambert law (Equation 
3.1) a value of ε450 of 3.21x10
9
 M
-1
cm
-132
 and a path length of 0.274 cm
-1
. 
 𝐴 = 𝜀𝑙𝑐 3.1 
  
The first library to be tested used 2-azido-2-deoxy glucose, 2-azido-2-deoxy galactose,  6-
azido-6-deoxy glucose, and, 6-azido-6-deoxy galactose in molar percentage ratios of 100:0, 
80:20, 60:40, 40:60, 20:80 and 0:100. For these initial investigations we chose to limit the 
library to bi-functional nanoparticles (2 different sugars per particle). With these conditions, 
36 unique sugar coated gold nanoparticles could be made, as shown in Table 3.4 
  
116 
 
Table 3.4: Heterogenous AuNP library formed with 2-azido-2-deoxy glucose, 2-azido-2-
deoxy galactose, 6-azido-6-deoxy glucose, and, 6-azido-6-deoxy galactose. 
Sample 
Ratio 
(mol %) 
Sugar 1 Sugar 2 
A1 100:0 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
A2 80:20 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
A3 60:40 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
A4 40:60 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
A5 20:80 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
A6 0:100 2-Azido-2-deoxy Glucose 2-Azido-2-deoxy Galactose 
B1 100:0 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
B2 80:20 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
B3 60:40 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
B4 40:60 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
B5 20:80 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
B6 0:100 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Glucose 
C1 100:0 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
C2 80:20 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
C3 60:40 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
C4 40:60 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
C5 20:80 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
C6 0:100 2-Azido-2-deoxy Glucose 6-Azido-6-deoxy Galactose 
D1 100:0 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
D2 80:20 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
D3 60:40 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
D4 40:60 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
D5 20:80 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
D6 0:100 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Glucose 
E1 100:0 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
E2 80:20 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
E3 60:40 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
E4 40:60 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
E5 20:80 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
E6 0:100 2-Azido-2-deoxy Galactose 6-Azido-6-deoxy Galactose 
F1 100:0 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
F2 80:20 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
F3 60:40 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
F4 40:60 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
F5 20:80 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
F6 0:100 6-Azido-6-deoxy Glucose 6-Azido-6-deoxy Galactose 
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3.3.4. Assay of 35nm gold nanoparticle library  
With our heterogeneous library in hand we proceeded to investigate lectin binding against 
each gold nanoparticle sample. The reported lectin specificities are shown in Table 3.5. 
Table 3.5: Lectin binding specificities. 
Lectin Stated binding ligand 
DBA N-Acetyl galctosamine 
PNA Galactose 
SBA N-Acetyl galctosamine 
WGA N-Acetyl glucosamine 
RCA120 Galactose 
 
The five lectins, DBA, PNA, RCA, SBA and WGA were reconstituted in HEPES buffered 
saline at 0.1 mg.mL
-1
(containing 0.1 mM Ca
2+
 and 0.01 mM Mn
2+
), with 12 serial dilutions 
from 0.1 mg.mL
-1
 to 97 ng.mL
-1
 plus a control at 0 mg.mL
-1
. It is crucial to note that PBS was 
not used, as unwanted calcium phosphate precipitation can complicate lectin binding results 
due to the removal of Ca
2+ 
necessary for lectin binding. 
This gives 2160 individual experiments from our single starting nanoparticle coating. In 
triplicate this is 6480 individual lectin-binding events, demonstrating the potential for 
evolution of complex data sets using scalable methods. In this first iteration this step was 
performed by hand.  
10uL of the AuNP to be tested was added to a well containing 10ul of Lectin solution, 
incubated at 37.5°C for 30 minutes, then placed into a UV-Vis plate reader and scanned from 
450nm to 700nm. An example 384 well plate is shown below in Figure 3.8.  
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Figure 3.8: (A) Example of 384 well plate. Red indicates no binding has occurred while blue 
shows lectin binding induced aggregation of the gold nanoparticles. Note: This image is for 
illustrative purposes only, due to loss of gold during the purification steps, the actual 
absorbance intensity was much lower, and as such the colour of the solutions very faint. This 
is discussed in more detail in the main text.  (B) Example binding curve showing the change 
in the absorption spectrum for galactosylated AuNP induced aggregation by SBA. The 
decrease in absorbance at the SPR peak at λ=530 nm and increase in absorbance at 700nm are 
clearly seen.  
A 
B 
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With no lectin present or in the presence of a non-binding lectin the solution stays red and 
there is a strong SPR peak at around 530 nm. If binding occurs then the solution turns blue 
and there is a reduction in the SPR peak and an increase in absorption at 700 nm.  The 
absorbance at 530 nm vs lectin concentration for each lectin is shown in Figures 3.10 to 3.40  
It is clear from the changes in absorbance that each particle set and lectin combination does 
display different trends in lectin-induced aggregation as glycan composition varies, 
particularly at the highest concentrations of lectin binding. However, it is apparent that the 
assay has a low resolution.  As discussed in section 3.3.3. purification of the gold led to a 
reduction in the gold concentration, due to aggregation. This has a proportional effect in 
reducing the absorption of the gold solution and potentially reducing the resolution of the 
assay. Plotting the raw absorbance data confirms this, as the absorption curves become rough 
and stepped, suggesting the absorption value at each wavelength is changing by amounts 
lower than the resolution of the instrument, Figure 3.9.  
Therefore, in order to improve this, the limit of detection for the assay was determined, as 
discussed in section 3.3.5.  
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Figure 3.9 Raw UV-Vis spectra for each lectin concentration of the binding between Sample 
F6 (6-AzGal-pHEAA25AuNP35) and DBA.  
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Figure 3.10: DBA binding to Nanoparticle group A containing sugars 2-Azido-2-deoxy 
Glucose and 2-Azido-2-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose: 2-Azido-2-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 2-Azido-2-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose.  
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Figure 3.11: DBA binding to nanoparticle group B; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Glucose. (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (C) 60:40 2-
Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy Glucose : 6-
Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (F) 
0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose   
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Figure 3.12: DBA binding to nanoparticle group C; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.13: DBA binding to nanoparticle group D; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Glucose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (C) 60:40 
2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose 
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Figure 3.14: DBA binding to nanoparticle group E; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-
6-deoxy Galactose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (C) 
60:40 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Galactose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose 
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Figure 3.15: DBA binding to nanoparticle group F; containing sugars 6-Azido-6-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 6-Azido-6-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 6-Azido-6-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.16: PNA  binding to nanoparticle group A containing sugars 2-Azido-2-deoxy 
Glucose and 2-Azido-2-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose: 2-Azido-2-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 2-Azido-2-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose. 
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Figure 3.17: PNA  binding to nanoparticle group B; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Glucose. (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (C) 60:40 2-
Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy Glucose : 6-
Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (F) 
0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose 
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Figure 3.18: PNA binding to nanoparticle group C; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.19: PNA binding to nanoparticle group D; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Glucose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (C) 60:40 
2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose 
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Figure 3.20: PNA binding to nanoparticle group E; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-
6-deoxy Galactose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (C) 
60:40 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Galactose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose 
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Figure 3.21: PNA binding to nanoparticle group F; containing sugars 6-Azido-6-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 6-Azido-6-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 6-Azido-6-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.22: RCA binding to nanoparticle group A containing sugars 2-Azido-2-deoxy 
Glucose and 2-Azido-2-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose: 2-Azido-2-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 2-Azido-2-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose.  
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Figure 3.23: RCA  binding to nanoparticle group B; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Glucose. (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (C) 60:40 2-
Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy Glucose : 6-
Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (F) 
0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose 
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Figure 3.24: RCA binding to nanoparticle group C; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.25: RCA binding to nanoparticle group D; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Glucose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (C) 60:40 
2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose 
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Figure 3.26: RCA binding to nanoparticle group E; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-
6-deoxy Galactose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (C) 
60:40 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Galactose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose 
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Figure 3.27: RCA binding to nanoparticle group F; containing sugars 6-Azido-6-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 6-Azido-6-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 6-Azido-6-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.28: SBA  binding to nanoparticle group A containing sugars 2-Azido-2-deoxy 
Glucose and 2-Azido-2-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose: 2-Azido-2-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 2-Azido-2-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose.  
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Figure 3.29: SBA  binding to nanoparticle group B; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Glucose. (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (C) 60:40 2-
Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy Glucose : 6-
Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (F) 
0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose 
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Figure 3.30: SBA binding to nanoparticle group C; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.31: SBA binding to nanoparticle group  D; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Glucose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (C) 60:40 
2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose 
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Figure 3.32: SBA binding to nanoparticle group E; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-
6-deoxy Galactose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (C) 
60:40 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Galactose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose 
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Figure 3.33: SBA binding to nanoparticle group F; containing sugars 6-Azido-6-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 6-Azido-6-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 6-Azido-6-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.34: WGA  binding to nanoparticle group A containing sugars 2-Azido-2-deoxy 
Glucose and 2-Azido-2-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose: 2-Azido-2-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 2-Azido-2-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 2-Azido-2-deoxy Galactose. 
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 Figure 3.35: WGA binding to nanoparticle group B; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Glucose. (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (C) 60:40 2-
Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy Glucose : 6-
Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose (F) 
0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Glucose  
147 
 
 
Figure 3.36: WGA binding to nanoparticle group C; containing sugars 2-Azido-2-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 2-Azido-2-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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Figure 3.37: WGA binding to nanoparticle group D; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Glucose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (C) 60:40 
2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Glucose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Glucose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Glucose 
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Figure 3.38: WGA binding to nanoparticle group E; containing sugars 2-Azido-2-deoxy 
Galactose and 6-Azido-6-deoxy Galactose (A) 100:0 2-Azido-2-deoxy Galactose : 6-Azido-
6-deoxy Galactose (B) 80:20 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (C) 
60:40 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose (D) 40:60 2-Azido-2-deoxy 
Galactose : 6-Azido-6-deoxy Galactose (E) 20:80 2-Azido-2-deoxy Galactose : 6-Azido-6-
deoxy Galactose (F) 0:100 2-Azido-2-deoxy Galactose : 6-Azido-6-deoxy Galactose 
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Figure 3.39: WGA binding to nanoparticle group F; containing sugars 6-Azido-6-deoxy 
Glucose and 6-Azido-6-deoxy Galactose (A) 100:0 6-Azido-6-deoxy Glucose : 6-Azido-6-
deoxy Galactose (B) 80:20 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (C) 60:40 
6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose (D) 40:60 6-Azido-6-deoxy Glucose 
: 6-Azido-6-deoxy Galactose (E) 20:80 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy 
Galactose (F) 0:100 6-Azido-6-deoxy Glucose : 6-Azido-6-deoxy Galactose 
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3.3.5. Determining the limit of detection 
To determine if the high variability in the binding we observed was due to the low 
concentration of gold tested, a study was undertaken to determine the limit of detection of 
gold for this assay, a point that had not yet been addressed in the literature. To do so we 
chose to use a homo-sugar coated gold nanoparticle in a system that has been shown to work 
previously. In work previously conducted within our group, galactosylated particles have 
shown ideal binding behaviour with the lectin soybean agguntinin (SBA). GalNH2-
pHEA25@AuNP40 were incubated at 37 °C in the presence of a fixed SBA concentration, and 
the UV-Vis spectra recorded at 4 time points from 0 to 150 minutes. The resulting absorbance 
at 700nm was recorded and plotted, shown in Figure 3.40. At all concentrations the general 
shape of the gold absorbance was still visible in the UV-Vis spectra, including an identifiable 
SPR peak. However, below a concentration of -10.5 log(Mol.L
-1
), equal to 31x10
-12
 Mol.L
-1
, 
the assay sharply loses resolution.  
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Figure 3.40: Incubation of GalNH2-pHEAA25@AuNP40  particles with SBA at at 6.25x10
-3
 
mg.mL
-1
 in HEPES buffered saline, against varying gold concentrations to investigate the 
limit of detection. Error bars correspond to one standard deviation.  
This is likely due simply to the decrease in the absorbance signal with concentration as 
described by the Beer-Lambert law, (Equation 3.1) therefore resulting in a lower signal to 
noise ratio, loss of resolution to the assay, and large error in the results.  Compared to our 
earlier assay which was performed at a concentration of 6.7x10
-11
 Mol.L
-1
 or -10.2 log(Mol.L
-
1
), the assay was performed on the limit of the resolution.  
To counteract this issue and prevent the loss of gold concentration during the purification 
process it we proposed that it would be possible to utilise the multivalent binding effect to our 
advantage. Due to the high efficiency of the strain promoted azide alkyne coupling between 
the azido-sugars and DBCO end group the concentration of sugar used to functionalise our 
particles was already low, 32μM in Milli Q water. By forgoing any purification the vast 
difference in Kd between the multivalent lectin binding to our nanoparticle surface (Kd 
~nM)
35
 and a simple monosaccharide (Kd ~mM)
36
 would render the purification step 
unnecessary. This would have the advantage of also improving the applicability of this 
method to large scale screening techniques, Figure 3.41.   
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Figure 3.41: Multivalency effects should allow us to outcompete monosaccharide binding 
and eliminate the need for purification methods.  
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3.3.6. Synthesis of gold nanoparticles via step growth 
In order to investigate the possibility of removing the purification steps a new nanoparticle 
library was synthesised. It was decided to move to a step growth synthesis for the gold 
nanoparticles as described by Bastús et al.
37
 to gain better control and reproducibility.  
Particles of size 40nm were targeted and the nanoparticle growth was monitored by UV-Vis 
spectroscopy, Figure 3.42 and Table 3.6: 
 
Figure 3.42: UV-Vis spectra of the step growth of gold nanoparticles. 
Table 3.6: Determination of the size of gold nanoparticles by UV-Vis.  
Step λspr (nm) Aspr/A450
 
Diameter (nm)
(a) 
1 521.5 1.57 12
(b) 
2 525.5 - 32 
3 527.9 - 40 
(a) As determined by comparison to Haiss et al.
32
 (b) For λspr <525.0, Aspr/A450 is used to 
determine nanoparticle size.  
The resulting particles were also characterised by transmission electron spectroscopy (TEM), 
the resulting images where processed in imageJ to obtain a histogram of nanoparticle size, 
Figure 3.43  
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Figure 3.43: (A) Histogram of nanoparticle sizes obtained from TEM n=160 (B) TEM image 
showing gold nanoparticle morphology.  
The nanoparticles where then coated with p(HEAA)25-DBCO, and used to generate a 
glycosylated nanoparticle library, as described in detail in the next section of this work. The 
polymer coating of the gold nanoparticles and subsequent addition of azido-hexoses was 
monitored using, UV-Vis, dynamic light scattering and zeta potential measurements, Table 
3.7. The zeta potential of the AuNPs was negative, in line with other reports of surface 
modified gold.
38
 The addition of both the polymer coating and then subsequent 
functionalisation with 1-azido-1-deoxy-galactose results in a change to the electrical double 
layer around the particle and results in an increase in the zeta potential (less negative).   
  
A B 
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Table 3.7: Dynamic light scattering and zeta potential. 
Gold Coating Size
 (a)
 (nm) Size 
(b) 
(nm) Size 
(c) 
(nm) Zeta Potential
(d)
 
(mV) 
Citrate 40 55 ±3.3 34.9 ±6.7 -38.1 ±1.0  
DBCO-HEAA 62 76 ±0.9 N/A -21.1 ±0.1 
Gal-HEAA 62 76 ±3.5 N/A -19.7 ±0.6 
(a) UV-Vis (b) Dynamic Light Scattering, Ð=0.4 (c) TEM (n=160) (d) Measured in milliQ 
water at pH=7.4 
 
3.3.7. Synthesis of 1-azido-1-deoxy- sugar coated 40nm gold 
nanoparticle library 
To follow on from work conducted in chapter one it was decided to investigate a 
heterofunctional galactose-mannose system. As such 1-azido-1-deoxy galactose and 1-azido-
1-deoxy mannose were mixed in 10% molar increments as shown in Table 3.8.  
Table 3.8: Heterofunctional library created using 1-azido-1-deoxy galactose, 1-azido-1-
deoxy mannose and 1-(8-azidooctyl)-1-deoxy mannose.  
Sample Ratio Sugar 1 Sugar 2 
G100AuNP40 100:0 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G90M10AuNP40 90:10 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G80M20AuNP40 80:20 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G70M30AuNP40 70:30 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G60M40AuNP40 60:40 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G50M50AuNP40 50:50 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G40M60AuNP40 40:60 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G30M70AuNP40 30:70 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G20M80AuNP40 20:80 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
G10M90AuNP40 10:90 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
M100AuNP40 0:100 1-azido-1-deoxy galactose 1-azido-1-deoxy mannose 
C8M100AuNP40 N/A 
1-(8-azidooctyl)-1-deoxy 
mannose 
N/A 
 
157 
 
In addition to this 1-(8-azidooctyl)-1-deoxy mannose was obtained from Martina Lahmann at 
the University of Bangor and used to generate a homofunctionalized nanoparticle to 
investigate the effect of the linker between the sugar and polymer coated particle, also shown 
in Table 3.8. It is well understood that secondary binding effects can play a role in lectin 
binding, and we hypothesised that the inclusion of the DBCO fused Pi-system close to the 
binding site may act as a large rigid hydrophobic domain that can play a role in lectin 
binding; alternatively, this large inflexible domain may inhibit binding by reducing the sugars 
ability to fit correctly into the lectin binding domain. Therefore, by introducing a flexible 
octyl linker and an extra 20Å distance (calculated assuming a carbon-carbon bond length of 
1.54Å and sp3 hybridised bond angle of 109.5°) between the DBCO moiety and the binding 
site the increased flexibility and space may have allowed the sugars to more correctly 
orientate themselves into the binding site of the lectin. Conversely however, by introducing 
more degrees of rotational freedom to the system, we may be dis-advantaging binding by 
increasing the entropic penalty that must be paid upon binding.
39
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3.3.8. Determining the effect of purification: can the multivalency 
effect out-compete monosaccharide binding?  
With our second heterogeneous gold nanoparticle library in hand, we first attempted to 
determine if the additional purification steps can be removed from the synthesis and what 
effect that would have upon the binding results. Using homofunctionalized galactosyl 
nanoparticles the assay was carried out as before using particles that had been prepared by 
centrifuging at 3,000g and washing with deionised water three times, and particles that had 
not been further purified after the addition of the 1-azido-1-deoxy galactose for the strain 
promoted azide alkyne coupling. As can be seen from the resulting plots of absorbance vs 
lectin concentration in Figure 3.44, there is very little difference in the binding profiles of the 
two sets of nanoparticles.  
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Figure 3.44: Effect of washed versus non-washed nanoparticles. Samples containing no 
lectin are represented at log -9. (A) DBA (B) PNA (C) SBA (D) WGA (E) RCA (F) Example 
UV-Vis trace showing the change in absorbance at 530nm, it is this value that is plotted for 
each concentration in (A) to (F).   
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To determine the significance of any differences between the preparation methods, a 
statistical T-test was carried out to determine if the mean absorbance value of each lectin 
concentration was equivalent between the washed and unwashed particles. The results of 
which can be seen for each lectin in Tables 3.9 to 3.13 below. 
Table 3.9: T test to determine if washed and unwashed give statistically difference results in 
the binding of DBA. 
DBA 
Concentration 
log(mg.mL
-1
)
 
T stat P T<Tcrit ? P > 
Alpha? 
Accept or Reject 
null Hypothesis?
(a)
 
-1 4.98 
7.56x10
-
3
 
NO NO 
Reject 
-1.3 1.17 0.30 YES YES Accept 
-1.6 0.49 0.64 YES YES Accept 
-1.9 1.29 0.26 YES YES Accept 
-2.2 1.83 0.13 YES YES Accept 
-2.5 0.67 0.53 YES YES Accept 
-2.8 1.47 0.21 YES YES Accept 
-3.1 0.95 0.39 YES YES Accept 
-3.4 1.18 0.30 YES YES Accept 
-3.7 0.58 0.58 YES YES Accept 
-4.0 0.82 0.45 YES YES Accept 
(a)Null hypothesis: Hypothesised mean difference = 0. TCrit =2.78, Alpha =0.05, Degrees of 
freedom = 4 
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Table 3.10: T test to determine if washed and unwashed give statistically difference results in 
the binding of PNA. 
PNA 
Concentration 
log(mg.mL
-1
)
 
T stat P T<Tcrit ? P > 
Alpha? 
Accept or Reject 
null Hypothesis?
(a)
 
-1 2.23 0.09 YES YES Accept 
-1.3 1.94 0.12 YES YES Accept 
-1.6 1.78 0.14 YES YES Accept 
-1.9 0.53 0.62 YES YES Accept 
-2.2 0.99 0.37 YES YES Accept 
-2.5 1.98 0.11 YES YES Accept 
-2.8 2.45 0.06 YES YES Accept 
-3.1 2.03 0.11 YES YES Accept 
-3.4 3.85 0.01 NO NO Reject 
-3.7 2.30 0.08 YES YES Accept 
-4.0 1.58 0.18 YES YES Accept 
(a)Null hypothesis: Hypothesised mean difference = 0, TCrit =2.78, Alpha =0.05, Degrees of 
freedom = 4 
Table 3.11: T test to determine if washed and unwashed give statistically difference results in 
the binding of SBA. 
SBA 
Concentration 
log(mg.mL
-1
)
 
T stat P T<Tcrit ? P > 
Alpha? 
Accept or Reject 
null Hypothesis?
(a)
 
-1 1.10 0.33 YES YES Accept 
-1.3 0.96 0.39 YES YES Accept 
-1.6 0.46 0.66 YES YES Accept 
-1.9 0.35 0.74 YES YES Accept 
-2.2 0.47 0.65 YES YES Accept 
-2.5 0.66 0.54 YES YES Accept 
-2.8 0.69 0.52 YES YES Accept 
-3.1 -0.06 0.95 YES YES Accept 
-3.4 0.85 0.43 YES YES Accept 
-3.7 1.27 0.26 YES YES Accept 
-4.0 0.72 0.50 YES YES Accept 
(a) Null hypothesis: Hypothesised mean difference = 0, TCrit =2.78, Alpha =0.05, Degrees of 
freedom = 4 
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Table 3.12: T test to determine if washed and unwashed give statistically difference results in 
the binding of WGA. 
 
 
 
 
 
 
 
 
 
 
(a)Null hypothesis: Hypothesised mean difference = 0, TCrit =2.78, Alpha =0.05, Degrees of 
freedom = 4 
Table 3.13: T test to determine if washed and unwashed give statistically difference results in 
the binding of RCA. 
RCA 
Concentration 
log(mg.mL
-1
)
 
T stat P T<Tcrit ? P > 
Alpha? 
Accept or Reject null 
Hypothesis?
(a)
 
-1 5.01 7.41x10
-3 
NO NO Reject 
-1.3 4.78 8.73x10
-3 
NO NO Reject 
-1.6 1.57 0.18 YES YES Accept 
-1.9 0.40 0.70 YES YES Accept 
-2.2 0.06 0.95 YES YES Accept 
-2.5 -0.43 0.68 YES YES Accept 
-2.8 0.06 0.94 YES YES Accept 
-3.1 0.82 0.45 YES YES Accept 
-3.4 1.08 0.33 YES YES Accept 
-3.7 0.49 0.64 YES YES Accept 
-4.0 -0.13 0.90 YES YES Accept 
(a)Null hypothesis: Hypothesised mean difference = 0. TCrit =2.78, Alpha =0.05, Degrees of 
freedom = 4.  
 
WGA 
Concentration 
log(mg.mL
-1
)
 
T stat P T<Tcrit ? P > 
Alpha? 
Accept or Reject 
null Hypothesis?
(a)
 
-1 2.18 0.09 YES YES Accept 
-1.3 2.72 0.05 YES YES Accept 
-1.6 1.51 0.20 YES YES Accept 
-1.9 1.10 0.33 YES YES Accept 
-2.2 1.38 0.23 YES YES Accept 
-2.5 1.22 0.28 YES YES Accept 
-2.8 1.21 0.29 YES YES Accept 
-3.1 2.26 0.08 YES YES Accept 
-3.4 1.16 0.30 YES YES Accept 
-3.7 1.36 0.24 YES YES Accept 
-4.0 0.82 0.45 YES YES Accept 
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As can be seen, for 3 of the 5 lectins there is essentially no difference in the binding profiles 
of the washed vs unwashed nanoparticle samples. In the case of PNA, at a concentration of 
log -3.4 mg.mL
-1
 there is a significant difference observed between the two nanoparticle sets, 
however this would likely not influence the interpretation of any assay result. Finally, for 
DBA and RCA, at the highest concentrations of lectin only there is a significant difference 
observed between the nanoparticle sets. Despite this the assay still performed well enough to 
distinguish between the different binding behaviours of the lectins. Therefore, as a first step 
screening method to determine heterogeneous surfaces of interest the unwashed particles 
performed satisfactorily.   
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3.3.9. Assay of heterogeneous 1-azido sugar coated 40nm gold 
nanoparticle library  
Finally, the mannose-galactose heterogeneous library was screened as before, against the five 
lectins at a concentration of 0.1 mg.mL to 97ng.mL in order to observe the dose-dependent 
response. As this is system is designed as a screening tool and we do not expect every sugar 
concentration to induce aggregation the aim was not to extract the dissociation constants (Kd). 
As such it does not matter if the full binding range has been covered.  However, we can fit 
the resulting curves with a dose dependant response to extract an estimated Kd for the 
identification of potential inhibitors, the results of which are shown in Table 3.14, particles 
that did not show potential inhibition are not shown. Therefore, we have shown that this 
technique is suitable for the development of large scale, high throughput screening assays. 
The SPR values at 530nm are plotted versus log lectin concentration in Figures 3.45 to 3.49.  
 
Figure 3.45:  SPR absorbance value at 530nm plotted against log DBA concentration for the 
heterogeneous coated nanoparticles. Particles are labelled galactose percentage (G), mannose 
percentage (M), gold nanoparticle size (AuNP40nm).  
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Figure 3.46: SPR absorbance value at 530nm plotted against log PNA concentration for the 
heterogeneous coated nanoparticles. Particles are labelled galactose percentage (G), mannose 
percentage (M), gold nanoparticle size (AuNP40nm). 
 
Figure 3.47: SPR absorbance value at 530nm plotted against log SBA concentration for the 
heterogeneous coated nanoparticles. Particles are labelled galactose percentage (G), mannose 
percentage (M), gold nanoparticle size (AuNP40nm). 
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Figure 3.48: SPR absorbance value at 530nm plotted against log WGA concentration for the 
heterogeneous coated nanoparticles. Particles are labelled galactose percentage (G), mannose 
percentage (M), gold nanoparticle size (AuNP40nm). 
 
Figure 3.49: SPR absorbance value at 530nm plotted against log RCA concentration for the 
heterogeneous coated nanoparticles. Particles are labelled galactose percentage (G), mannose 
percentage (M), gold nanoparticle size (AuNP40nm). 
The lectins DBA, SBA and RCA all show improved binding towards nanoparticles with 
heterogeneous mixtures of galactose and mannose. DBA shows binding towards all 
nanoparticles regardless of composition, SBA has an increased avidity between 20 and 40% 
mannose density and RCA shows increased avidity towards particles containing 30% to 
100% mannose, with the exception of the 50% mannose particle.  The best activity was 
shown against DBA, the estimated Kd’s are shown in Figure 3.50. 
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Figure 3.50: Estimated Kd’s for heterogeneous galactose-mannose particles against (A) DBA 
and (B) SBA. (Kd’s with error greater than 1SD removed). 
 
As can be seen in Figure 3.50A, the particle that DBA had the highest affinity towards 
(lowest Kd) was G90M10Au40, which has 10% mannose density. However all the mannose 
containing particles had improved affinity for DBA over the galactosylated particle. For 
SBA, affinity increased dramatically with increasing mannose density between 20 and 40% 
inclusion of mannose, Figure 3.50B while the other combinations didn’t result in significant 
aggregation. 
  
A B 
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Table 3.14: Estimated Kd values extracted from fitting a dose-response curve. Particles that 
did not show potential inhibition are not shown.  Estimated Kd is defined as the concentration 
of lectin predict to be at the midpoint of the dose dependent response curve. 
Lectin Sample Estimated Kd (μM) Error in Fitting 
DBA G100AuNP40 9.91 54 
DBA G90M10AuNP40 9.10 0 
DBA G80M20AuNP40 11.36 1.57x10
-3
 
DBA G70M30AuNP40 17.96 28.6 
DBA G60M40AuNP40 10.29 5.78 x10
-3
 
DBA G50M50AuNP40 11.93 5.38 x10
-2
 
DBA G40M60AuNP40 10.02 1.55 x10
-3
 
DBA G20M80AuNP40 10.02 6.33 x10
-4
 
DBA G10M90AuNP40 10.84 2.25 x10
-2
 
DBA M100AuNP40 10.09 4.45 x10
-3
 
SBA G90M10AuNP40 223.74 10091.91 
SBA G80M20AuNP40 10.65 3.15 x10
-3
 
SBA G70M30AuNP40 10.01 9.84 x10
-3
 
SBA G60M40AuNP40 9.16 4.83 x10
-3
 
SBA G50M50AuNP40 17.09 20.6 
SBA G40M60AuNP40 15.09 4.49 
RCA G90M10AuNP40 8.33 0 
RCA G60M40AuNP40 1112.16 0 
RCA G40M60AuNP40 8.33 1.62 x10
10
 
 
3.3.10. The role of the octyl-linker in the binding of mannosylated 
nanoparticles 
The effect of the octyl linker on the binding with mannose is shown in Figure 3.51:  
It is apparent that inclusion of the linker causes a decrease in the binding avidity towards the 
lectins compared to the mannose without linker. While none of the mannosylated particles 
have strong binding responses (as would be predicted by the stated binding targets for each 
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lectin) it is apparent that the presence of the linker substantially reduces the binding response 
and increases the error associated with the measurements. This is most likely due to the 
increased entropic cost associated with binding to a more flexible linker and the associated 
restriction in the degrees of freedom of the system. This highlights the importance to consider 
entropic effects when designing both inhibitors and sensor systems, and undermines any 
assumption that greater flexibility (to allow easier access to binding sites) leads to greater 
binding avidities. Instead, we must aim to develop methods that allow access to rigid 
scaffolds that match the target of interest. However, the use of generic systems to allow initial 
screening of a large number of ligands and proteins as presented here, will allow the 
identification of starting points for ligand synthesis that may not have been identified by 
traditional rational design.  
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Figure 3.51 Binding curves for 100% mannosylated nanoparticles with and without octyl 
linker.  
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3.4. Conclusions and further work 
We have shown the development of a high-throughput gold nanoparticle based, label free, 
screening system for the analysis of protein-carbohydrate interactions. The limit on the 
minimum concentration of gold was probed and determined to be at least 6.7x10
-11
 Mol.L
-1
. 
With this in mind, we investigated if multivalent binding effects could be used to out compete 
unreacted monosaccharides, and so reduce the need for purification steps. This is 
advantageous as it simplifies the synthesis and workflow, reduces the loss of gold due to 
purification, and, increases the applicability of this system to industrial, high-throughput use. 
It was shown that heterogeneous environments containing nominally non-binding sugar 
moieties can result in increased binding in a wide range of lectins, including in RCA120, a 
possible chemical weapon. Furthermore it was shown that the inclusion of a flexible octyl 
linker between the sugar and polymer scaffold, resulted in reduced avidity, most likely due to 
the increase in entropic penalty that must be paid. These observations highlight the need to 
consider both the scaffold and binding ligand when developing inhibitors and biosensors. The 
use of large scale screening systems such as shown here may allow the identification of 
potentially effective inhibitors that may have unexpected structures and/or sugar 
compositions, as well as acting as a high through put method for the identification of 
unknown carbohydrate binding proteins.  
To take this work further a greater number of lectins can be screened against, the role of 
different types of linker investigated and the work extended to probe more monosaccharides 
or more complex carbohydrates.  
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3.5. Experimental 
3.5.1. Materials 
2-Chloro-1,3-dimethylimidazolinium chloride, and GM-1 Ganglioside was purchased from 
Carbosynth. D-(+)-Galactose was purchased from MP Biomedicals. D-(+)-Mannose, 
trimethylamine, sodium azide, pentafluorophenol, methacroyl chloride, 2-cyano-2-propyl 
benzodithioate, 4,4′-azobis(4-cyanovaleric acid), 1,4-dioxane, dichloromethane, DBCO-
amine, DMF,2-aminoethan-1-ol, 2,6-lutidine 99% was purchased from Acros Organics. 
DBA, RCA, SBA, WGA and RCA120 was purchased from Vector labs. Ultrapure milli Q 
water was obtained from a Merk Milli-Q water purifier at 18.2 MΩ.cm resistivity at 25 °C.  
3500 MWCO ‘snakeskin’ dialysis tubing was purchased from Thermofisher (UK). Mannose-
C8-N3 obtained from Martin Lahmann. Galactose-amine coated gold nanoparticles obtained 
from Sarah Jane Richards.  
3.5.2. Analytical methods 
1
H, 
13
C NMR, and 
19
F spectra were recorded on Bruker HD-300, HD-400, and AV-500 
spectrometers using deuterated solvents purchased from Sigma-Aldrich. Chemical shifts are 
reported relative to residual non-deuterated solvent. Mass spectrometry was performed on an 
Agilent 6130B single Quad (ESI). FTIR spectra were acquired using a Bruker Vector 22 
FTIR spectrometer with a Golden Gate diamond attenuated total reflection cell. Raman 
spectra were collected on a Reinshaw inVia Reflex Raman using a 442 nm HeCd laser. 
Liquid handling was performed by Gilson Pipette Max. 96-well plates were read using a 
Bioteck Synergy plate reader set at 25 °C. Uv-Vis spectra were obtained an Agilent Cary 
spectrometer.  DMF SEC was performed on a varian 390-LC MDS system equipped with a 
PL-AS RT/MT autosampler, a PL-gel 3 μm (50 x 7.5 mm) guard column, two PL-gel 5 μm 
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(300 x 7.5 mm) mixed-D columns using DMF with 5 mM NH4BF4 at 50 °C as eluent at a 
flow rate of 1.0 mL.min-1. The SEC system was equipped with ultraviolet (UV)/visible (set 
at 280 and 461 nm) and differential refractive index (DRI) detectors. Narrow molecular 
weight PMMA standard (200 – 1.0 x 106 g.mol-1) were used for calibration using a second 
order polynomial fit. TEM images were obtained on a JEOL 2000FX transmission electron 
microscope, 200 kV, LaB6 instrument operated with a beam current of ~115 mA. Images 
were captured using a Gatan Orius 11 megapixel camera. Samples were prepared by 
deposition and drying of nanoparticle samples (10 µL of ethanol or water suspensions) onto 
formvar-coated 300 mesh copper Tem grids (Agar Scientific) 
Assays  
Lectin binding assay  
For each gold sample in the library; 20 μL of each lectin made up in HEPES buffered saline 
solution was transferred by liquid handling robot to 3 separate wells of a 384-well micro-titre 
plate.  The lectin was then serially diluted 11 times with HEPES buffer and a blank added to 
well 12. Next 10μL of gold sample was added to each well, and the plate incubated at 37°C 
for the duration of the assay. After incubation the plates were placed into an  Agilent Cary 
spectrometer and full spectral scans from 400nm to 700nm were taken. This was repeated 
three times for each gold sample. The resulting scans were then normalised to the absorbance 
at 450nm and the mean absorbance value at the gold SPR peak of 530nm was recorded for 
each plate. Plots were then made using the mean and standard deviation of each plate mean.  
Limit of detection assay 
The concentration of SBA was fixed at 6.25x10
-3
 mg.mL
-1
 in HEPES buffer. 20 µL of gold 
added to 384 microtitre plate and serially diluted 11 times and 12
th
 well filled with blank. 
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Control with no lectin also plated.  10µL of Lectin was added and the plate  incubated at 37 
°C. UV-Vis spectra were taken at time-points T=30, 60 and 360 minutes. Gold concentration 
was calculated using Equation 3.2: 
 
𝑐 =
𝐴450
𝜀450 𝑥 𝑙
 
3.2. 
  
Where A450 is the absorbance value at 450nm and experimentally determined. ε450 is the 
molar decadic extinction coefficient, taken from Haiss et al.
32
   (4.92x10
9
  M
-1
Cm
-1
)  and L is 
the path length, calculated to be 0.274 cm for 20 µl water in a 384 well plate.  
Statistical determination of Kd Values 
To determine the estimated Kd values the whole UV-Vis spectra were recorded on an Agilent 
Cary spectrometer and the data exported to a spreadsheet. Using the inbuilt spreadsheet 
functions the data was formatted to group sample’s and repeats together. The data was then 
normalised to the absorption at 450nm. The average value and standard deviation of 530nm 
SPR peak was then calculated and the data transposed for exporting to origin.  
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3.5.3. Synthetic procedures 
Synthesis of Azido-Monosaccharides 
2-Chloro-1,3-dimethylimidazolinium chloride (2.82 g, 16.7 mmol) was added to a solution of 
galactose/mannose (1.00 g, 5.6 mmol), trimethylamine (7.7 mL, 55 mmol) and sodium azide 
(3.61 g, 55.5 mmol) dissolved in ultrapure milli Q water (20 mL), sitting on ice. The solution 
was stirred for 40 minutes on ice before removing the solvent in vacuo.  Ethanol (40 mL) was 
added to precipitate NaN3, filtered, and the solvent removed (Repeat to ensure complete 
removal of NaN3). The resulting solid was then dissolved in ultrapure milli Q water (10 mL) 
and washed three times with dichloromethane. The water layer was freeze dried to give a 
yellow solid. The product was then purified on a silica column using 5:1 chloroform: 
methanol (Rf = 0.3) to give an off-white product. Yield: 0.98 g 86% 
1-Azido-1-deoxy-galactose 
1
H NMR (MeOD) 400MHz, ppm: 5.57 (1H, d, J1-2= 4.40Hz, H1, α anomer 23.7%), 4.67 (1H, 
d, J1-2=8.68Hz, H1, β anomer 76.3%), 3.96 (1H, d, J1-2 = 3.30Hz, H5), 3.79-3.78 (1H, m, H4), 
3.77-3.75 (2H, m, H6), 3.70 (1H, dd J1-2 = 3.42, J3-4 = 9.78Hz, H3) 3.53 (1H, t, J1-2 = 9.78, 
H2) 
13C NMR (MeOD) 75MHz, ppm: 90.55 (β C1), 89.44 (α C1) 77.21 (β C4), 75.88, 75.13, 
74.23, 73.06, 72.64 (β C3), 71.20 70.32 (β C2), 69.19, 68.51(β C5), 68.20, 64.20, 63.46, 
61.17, 60.94 (β C6)  
MS (ESI +): Observed: 228.00 Expected: 228.17 [M+Na]
+
 
IR: 2107cm
-1 
(-N3) 
 
176 
 
1-Azido-1-deoxy-mannose 
1
H NMR (MeOD) 400MHz, ppm: 5.46 (1H,d, J1-2 = 1.71 Hz, alpha 100%) 3.92 (1H, d, 
J=10.27 Hz) 3.86 (1H, dd, J1-2 = 1.96, J3-4 = 3.18 Hz ,H
2
) 3.78, (2H, m) 3.75-3.72 (2H, m), 
3.64 (1H, t, J1-2 = 9.54Hz)    
13
C NMR (MeOD) 75MHz, ppm: Major Anomer (100%): 90.57 (C1), 78.47 (C5), 70.36 
(C2), 70.37 (C3), 66.60 (C4), 61.10(C6) 
Mass Spec:  Observed: 228.00 Expected: 228.17 [M+Na]
+
 
IR: 2107cm
-1
 (-N3) 
Synthesis of perfluorophenyl 2-(((dodecylthio)carbonothioyl)thio)-2-methylpropanoate 
(DMPPFP) 
DMPPFP was synthesised using a method similar to that already reported
40,41
. First 2-
(dodecylthiocarbonothioylthio)-2-methypropanoic acid (DMP) was synthesised as below. 
Dodecane thiol (4.00 g, 19.76 mmol) was added dropwise to a stirring suspension of K3PO4 
(4.20g, 19.76 mmol) in acetone (60 mL) over 25 minutes. CS2 (4.10 g, 53.85 mmol) was 
added and the solution turned bright yellow. After ten minutes 2-bromo-2-methylpropionic 
acid (3.00 g, 17.96 mmol) was added and KBr precipitation was observed. After stirring for 
16 hours, the solvent was removed by rotary evaporation and the residue was extracted into 
Dichloromethane (DCM) (2 x 200 mL) from 1M HCl (200 mL). The organic extracts were 
washed with water (200 mL) and brine (200 mL) and further dried over MgSO4. The solvent 
was removed under reduced pressure and recrystallized from Hexane to give DMP as a bright 
yellow solid (3.71g, 56 %). 
H
1
 NMR (400MHz): δppm: 3.26 (2H, t, J12-11 = 7.16 Hz, H12); 1.72 (6H, s, H13); 1.65(2H, 
m, Hz, H11); 1.63 (2H, m, H10); 1.56 (16H, m, H2-9); 0.86 (3H, t, J1-2 = 6.03 Hz, H1). 
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IR cm
-1
: 2955 (alkyl-H stretch); 1712 (C=O stretch); 1066 (S-(C=S)-S stretch)  
MS m/z (ESI-POS): 365 (M+H)  
Following this DMPPFP was synthesised. DMP (3.7g, 10.13mmol), EDC HCl (2.91g, 
15.20mmol), DMAP (1.86g, 15.20mmol) and 80.0mL of DCM were placed in a one-neck 
round bottom flask and sealed. The solution was stirred for 10 min under nitrogen 
atmosphere before Pentafluorophenol (PFP) (6.06g, 3.93mmol) dissolved in DCM was added 
via syringe, and then, stirred for overnight at RT.  After that, the solution was washed in 
sequence with 3M HCl, 1M NaHCO3 and 0.5 M NaCl aqueous solutions.  The organic layer 
was dried with anhydrous MgSO4.   The solvent was removed by rotary evaporation under 
vacuum to generate the product as a dark yellow viscous liquid (4.62g, 86.3%) 
H
1
 NMR (400MHz): δppm: 3.26 (2H, t, J12-11 = 7.16 Hz, H12); 1.72 (6H, s, H13); 1.65(2H, 
m, Hz, H11); 1.63 (2H, m, H10); 1.56 (16H, m, H2-9); 0.86 (3H, t, J1-2 = 6.03 Hz, H1). 
IR (cm
-1
): 2955 (alkyl-H stretch); 1712 (C=O stretch); 1066 (S-(C=S)-S stretch) 1176 (C-F 
Stretch) 
MS m/z (ESI-POS): 531 (M+H) 
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Synthesis of p(hydroxylethyl acrylamide) pentafluorophenol ester 
HEAA (0.5g, 4.34mmol, 25eq) plus varied amounts of DMPPFP (1eq) and 4,4′-Azobis(4-
cyanovaleric acid)  (AVCA) as the initiator (0.5eq) where placed into a glass vial with 4.0mL 
of a 1:1 mix of Toluene and Methanol. 200 μL of mesitylene as an internal NMR standard 
was added. A sample for NMR is taken and dissolved in deuterated chloroform. The glass 
vial was then sealed and degassed using N2 for 30 minutes. Following this the reaction 
mixture is heated to 70 °C for 90 minutes at which time the reaction is quenched by exposure 
to air followed by cooling in liquid N2. An NMR sample of the crude mix is made up in 
deuterated Methanol and the mixture is precipitated into Diethyl Ether from Methanol three 
times to give a yellow solid. Average: 92% conversion. Ð=1.18 
1
H NMR (MeOD) 300MHz, ppm: 3.65 (br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-
1.5 (br, Backbone CH2) 
19
F NMR (CDCl3) 376MHz, ppm: -150.35 (1F,br s), -151.44 (1F, br s), -156.97 (1F, br s), -
162.11 (1F, br s) 
Synthesis of p(hydroxyethyl acrylamide) dibenzocycoloctyne amide 
Poly(HEAA) (1 eq), DBCO (10mg, 36.2uM,  1.05eq) and Triethylamine (TEA) (2eqs) are 
dissolved in 2 mL of deuterated methanol.  The reaction mixture is then heated to 50°C for 16 
hours. The solution is then concentrated to approximately 0.5mL and submitted for F19 
NMR. Following this the mixture is diluted to 20mL of distilled H2O and dialysed using 
dialysis tubing with an appropriate molecular weight cut off. The sample was then freeze-
dried to afford the final product as a white powder, yield ~69% 
1
H NMR (MeOD) 300MHz, ppm: 7.5-7.0 (br, Benzyl) 4.42 (br, cyclooctyne ring CH2) 3.65 
(br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2)
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19
F NMR indicated no presence of fluorine left in sample 
Raman (cm
-1
): 1600 (Aromatic C-C) and 2159 (Alkyne) 
Synthesis of Gold nanoparticles by one pot growth 
Gold nanoparticles where synthesised using the citrate reduction method first proposed by 
Turkevich . 
31
 The size of the nanoparticles can be tuned by varying the ratio of gold to citrate 
as shown by Frens. 
42
 HAuCl4∙3H2O (10mg, 1eq) is dissolved in 35mL of deionised water 
which is then heated to boiling.  Following this trisodium citrate dehydrate (14.95mg, 2eqs) 
in 2ml of deionised water are added in one portion and the temperature maintained for 30 
minutes. After ten minutes a deep red colour is observed. After 30 minutes the solution is 
allowed to cool slowly. To wash the Au NPs the solution is centrifuged at 3000g for 15 
minutes, the supernatant decanted and the particles re-suspended in deionised water.   
DLS: 32 ± 0.2 nm 
UV-Vis: 32nm 
TEM: 19.2 ±7.6 nm 
Synthesis of Gold nanoparticles by step growth 
The 40nm gold nanoparticles used later in this work were synthesised using a step growth 
procedure described by Bastús et al.
37
  Care must be taken to ensure extremely clean 
glassware and accurate temperature control throughout the synthesis. 
A 25 mM stock solution of HAuCl4 and a 60 mM stock of sodium citrate were prepared.  150 
mL of 2.2 mM sodium citrate was brought to 100 °C in a three necked RBF, and 1 mL of 
stock HAuCl4 solution was injected, to generate gold seeds of approximately 10nm in size at 
a concentration of ~3x10
12
 nanoparticles per mL. The solution immediately turns grey-blue 
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and deepens to a bright wine red colour over the course of approximately 5 minutes. This is 
labelled generation 0. The solution was then cooled to 90 °C and a further 1 mL of stock 
HAuCl4 solution added. After 30 minutes nanoparticle growth for this step is finished. 
Another 1 mL of stock HAuCl4 is added. After 30 minutes the sample is diluted by removing 
55 mL of sample (used for analysis) and 53 mL of milli Q water and 2 mL of 60 mM sodium 
citrate (N.B. Keep both milli Q water and sodium citrate stock warmed at 90 °C to prevent 
temperature changes on addition). This solution is now generation 1 and the process is 
repeated until the desired gold nanoparticle size is achieved. Bastús et al. report successful 
synthesis of gold nanoparticles up to 180nm in size with this method.  
Recorded nanoparticle step sizes using UV-Vis:  
Step 1: 12nm 
Step 2: 32nm 
Step 3: 40nm 
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Gold Nanoparticle Coating with DBCO-HEAA Polymer 
Gold nanoparticles were coated with polymer at a concentration of 1mg.mL
-1
 polymer. 1.5 
mL of stock gold nanoparticle solution was taken and 1.5 mg of DBCO-pHEAA25 polymer 
was added. The reaction was allowed to proceed for 30 minutes at room temperature. The 
gold nanoparticles were washed three times by centrifugation at 3,000 x g for 30 minutes 
before being re-suspended in 2 mL deionised water.  
Appending Azido-Sugars to DBCO-HEAA Coated Gold Nanoparticles 
A five times excess of sugar is used. A stock solution of each sugar was made up with 
6.66mg (32μM) of sugars in 16.65 mL of deionised water. The Coated AuNPs were 
centrifuged at 3,000g for 30 minutes and 1.5 mL of water was removed. The stock sugar 
solutions where combined in 100:0,80:20,60:40,40:60,20:80 and 0:100 volume ratios to give 
a final volume of 1.5 mL, added to the centrifuged gold and left at room temperature 
overnight. The gold nanoparticles were then washed three times by centrifugation at 
10,000rpm for 30 minutes before being re-suspended in 2 mL deionised water. For later work 
this washing step was removed, as discussed in the main text above. Characterisation shown 
in table 3.7, reproduced below. 
Gold Coating Size
 (a)
 
(nm) 
Size 
(b) 
(nm) 
Size 
(c) 
(nm) Zeta Potential
(d)
 
(mV) 
Citrate 40 55 ±3.3 34.9 ±6.7 -38.1 ±1.0  
DBCO-HEAA 62 76 ±0.9 N/A -21.1 ±0.1 
Gal-HEAA 62 76 ±3.5 N/A -19.7 ±0.6 
(a) UV-Vis (b) Dynamic Light Scattering (c) TEM (n=160) (d) Measured in milliQ water at 
pH=7.4  
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 Chapter Four 
Remodelling Cell Surfaces with Synthetic 
Polymers by Tandem Glycan Metabolic Labelling 
and Copper-Free Click Conjugation 
Declarations 
The work submitted in this chapter was performed by myself, except for Cell culture 
experiments which were performed with assistance from Trisha Bailey, Gibson Group, 
University of Warwick. Trisha Bailey performed maintenance of the cell line, cytotoxicity 
assays and initial plating of cells. I performed the addition of the metabolic labelling reagents, 
washing, analysis and imaging.  
4.1. Abstract 
Cell surfaces are coated with a dense layer of glycoproteins, glycans and glycolipids which 
constitute the glycocalyx. The glycocalyx directs cell-cell communication, is the first site of 
adhesion for pathogens, and defects are associated with cellular dysfunction. Chemical 
modifications to ‘remodel’ the glycocalyx are an essential tool to investigate its function, or 
as a scaffold for modifying cell surfaces for biotechnological or medical applications. As 
carbohydrates are a post-translational modification, genetic techniques to achieve this are 
rare, and challenging.  Here we make use of the metabolic processing of azido-
monosaccharides into cell surface azido O-linked glycans and azido-sialic acid residues and 
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‘hijack’ the systems to introduce azides onto the cell surface. These azides act as a bio-
orthogonal handle to enable synthetic polymers to be grafted to the surface to chemically 
remodel the glycocalyx, providing a versatile tool to control this complex interface. 
4.2. Introduction 
Cell surfaces are multifunctional dynamic environments that provide vital communication 
pathways within the body.  The cell surface assists in intracellular communication,
1
 (non)self-
recognition for the immune system,
2–4
 inflammation
5,6
 and more. The surface of the cell itself 
is a highly dynamic, consisting of lipids, proteins and carbohydrates, at various length scales 
and with diverse functionalities. Figure 4.1 shows a depiction of a cell surface.
7
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Reprinted by permission from Macmillan Publishers Ltd: Nature Chemistry7 copyright 2011.   
Figure 4.1: (A) A representation of the cell surface showing the lipid membrane in pink, 
important proteins in blue and the glycocalyx in orange. Heterogeneity in the lipid membrane 
has been ignored for simplicity (B) Relative size of the glycocalyx. (C) Schematic of the over 
expression of HER2 protein in cancerous cells vs heathy cells.
8
 (D) Examples of the chemical 
modifications which the carbohydrates of the glycocalyx can undergo.  
The glycocalyx of the cell surface is the outermost component, attached to the cell membrane 
and is therefore the first component of the cell encountered by external agents.  Figure 4.1B 
demonstrates the relative sizes of the glycocalyx for an endothelial cell (more than 200 nm) 
and red blood cell (10 nm), demonstrating the vast difference in physical size the glycocalyx 
can exhibit depending on cell type.  The cell surface also indicates the underlying cell 
physiology.
4,9–14
 Cancerous tissues exhibit modified cell surfaces,
8
 such as the overexpression 
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of HER2 protein as shown in Figure 4.1C, which can cover more than 15% of the surface 
area of the cell in cancerous tissue. Other modifications include the over-expression of sialic 
acid residues. In fact, hyper-silyation has been noted to confer increased resistance to chemo- 
and radio-therapy techniques in cancerous tissues, aids in immune evasion by the tumour 
decreasing the effectiveness of immunotherapy
15
 (such as Herceptin
©
  to target HER2 
overexpression) and is linked to poor prognosis.
16
  In addition, alternative strategies to 
common antibiotics, such as anti-adhesion therapy, offer a method to tackle the growing 
antibiotic resistance problem.
17,18
 To fully exploit anti-adhesion as a viable treatment option, 
the interaction of cell surfaces must be well characterised and understood. Therefore it will be 
necessary to develop new methods of probing these environments. 
The ability to add abiotic functionality to the cell surface offers the chance to more 
effectively monitor the interactions taking place and the effect of any added external stimuli. 
Furthermore, the ability to structurally engineer the cell surface allows the introduction of a 
greater range of functionality to an already highly functional surface. This allows the creation 
of hybrid cells that can perform functions that differ greatly from their original intention, for 
use in tissue engineering,
19
 microelectronics fabrication,
20
 and as biosensors.
21,22
 
One way of directly observing the glycosylation state of cells is metabolic glycan labelling. 
Developed by Bertozzi and co-workers,
23,24,24–31
 glycan labelling exploits intracellular 
biosynthetic pathways to re-engineer glycans. The sialic acid metabolic pathway from N-
acetylmannosamine is very tolerant to modifications at the N-actyl group enabling bulky 
substituents to be carried through all the way to sialic acid. As long as the chemical moiety 
used to tag the sugar is small it will be tolerated by the metabolic pathway and incorporated 
into glycans as if it were the native sugar. Wong et al. demonstrated that side chains up to 5 
atoms long are tolerated by the sialic acid pathway of mannosamine.
32
  Several metabolic 
190 
 
pathways are open to investigation in this manner: N-acetylmannosamine, N-
acetylglucosamine, N-acetylgalactosamine and the fucosylation pathway.  
In particular the N-acetylgalactosamine (GalNAc) salvage pathway is of interest as it allows 
access to O-linked glycans. The two main forms of glycosylation of proteins are N-linked and 
O-linked glycans. N-linked glycans are attached to asparagine residues and are produced by 
the action of a single enzyme, oligosaccharyl transferase, that recognises a particular amino 
acid sequence (asparagine-X-serine/threonine, where X≠proline).  This means that N-linked 
glycans can be predicted based upon analysis of the protein sequences and coupled with 
techniques like mutagenesis.  O-linked glycans on the other hand, are attached through serine 
or threonine residues and are installed by a collection of transferases found within the Golgi 
apparatus of the cell. They are of interest as O-linked glycoproteins play an important role in 
several biological processes and disease states, including the Ebola glycoprotein required for 
the cytotoxicity of Ebola,
33,34
 the MUC1 tumor antigen present in the altered glycans of 
cancer cells,
35,36
 and the development of Alzheimer’s disease.37,38  
By introducing the unnatural sugar of N-azidoacetylgalactosamine (GalNAz) into the N-
acetylgalactosamine salvage pathway, Figure 4.2A, followed by the addition of an azide 
reactive probe such as an alkyne or Staudinger reagent, Figure 4.2B, direct conjugation to the 
glycocalyx can be achieved. This method has been utilised by Bertozzi et al., to label and 
isolate O-linked glycosylated mucin-type proteins in Jurkat cells, separating them from other 
GalNAc metabolite products such as glycosphingolipids and chondroitin sulfate 
proteoglycans.
39
  The technique has also been used less specifically to observe the evolution 
of glycans in developing zebra fish with fluorescent probes. 
40–43
 It is possible for GalNAz to 
be epimerised into ManNAz via UDP-GlcNAc 2-epimerase and GlcNAc 2-epimerase 
enzymes, where upon ManNAz is incorporated into the terminal sialic acid residues of the 
glycocaylx.
39
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Figure 4.2: (A) Labelling the N-acetylgalactosamine salvage pathway with unnatural 
GalNAz (B) Introducing a probe to the labelled O-glycosylated proteins using the Staudinger 
ligation.   
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So far two main glycan labelling systems have been developed, the Staudinger Ligation,
44
 
Figure 4.3A and Copper-free alkyne-azide cycloaddition,
45
 Figure  4.3B.  
 
 
 
 
 
 
 
 
 
Figure 4.3: Bio-orthogonal reagents for metabolic labelling. 
Both fulfil the requirements of a bio-orthogonal probe, they are non-toxic reagents that react 
selectively to produce chemically and biologically-inert products. However, the rate of 
reaction for the Staudinger ligation is too low compared to the rate at which the 
phenylphosphine based reagent is cleared from the body to give a good signal to noise ratio.
46
  
Bertozzi et al. developed cyclooctyne reagents to remove the need for toxic copper and allow 
the azide-alkyne coupling to occur in vivo.
45,47–56
  However, there are currently very few 
water-soluble cyclooctyne reagents available,
55
 resulting in the need to use DMSO, and 
precluding their use in animals, including humans. Conjugating the cyclooctyne reagents to 
water soluble polymers might overcome this and have the benefit of improved 
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pharmacokinetics. One commercially available reagent is dibenzocyclooctyne (DBCO), see 
Figure 4.4, which has a comparable reaction rate to the fastest reported cyclooctyne reagent.
52
   
 
Figure 4.4: Dibenzocyclooctyne (DBCO). 
Various other sugar modifications and bio-orthogonal reactions have been developed in 
recent years, an overview of which are shown below in Table 4.1.  
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Table 4.1: Summary of some of the unnatural sugars and probes used for metabolic glycan 
labelling.  
Label Probe Target 
Ac4ManNAz
57
 
 
 
Staudinger Ligation  
Cu-catalysed Alkyne Azide 
coupling 
Strain promoted Alkyne Azide 
coupling 
Sialic Acids 
Ac4GalNAz
57
 
 
 
Staudinger Ligation  
Cu-catalysed Alkyne Azide 
coupling 
Strain promoted Alkyne Azide 
coupling 
O-linked Glycans 
Ac4GluNAz
57
 
 
 
Staudinger Ligation  
Cu-catalyised Alkyne Azide 
coupling 
Strain promoted Alkyne Azide 
coupling 
N-linked Glycans 
FucAz
41,58,59
 
 
 
Staudinger Ligation  
Cu-catalysed alkyne azide 
coupling 
Strain promoted alkyne azide 
coupling 
Fucose salvage 
pathway 
 
Ac4ManNAl
32,60
 
 
 
 
Cu-catalysed alkyne azide 
coupling with biotin-azide  
 
Sialic Acids 
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Nitrile Mannosamine
61
 
 
 
 
Sialic Acid 
Pathway 
Nitrile Glucosamine
61
 
 
 
N-Linked 
Glycans 
3-deoxy-D-manno-
octulosonic acid
57
 
 
Cu-Catalysed Azide-Alkyne 
coupling with Alkyne-
Alexafluor488 
Labelling of gram 
negative bacterial 
membranes  
 
 
Bifunctional Sialic 
acids
57
  
9-AzSiaNAl 
 
 
9-AzSiaDaz 
 
 
 
 
 
 
Cu-Catalysed Alkyne Azide 
coupling with BTTAA
57
 
 
 
UV activated crosslinking  
 
 
  
 
 
Sialic Acids 
 
One of the biggest challenges to the wider applicability of this method is the insolubility of 
the acetylated sugars required to enable passage through the cell membrane (for mannose, 
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acetylation increases uptake over 100-fold 
57
) before subsequent de-acetylation by 
intracellular enzymes.
31,46,62,63
 Furthermore many fluorophores, other potential probe 
reagents, and abiotic functionality that researchers may want to introduce are hydrophobic 
and so precluded from use without the use of organic solvents such as DMSO, which is not 
passive and can damage cells. The ability to add polymers onto the cell surface can also be 
advantageous in and of itself. Work by Godula and co-workers has shown that synthetic 
neoproteoglycans based on an acrylamide backbone can be used to control stem cell 
differentiation by recruiting additional growth factors, which bind the synthetic materials 
immobilised onto the cell surface.
64
 Bertozzi and co-workers utilised lipid-functionalised 
glycopolymers to investigate oligomerisation by galectins.
65
 Hawker and co-workers have 
used the surface of yeast and mammalian Jurkat cells as a macro chain transfer agent for 
RAFT polymerisation performed directly on the cell surface.
66
    
The work in this chapter explores the use of water-soluble polymeric labelling reagents to 
enable both the visualisation of metabolically labelled glycans, but also as a new platform 
technology to enable the remodelling of cell surface using biocompatible, covalent chemistry. 
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4.3. Results and discussion 
4.3.1. Synthesis of Ac4GalNAz metabolic label 
In order to introduce the orthogonal azide label into the cell surface, tetraacetylated 
galacosamine azide (Ac4GalNAz) was synthesised using a procedure modified from Fürniss 
et al 
67
, shown below in Scheme 4.1: 
 
Scheme 4.1: Synthesis of Ac4GalNAz. 
Galactosamine was first reacted with choloroacetic anhydride. Formation of the N-
chloroacetic galactosamine was confirmed using mass spectroscopy and the crude product 
was used without further workup. The chlorine was then displaced by sodium azide 
[Caution: Care must be taken when handling NaN3. Please read notes in experimental 
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section]. The produced N-azidogalactosamine (GalNAz) was then directly acetylated using 
acetic anhydride and pyridine, again without isolation, to give the tetraacetylated product 
(Ac4GalNAz), which was isolated via column chromatography. The presence of the azide 
was confirmed via infra red spectroscopy and the product characterised by nuclear magnetic 
resonance spectroscopy and mass spectrometry. In addition to the azido-monosaccharides, 
polymeric labelling reagents were also required. The design principle was to obtain a water-
soluble polymer containing a fluorophore for labelling, and the necessary bio-orthogonal 
handle for cell-surface conjugation. To enable end group control, the polymer was 
synthesised as a copolymer using the RAFT polymerisation technique. 
4.3.2. Synthesis of fluorescent polymers 
A fluorescent monomer, hostasol methacrylate, Scheme 4.2, was chosen (kindly provided by 
the Haddleton Group, University of Warwick). By directly incorporating the dye into the 
polymer backbone, as opposed to the ω-end group, we could have multiple fluorescent units 
per polymer which means a greater total signal could be generated compared to traditional 
dyes which give a single fluorophore per conjugation. However, hostasol methacrylate is not 
water soluble, so it was copolymerized with N-hydroxyethyl acrylamide as it is a well-
established, water soluble monomer which is non-cytotoxic (note lack of cytotoxicity does 
not prove, nor rule out, in vivo biocompatibility but shows it is suitable for cell-based 
studies). We chose to use RAFT polymerisation as our already prepared PFPDMP RAFT 
agent would be effective for polymerising both acrylamides and methcarylates, while 
installing the amine reactive PFP ester to the α-end group of our polymer, allowing the 
installation of DBCO-amine as the bio-orthogonal handle. DBCO is not compatible with 
controlled radical polymerisation hence this post-polymerisation approach is required.  This 
would be difficult to achieve via another polymerisation method such as atom transfer radical 
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polymerisation (ATRP), as fine tuning the ligands to co polymerise both an acrylamide and 
methacrylate as a one pot reaction would be a time consuming task.
68–71
 Further, by choosing 
RAFT over ATRP we avoid the use of copper which would have needed complete removal 
prior to use with the cells.  We chose 2 mol % hostasol methacrylate inclusion into polymers 
with a targeted degree of polymerisation of 25 and 75, giving polymers with a final dye 
incorporation of 0.5 and 1.5 per chain respectively.  This allows us to see the effect of lower 
and higher fluorophore density on a single tag, and notice any quenching effects that may 
occur in a higher density probe.  
Poly(N-hydroxyethyl acrylamide-co-hostasol methacrylate) was synthesised in a one-pot 
reaction as shown in Scheme 4.2.  
 
Scheme 4.2: Reaction scheme for the synthesis of (A) the statistical copolymer PFP 
terminated Poly(N-hydroxyethyl acrylamide-co-hostasol methacrylate) (B) Functionalisation 
of end group with DBCO. 
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The resulting polymers were characterised by NMR spectroscopy and size exclusion 
chromatography (SEC), the results of which are summarised in Table 4.2. The SEC traces 
showed extremely strong fluorescence responses that align with the elution time of the 
polymers from the RI detector, saturating the detector at the 1 mg.mL
-1
 concentration 
required for SEC analysis. This confirmed the inclusion of the hostasol fluorophore. It is 
important to note that although methacrylates and acrylamides have different reactivity ratios, 
the very low molar ratios means the challenges associated with statistical verses block 
copolymerisation are not relevant.  Although the methacrylate will favour homo-
polymerisation, the raft agent favours acrylamide propagation, this should result in the 
distribution of methacrylate across the whole polymer backbone, with some favour towards 
the alpha end of the polymer and some block-like character. Determining the exact 
composition of the polymer however was beyond the scope of our aim to investigate to what 
extent we could modify the cell glycocalyx, and the subsequent effect on cell function.  
Table 4.2: Table summarising characterisation of fluorescent polymers.  
Polymer [HEAA] 
:[HSM] 
:[CTA] 
Conversion
(a) 
Mtheo Mn
(b) 
(g.mol
-1)
 
Mw/Mn 
pHEAA25-co-HMA0.5 25:0.5:1 96.6% 3100 6500 1.23 
pHEAA75-co-HMA1.5 75:1.5:1 88.3% 9300 13000 1.27 
(a) Calculated by integration of HEAA vinyl peaks to mesitylene standard (b) DMF SEC 
As a final step the DBCO-amine was installed at the α-end group by displacement of the 
pentafluorophenyl ester, using methods discussed in previous chapters, to give the final 
fluorescent water soluble co polymer shown in Scheme 4.2 Incorporation was confirmed by 
19
F NMR which enables monitoring of the release of the PFP group, as shown in Figure 4.5. 
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Figure 4.5: 
19
F NMR of PFP-PHEAA75-co-HMA1.5 on addition of DBCO at time = 0 (Red) 
and time = 16 hours (green).  Note partial hydrolysis of the PFP end group is present even at 
time zero, we attribute this to the delay between taking the sample and the NMR spectrum 
being performed.  Peaks A, B, and C correspond to fluorine in the polymer, Peaks D, E, and F 
correspond to solvated pentafluorophenol formed in the time = 0 sample before measurement. 
Peaks G, H and I correspond to solvated pentafluorophenol after 16 hours reaction time.  
4.3.3. Testing the surface bound alkyne-azide coupling reaction 
with azide functionalised glass slides 
 
With the above polymers with the necessary functionality; fluorescence read-out and DBCO-
end group required for copper free click, a model system was set up to study the surface-
binding properties. Azide coated glass slides were prepared as a simple mimic of a 
metabolically labelled cell surface. Glass slides were first cleaned using “Piranha solution”, a 
solution consisting of a 3:1 (v/v) mix of 98% H2SO4 and 30% H2O2. [Note that Piranha 
A 
B 
C 
D E 
F 
G H 
I T = 16 Hours 
T = 0 Hours 
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solution is extremely hazardous and should always be freshly prepared in small 
quantities; consult experimental section for further details]. After cleaning the glass 
slides were functionalised with (3-glycidyloxypropyl)trimethoxysilane before reacting them 
with sodium azide, Figure 4.6.  
 
 
Figure 4.6: Synthetic procedure for the production of azide coated glass slides.  
The successful incorporation of the azide onto the glass slide was confirmed using a drop 
shape analyser to confirm a change in the water contact angle between uncoated and coated 
slides, Figure 4.7 and Table 4.3: 
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Figure 4.7: (A) Graph to show observed water contact angle measurements (B) Drop shape 
analysis of uncoated SiO2 (C) Drop shape analysis of azide functionalised slide.  
Table 4.3: Water contact angle measurements of coated and uncoated glass slides. 
Slide Water Contact angle (°) Standard Deviation (°) 
Uncoated SiO2 19.4
(a)
 1.5 
Azide-modified 53.4
(b)
 0.6 
 (a) Average of 3 measurements (b) Average of 6 measurements 
These azido-functional slides were used to investigate the surface binding reaction of 
PHEAA25-co-HMA0.5. The azide-reactive polymer was added to the glass slides at 0.1 
mg.mL
-1
 and 0.01mg.mL
-1
 for 2 hours at room temperature. Following this the slides were 
washed copiously with de-ionised water and imaged using a micro array scanner. The array 
scanner images and analysis with ImageJ showed a clear localisation of the fluorescent 
polymers on the azido-slides, while uncoated glass slides showed no fluorescence (not shown 
due to lack of colour) post-washing, confirming the conjugation had occurred Figure 4.8.  
A B 
C 
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Figure 4.8:  The localisation of PHEAA25-co-HMA0.5 on the slide at 0.1 (Left two columns) 
and 0.01 (right three columns) mg.mL
-1
.(Excitation at 532 nm and 633 nm). 
4.3.4. Metabolic labelling of A549 carcinoma cells 
Encouraged by the successful results on glass slides, a cell-based assay was devised for the 
metabolic labelling and capture to be explored. The immortalised human carcinoma A549 
adherent cell line was chosen as the cell line to label as it is stable, well characterised
72
 and 
widely used in the research group. To screen for toxicity Ac4GalNAz was drop cast from 
ethanol into collagen coated plates, to give final Ac4GalNAz at concentrations of 0, 50 μM 
and 100 μM. A549 cells were then grown for 48 hours, after which the cells were observed 
for any morphological irregularities, stained with Alamar blue to check for cell viability and 
counted using a hemocytometer. No cytotoxicity was observed with cell viabilities above 90 
% being obtained with the addition of the sugars. One way analysis of variance (ANOVA) 
showed no difference between the control and test groups (Null hypothesis mean variance = 
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0, null hypothesis accepted as calculated F (0.628) is less than or equal to Fcritical (4.066)).  
Morphological analysis also confirmed the cells were unaffected by the addition of the 
glycan. Figure 4.9. 
 
Figure 4.9: (A) 20x magnification brightfield image, showing healthy cell morphology (B) 
Cell counts, concentrations are of final plate concentration of Ac4GalNAz.  
Satisfied with the control experiment above that the Ac4GalNAz sugar was not toxic we 
proceeded to metabolically label the cells. As before, Acetylated sugars were drop cast from 
ethanol onto the wells of a 96-well tissue culture plate to give a final concentration of 100 
μM. N-acetylgalactosamine (GalNAc) was used as an azide-negative control. The cells were 
cultured to confluency over 48 hours in the presence of the sugar, after which serially diluted 
solutions of the fluorescent polymers, from 10 mg.mL
-1
 to 0.01 μg.mL-1 were added and 
incubated for a further 2 hours. Following this the cells were extensively washed with PBS to 
remove the excess unattached fluorescent polymer. It was found that at polymer 
concentrations greater than 0.6 mg.mL
-1
, the cells would detach from the plate and so PBS 
washes were kept to a minimum. This could be due to surface modification at higher 
concentrations reducing the cells ability to adhere to the plates. After washing, the 
fluorescence was recorded using a plate reader (excitation: 485 nm and emission: 528 nm) 
and the cells were also viewed under a fluorescence microscope. Typical microscopy images 
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along with a brightfield-fluorescence composite is shown in Figure 4.10. The cells appear 
normal and healthy with signs of epithelial-like morphology, as can be seen in Figure 4.10A  
It is immediately apparent from Figure 4.10B and 4.10C that the highest fluorescence 
intensity appears localised to the cell membrane surface, consistent with successful labelling.  
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Figure 4.10: Microscope images of A549 cells metabolically labelled with PHEAA25-co-
HMA0.5 at a concentration of 0.31 mg.mL
-1
 (A) 20x objective brightfield image, note the 
regular appearance of the cells  (B) 20x objective fluorescence under blue filter, the 
fluorescence intensity appears localised to the cell membrane only (C) 20x objective 
composite overlay of green channel and brightfield performed in Image J.  (D) 40x objective 
fluorescence under blue filter. 
Whilst the imaging suggested we had successfully labelled the cell membrane, total 
fluorescence read by the plate reader showed conflicting results, as shown in Figure 4.11A 
and B.  ANOVA analysis showed that there is no significant difference between the positive 
(Ac4GalNAz) for azide and negative for azide (Ac4GalNAc) experiments. This may be 
explained by two observations. First, at concentrations of 0.63 mg.mL-1 and upwards, 
crystalline polymer regions forming during the incubation period that then would not wash 
A B 
C D 
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away were observed, Figure 4.12. Secondly, the polymer will non-specifically bind to the 
proprietary coating of the wells and to a certain extent the cells themselves. Any incomplete 
washing of polymer from the well will lead to variation in the fluorescence count but multiple 
wash steps lead to cell detachment. One method to overcome these issues in the future would 
be the use of flow cytometry to simultaneously count cells and observe the fluorescence. 
Unfortunately time and equipment restraints precluded this. 
 
 
Figure 4.11: Left: PHEAA25-co-HMA0.5. Right: PHEAA75-co-HMA1.5. Concentration 
expressed in Log Molar with blank set to -7. 
 
Figure 4.12: (A) 10x objective brightfield image (B) 10x objective fluorescence image with 
blue filter. Both images at a polymer concentration of 10 mg.mL
-1
. 
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4.3.5. Titration of sugar concentration 
Therefore, to attempt to confirm that metabolic labelling is occurring as expected a titration 
of sugar concentration was performed. It was hypothesised that in the presence of 
Ac4GalNAz, a concentration dependent fluorescence response to the sugar would be 
observed, while the negative control would give a concentration independent response. This 
would also give an estimate for the background fluorescence occurring. To give the best 
chance of observing an effect, a wide concentration of sugar was used:  0, 10 μM, 100 μM, 
250 μM, 500 μM, 1000 μM, and 5000 μM. This goes to a concentration considerably above 
the upper limit of toxicity previously tested, as we are not concerned if the cells lose viability 
due to the assay.  
The cells were labelled with PHEAA25-co-HMA0.5, at a concentration of  
0.6 mg.mL
-1
.This concentration was chosen as it was within the range that we saw labelling 
under the microscope, but not so high that it appeared to be making the cells lose the ability 
to adhere. The same metabolic labelling protocol as before was used. The fluorescence 
intensity obtained by the plate reader is shown in Figure 4.13.  
 
Figure 4.13:  Plate reader obtained fluorescence data for titration of Ac4GalNAz against 
pHEAA25-co-HMA0.5. Concentration expressed in Log Molar with blank set to -1.  
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It seems that when no azide is present, the fluorescence response is largely concentration 
independent, while in the presence of azide there is a concentration dependent response, 
however the fluorescence intensity decreases rather than increases. As before, as the 
concentration of sugar increases (and theoretically therefore an increased extent of labelling) 
the cell count observed in each well decreases substantially. To correct for the variation in the 
cell count between wells, 4x magnification images of the wells were processed using ImageJ 
software to count the cells, Figure 4.14.  
 
 
 
Figure 4.14: (A) Example of the reduced cell count observed in the higher concentration 
samples  and (B) The output after processing with ImageJ to allow cell counts.  
The average cell count for each concentration is shown in Figure 4.15A while there is 
considerable variation in the cell count between all concentrations in both the positive and 
negative azide experiment, there is a clear reduction in cell count at higher sugar 
concentrations in the case of the positive azide. It is possible that increased labelling is 
reducing the ability for the cells to adhere to the plate. Alternatively the reduced binding is a 
direct result of the increased sugar concentration, or a combination of the two.  The 
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fluorescence per cell is shown in Figure 4.15B. ANOVA analysis of the data shows that there 
is statistically no significance between the positive and negative azide curves. 
 
 
Figure 4.15: Results after incubation with pHEAA25-co-HMA0.5 (A) Average cell counts 
(n=3).  (B) The calculated average fluorescence per cell (n=3) In both cases concentration 
expressed in Log Molar with blank set to -1. 
To evaluate if the surface labelling was occurring, the cells were imaged under a fluorescence 
microscope. To determine the extent to which the fluorescence was localised onto the cells 
(or not) fluorescence intensity slices were averaged over the area of the images, as shown in 
Figure 4.16. It is apparent that the fluorescence intensity is consistently localised only onto 
the cells in the experiments containing Ac4GalNAz (Figure 4.16A, C, and, E), while in the 
negative control experiments containing Ac4GalNAc (Figure 4.16 B, D, and, F), the 
fluorescence is delocalised across the whole image area, indicating non-specific adsorption of 
the polymer onto the well surface and to some extent the cells. This confirmed to us that the 
labelling had occurred successfully, and we had a method for easily modifying cell surfaces 
with polymers.  
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Figure 4.16: 40x fluorescence images of (A)(C) and (E) 5000μM positive azide and (B)(D) 
and (F) 5000μM negative azide after incubation with 0.6 mg.mL-1 PHEAA25-co-HMA0.5 for 2 
hours. Each image is from a separate repeat. Inset: Slice of fluorenscent intensity averaged 
from entire image area shown in yellow.   
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4.3.6. Investigating cell surface viability with fluorescently 
labelled WGA 
Having confirmed that we had successfully modified the cell surface, we wished to determine 
the extent to which the labelling may be impacting cell function. Therefore an assay was 
developed to see to what extent the cell glycocalyx was still accessible, despite the steric 
hindrance of the polymer conjugations.  
To do this fluorescein isothioscyanate-labelled wheat germ agglutinin (FITC-WGA) was 
used. WGA is a known to bind to both terminal sialic acid residues and O-linked N-
acetylgalactosamine residues on the cell glycocalyx.
73,74
 Ac4GalNAz is metabolically 
incorporated primarily into O-linked N-acetylgalactosamine but will also access the sialic 
acid biosynthetic pathway. Therefore, by metabolically labelling the cells before the 
introduction of the FITC-WGA and monitoring the fluorescent output, we could determine if 
there was a reduction in fluorescence and consequently if access to the cell surface had been 
restricted. To minimise any interference that could arise from multiple fluorophores being 
present on the cell surface, such as quenching of the fluorescence intensity, pHEAA25-DBCO 
and pHEAA75-DBCO from chapter three were used as non-fluorescent analogues of the 
hostasol-dye polymers.  
With these non-fluorescent polymers in hand, the first step was to perform a titration 
experiment using the FITC-WGA to determine what concentration to use on unlabelled cells. 
A549 cells were added to a 96 well plate at a concentration of 40,000 cells per well and left 
for 2 hours to allow adherence to the plate. Serially diluted solution of FITC-WGA was then 
added and the cells were incubated for 30 minutes as before. The cell media was then 
removed and the cells washed three times with PBS to ensure complete removal of any un-
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adhered FITC-WGA and the fluorescence recorded, see Figure 4.18, the concentration of 
FITC-WGA used in later experiments is marked in red.  
Figure 4.17: Titration curve of FITC-WGA against unlabelled A549 cells. Circled data point 
represents the concentration chosen for further experiments.  
A concentration at the lower end of the binding curve was chosen to ensure that any 
inhibition of the cell surface was more likely to be observed.  
A further batch of A549 cells were then metabolically labelled as before. After incubation for 
48 hours the cell media was removed and pHEAA-DBCO solutions in cell media were added. 
The cells were incubated for 2 hours at 37°C before the media was removed and FITC-WGA 
solution added and incubated for a further 30 minutes, after which the cells were washed 
three times with PBS buffer and the fluorescence recorded. The resulting data is plotted 
below in Figure 4.18.  
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Figure 4.18: Fluorescent response of cells after incubation with pHEAA25-DBCO or 
pHEAA75-DBCO and subsequent addition of FITC-WGA.  
There is no difference between the experiments performed in the presence of Ac4GalNAz 
(positive azide) and Ac4GalNAc (negative azide). This confirmed that although the cells are 
being labelled with the polymers, the function of the glycocalyx, essential for healthy cell 
growth, is being maintained and the modification is passive. This is consistent with relatively 
low levels of labelling, suggesting this could find application where additional functionality 
is needed, rather than for ‘turning off’ cell immunogenicity, for example. Such materials will 
find use in mapping cell surface glycans or by adding an additional, abiotic, layer of 
functionality to the cell surface.  
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4.4. Conclusions 
We have shown that the polymeric modification of the cell glycocslyx is possible via 
metabolic engineering of O-linked glycans and sialic acid biosynthesis. However there are 
difficulties associated with quantifying the effects using fluorescent analysis methods that 
quantify an average over the area of a well. Flow cytometry may offer a way to circumvent 
this issue by coupling the fluorescence detection to cell count.  
Coupling the metabolic labelling method with polymer chemistry is an attractive route to 
utilising the multiple metabolic pathways to tag particular regions of the glycocalyx with 
different polymeric functionality, either for later lysing and analysis or for probing the 
glycocalyx. Polymers offer the ability to introduce any bio-compatible chemical functional 
groups at controlled local density without worry for issues of solubility etc. This method 
circumvents the issues associated with cell-surface initiated polymer growth, such as 
maintaining cell viability while subjecting the cells to the conditions required for 
polymerisation. This method for the installation of polymers onto the glycocalyx could be 
coupled with knowledge of protein and glycan over-expression in certain disease states such 
as tumours and Alzheimer’s as well as for fundamental study of glycocalyx interactions.  
Further work requires a more complete study of the extent of labelling, using flow cytometry 
and confocal microscopy coupled with multiple stains to confirm the location of the cell 
labelling.   
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4.5. Experimental 
4.5.1. Materials 
d-(+)-Galactose was purchased from MP Biomedicals. Trimethylamine, sodium azide, 4,4′-
azobis(4-cyanovaleric acid), 1,4-dioxane, dichloromethane, DBCO-amine, DMF, 2,6-lutidine 
99% was purchased from Acros Organics. WGA was purchased from Vector labs. Ultrapure 
milli Q water was obtained from a Merk Milli-Q water purifier at 18.2 MΩ.cm resistivity at 
25 °C.  3500 Da MWCO ‘snakeskin’ dialysis tubing was purchased from Thermofisher (UK). 
Choloroacetic anhydride, acetic anhydride, were purchased from Sigma-Aldrich. Hostasol 
methacrylate was synthesised by Julien Nicolas, the Haddleton Group at the University of 
Warwick
75,76
, using hostasol dye provided by Clariant. 
4.5.2. Analytical methods  
1
H, 
13
C NMR, and 
19
F spectra were recorded on Bruker HD-300, HD-400, and AV-500 
spectrometers using deuterated solvents purchased from Sigma-Aldrich. Chemical shifts are 
reported relative to residual non-deuterated solvent. Mass spectrometry was performed on an 
Agilent 6130B single Quad (ESI). FTIR spectra were acquired using a Bruker Vector 22 
FTIR spectrometer with a Golden Gate diamond attenuated total reflection cell. Drop shape 
analysis was performed with a Krüss DSA 100.  Solid state Raman spectra were collected on 
a Reinshaw inVia Reflex Raman using a 442 nm HeCd laser. 96-well plates were read using 
a Bioteck Synergy plate reader set at 25 °C. Uv-Vis spectra were obtained an Agilent Cary 
spectrometer. Glass slides were imaged using an Agilent Technologies 2 Colour Array 
Scanner using two lasers; a SHG-YAG laser (532 nm) and a helium-neon laser (633 nm). 
DMF SEC was performed on a varian 390-LC MDS system equipped with a PL-AS RT/MT 
autosampler, a PL-gel 3 μm (50 x 7.5 mm) guard column, two PL-gel 5 μm (300 x 7.5 mm) 
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mixed-D columns using DMF with 5 mM NH4BF4 at 50 °C as eluent at a flow rate of 1.0 
mL.min
-1
. The SEC system was equipped with ultraviolet (UV)/visible (set at 280 and 461 
nm) and differential refractive index (DRI) detectors. Narrow molecular weight PMMA 
standard (200 - 1.0 x 106 g.mol
-1
) were used for calibration using a second order polynomial 
fit.  
ImageJ analysis
77
 
To make overlays of fluorescence and brightfield images, the following operations were 
performed in ImageJ. First the images were converted to 8-bit, merged by colour and 
converted to RGB. To perform cell counting the images were converted to 8-bit. The 
background was subtracted using a rolling ball radius of 100 pixels. A threshold was applied 
to the image to give the greatest separation of cells from the background. The binary “Fill 
Holes” process was applied to solidify the cells to be counted. The image was converted to 
mask and “watershed” was applied. Finally the particle count was applied between the size of 
8 to 1000 pixels.  
To obtain profile slices, either a line or box was drawn over the area and “plot profile” used.  
Cell culture 
Human Caucasian lung carcinoma cells (A549 (ECACC 86012804)) were obtained from 
European Collection of Authenticated Cell Cultures (Public Health England, UK) and grown 
in 175 cm
2
 Nunc cell culture flasks (ThermoFisher, Rugby, UK). Standard cell culture 
medium was composed of Ham's F-12K (Kaighn's) Medium (F-12K) (Gibco, Paisley, UK) 
supplemented with 10% USA-origin fetal bovine serum (FBS) purchased from Sigma 
Aldrich (Dorset, UK), 100 units/mL penicillin, 100 µg/mL streptomycin, and 250 ng/mL 
amphotericin B (PSA) (HyClone, Cramlington, UK). A549 cells were maintained in a 
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humidified atmosphere of 5% CO2 and 95% air at 37 °C and the culture medium was 
renewed every 3–4 days. The cells were subcultured every 7 days or before reaching 90% 
confluency. To subculture, cells were dissociated using 0.25% trypsin plus 1 mM EDTA in 
balanced salt solution (Gibco) and reseeded at 1.87 ∙ 105 cells per 175 cm2 cell culture flasks.  
Cell toxicity screening  
Prior to plating cells, 100 uL of either ethanol or sugar solution was added to 6-well plates 
(ThermoFisher) and left to dry to allow ethanol to evaporate, control wells received no added 
solution.  Cells were then seeded at 5X10
5
 cells per well in 2 mL of cell culture medium. 
Cells were allowed to attach to the entire free surface of the bottom of the well and formed a 
confluent layer not greater in height than one cell. Cells were incubated for 48h in a 
humidified atmosphere of 5% CO2 and 95% air at 37 °C. After the incubation period, cells 
were then dissociated using 0.25% trypsin plus 1 mM EDTA in balanced salt solution. The 
number of viable cells was determined by counting with a hemocytometer (Sigma Aldrich) at 
room temperature after 1:1 dilution of the sample with 0.4% trypan blue solution (Sigma 
Aldrich). The initial cell medium was discarded such that any non-attached cells were not 
included in the assessment.  The fold change of recovered cells was calculated by dividing 
the number of recovered cells with intact membranes by the number of cells initially plated. 
 
Statistical analysis   
Data were analyzed with a one-way analysis of variance (ANOVA) on ranks followed by 
comparison of experimental groups with the appropriate control group (Holm–Sidak method) 
followed by Tukey’s post hoc test. Excel 2013 (Microsoft, Redmond, WA) and R (R 
Foundation for Statistical Computing, Vienna, Austria) were used for the analyses. 
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Plate Coating procedure 
 Ac4GalNAz (4.3mg) and Ac4GalNAc (3.8mg), as a negative control, where dissolved in 5 
mL ethanol to give 2mM solutions.  10 µL of sugar solution was added to each well and 
ethanol was allowed to evaporate off for a minimum of 30 minutes to give a final 
concentration of 100 μM in 200 μL of cell media.  Plates were not stored and used 
immediately.    
Analysis of A549 cells 
Cells were seeded at 0.2x10
4
 cells per well in 200 µL of cell culture medium in 96-well 
sugar-coated plates (ThermoFisher). Cells were incubated for 48 h in a humidified 
atmosphere of 5% CO2 and 95% air at 37 °C. Cell media was then removed and 100 μL of 
polymer solution added. The plates were returned to the incubator for another 2 hours. For 
the cell surface viability tests the polymer solutions were removed and FITC-WGA in cell 
media added and the plate incubated for a further 30 minutes, before removing the FITC-
WGA solution. Otherwise the plate was then washed with PBS buffer and fluorescence 
recorded using a Bioteck Synergy plate reader, with excitation and emission values set to, 
485 nm and 525 nm, with gain set to 75. Finally the wells were imaged on an Olympus ckx41 
microscope with camera xc30 and processed using Olympus CellSens software. 
FITC-WGA Activity Test 
WGA-FITC was serially diluted from 0.1 mg.mL to 4.88x10
-5
 mg.mL
-1
 (11 serial dilutions 
plus a blank) with cell media and sterile filtered.  
A549 Cells (40,000 per well) were added to a 96 well plate in 200 μL of cell media (F12K, 
with 10% FBS, 1x PSA) and incubated for 2 hours to allow adherence to the plate. The cell 
media was then removed and the WGA solutions added. The plate was incubated for 30 
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minutes in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. The cell media was 
then removed and the wells washed with PBS buffer three times. Fluorescence was then 
measured using a Bioteck Synergy plate reader, with excitation and emission values set to 
485 nm and 525 nm, with gain set to 75. Following this the cells were then imaged under an 
Olympus ckx41 microscope with camera xc30 and processed using Olympus CellSens 
software. This was repeated three times, the data plotted and a midpoint of the curve chosen 
as the WGA concentration to be used in further experiments.  
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4.5.3. Synthetic Procedures 
Synthesis of tetraacetyl N-azidoacetylgalactosamine 
Sodium methanolate (30% w/w NaOMe in MeOH, 1.66 mL, 4.64 mmol, 1.00 equivalent) 
was added to a solution of d-galactosamine hydrochloride (1.00 g; 4.64 mmol) in 50 mL of 
methanol. The mixture was left at room temperature for 30 min until complete dissolution. 
Triethylamine (0.47 g; 4.64 mmol, 1.00 equiv) and chloroacetic anhydride (871 mg; 5.10 
mmol, 1.10 equiv) were added and the reaction was stirred at room temperature overnight. 
The solvent was removed under vacuum and the resulting N-chloroacetylgalactosamine solid 
was used in the following reaction without any further workup. 
The N-chloroacetylgalactosamine was dissolved in a 20 mL:2 mL methanol:water mix and 
sodium azide (1.06 g; 16.24 mmol, 3.50 equiv) was added. The solution was stirred for 5 h at 
65 °C. Following this the solvent was removed under vacuum. The resulting solid was then 
fully suspended in 20 mL pyridine and cooled on ice with an air condenser in place. 20 mL of 
acetic anhydride was then slowly added to the solution and left overnight.  The solvent was 
then removed under vacuum and re-dissolved in 50 mL of ethyl acetate. The solution was 
washed with 50 mL of 1 M hydrochloric acid, 50 mL of sodium hydrogen carbonate and 50 
mL of brine, and dried with magnesium sulphate. The crude product was then purified by 
silica gel column chromatography using 1:1 cyclohexane:ethyl acetate to give the final 
product as an oil that solidified after freeze drying under high-vacuum on a schlenk line. 0.48 
g (25%) 
1H NMR (400MHz): δppm: 1.83 (3H, S) 1.94 (3H, S) 1.96 (3H, S) 1.97 (3H, S) 2.05 
(3H, S) 2.05 (3H, S) 2.11 (3H, S) 2.12 (3H, S) 3.87 (S), 3.97-4.28 (M) 4.37 (dt, 
J=11.04, 9.03), 4.64 (M), 5.18 (M), 5.33(dd, J=8.03, 2.67) 5.34 (d, J=2.01) 
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13
C NMR (75MHz): δppm: 169.61, 169.17, 168.61, 168.21 (Carbonyl) 150.02 (Amide) 
142.88 (C1) 69.66, 69.02, 67.16 (C3,4, 5) 60.89 (CH2) 49.57 (C2) 19.66 ,19.63, 19.14 (Me)  
IR (cm
-1
): 3353 (N-H Stretch) 2109 (-N3) 1739 (Ester C=O) 1689 (Amide C=O) 
1534 (Amide N-H Bend) 1040 (Ester C-O)  
MS m/z (ESI-POS): Expected: 430 Observed: 453 (M+Na
+
) 
 
Synthesis of p(hydroxyethylacrylamide) 
HEAA (0.5g, 4.34mmol, 25eq) plus varied amounts of DMPPFP (1eq) and 4,4′-Azobis(4-
cyanovaleric acid)  (AVCA) as the initiator (0.5eq) where placed into a glass vial with 4.0mL 
of a 1:1 mix of Toluene and Methanol. 200ul of Mesitylene as an internal NMR standard was 
added. A sample for NMR is taken and dissolved in deuterated Chloroform. The glass vial 
was then sealed and degassed using N2 for 30 minutes. Following this the reaction mixture is 
heated to 70°C for 90 minutes at which time the reaction is quenched by exposure to air 
followed by cooling in liquid N2. An NMR sample of the crude mix is made up in deuterated 
Methanol and the mixture is precipitated into Diethyl Ether from Methanol three times to 
give a yellow solid. 92% conversion. Ð = 1.18 
 1
H NMR (MeOD) 300MHz, ppm: 3.65 (br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-
1.5 (br, Backbone CH2) 
19
F NMR (CDCl3) 376MHz, ppm: -150.35 (1F,br s), -151.44 (1F, br s), -156.97 (1F, br s), -
162.11 (1F, br s) 
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Synthesis of p(hydroxyethyl acrylamide) dibenzocycoloctyne amide 
Poly(HEAA) (1 eq), DBCO (10 mg, 36.2 μM,  1.05 eq) and triethylamine (TEA) (2 eqs) are 
dissolved in 2 mL of deuterated methanol.  The reaction mixture is then heated to 50 °C for 
16 hours. The solution is then concentrated to approximately 0.5mL and submitted for 
19
F 
NMR. Following this the mixture is diluted to 20 mL of distilled H2O and dialysed using 
dialysis tubing with an appropriate molecular weight cut off. The sample was then freeze-
dried to afford the final product as a white powder, yield ~69% 
1
H NMR (MeOD) 300MHz, ppm: 7.5-7.0 (br, Benzyl) 4.42 (br, cyclooctyne ring CH2) 3.65 
(br, NH-CH2-CH2-), 3.28 (br, -NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2)
 
19
F NMR indicated no presence of fluorine left in sample 
Raman (cm
-1
): 1600 (Aromatic C-C) and 2159 (Alkyne) 
Synthesis of p(hydroxyethylacrylamide-co-hostasol methacrylate) pentafluorophenol  
The reaction and product are kept shield from light using aluminium foil at all times. HEAA 
(0.5 g, 4.34 mmol, 25 eq), 2% hostasol methcrylate (39.7 mg, 86 μmol, 0.5 eq), plus varied 
amounts of DMPPFP (1 eq) and 4,4′-Azobis(4-cyanovaleric acid)  (AVCA) as the initiator 
(0.5 eq) where placed into a glass vial with 8.0 mL of a 1:1 mix of toluene and methanol. 200 
μl of mesitylene as an internal NMR standard was added. A sample for NMR is taken and 
dissolved in deuterated chloroform. The glass vial was then sealed and degassed using N2 for 
30 minutes. Following this the reaction mixture is heated to 70 °C for 180 minutes at which 
time the reaction is quenched by exposure to air followed by cooling in liquid N2. An NMR 
sample of the crude mix is made up in deuterated methanol and the mixture is precipitated 
into diethyl ether from methanol three times to give an orange solid. Average 92% 
conversion.  
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1
H NMR (MeOD) 400MHz, ppm: 8.17-8.09 (br Hostasol aromatics) 5.52 (br, C5H10 3.68 (br, 
NH-CH2-CH2-), 2.5-1.5 (br, Backbone CH2) 0.94 (br, Me) 
19
F NMR (MeOD) 376MHz, ppm: -150.35 (1F,br s), -151.44 (1F, br s), -156.97 (1F, br s), -
162.11 (1F, br s) 
p(hydroxyethylacrylamide-co-hostasol methacrylate) dibenzocylcooctyne 
p(hydroxyethylacrylamide-co-hostasol methacrylate) pentafluorophenol (1 eq), DBCO (10 
mg, 36.2 μM,  1.05 eq) and triethylamine (TEA) (2e qs) are dissolved in 2 mL of deuterated 
methanol.  The reaction mixture is then heated to 50 °C for 16 hours. The solution is then 
concentrated to approximately 0.5 mL and submitted for 
19
F NMR. Following this the 
mixture is diluted to 20 mL of distilled H2O and dialysed using dialysis tubing with an 
appropriate molecular weight cut off. The sample was then freeze-dried to afford the final 
product as a white powder, yield ~69% 
1
H NMR (MeOD) 400MHz, ppm: 8.17-8.09 (br Hostasol aromatics) 7.5-7.0 (br, Benzyl) 5.52 
(br, C5H10 3.68 (br, NH-CH2-CH2-), 4.42 (br, cyclooctyne ring CH2), 2.5-1.5 (br, Backbone 
CH2) 0.94 (br, Me) 
19
F NMR indicated no presence of fluorine left in sample 
Synthesis of Azide coated glass slides  
Glass microscope slides were first cleaned using a ‘Piranha’ solution consisting of a 3:1 (v/v) 
mix of 98% H2SO4 and 30% H2O2. [Note that Piranha solution is extremely hazardous and 
should always be freshly prepared in small quantities and handled using heavy nitrile gloves. 
Do not wipe up spillages with cloth or tissue as this will result in a fire.  Piranha solution 
should always be disposed of with care using first manganese dioxide to destroy the peroxide 
and then sodium bicarbonate to neutralise the solution.]  Piranha solution was prepared by 
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slow dropwise addition of H2O2 to H2SO4 [Note in this step the water component is being 
added to the acid component, the opposite of usual guidelines for preparing acidic solutions]. 
The glass slides were cleaned for 20 minutes, during the cleaning procedure the solution was 
kept on ice. Following this slides were rinsed with DI water and dried under N2. Immediately 
afterwards the slides were immersed in 5mL of toluene solution containing 100 μL of (3-
Glycidyloxypropyl)trimethoxysilane for 2 hours at room temperature. Subsequently the slides 
were washed with toluene and DI water and dried with N2. The epoxy glass slides were then 
immersed into a bath containing a DMSO solution of NaN3 (0.1177g, 4 eq) and NH4Cl 
(0.0968g, 4 eq) wrapped in tin foil and held at 80 °C for 8 hours. The slides where then rinsed 
with DMSO, Ethanol, DI water and dried with N2. Measured water contact angle: 53.4 ±0.6 ° 
Labelling of azido-glass slides using poly hydroxyethylacrylamide-co-hostasol 
methacrylate 
1 μL of polymer at 0.01, 0.001 and 0.0001 mg.mL-1 in DI water, were pipetted onto the azide 
slide and left for 2 hours. After which time the slide was washed exhaustively with DI water 
for 15 minutes and then imaged using a agilent microarray scanner, Red and Green Channels, 
using two lasers; a SHG-YAG laser (532 nm) and a helium-neon laser (633 nm). 
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Chapter Five 
Conclusions 
5.1 Conclusions 
Glycans interactions with multivalent receptors and proteins are vitally important controllers 
of information in biological systems. Developing new methods to probe these fundamental 
interactions is vitally important. In this work we have highlighted the importance of subtleties  
involved in probing glycan-protein interactions. In chapter two, we have shown that 
increasing glyco-conjugate density does not necessarily correlate with increased affinity, or 
increased inhibition, and that conversely, a lack of inhibitory activity does not correlate to no 
interaction. Careful assay design is vital if the purpose is to investigate the interactions taking 
place over identifying potential inhibitory compounds. The inclusion of nominally non-
binding mannose to multivalent heterogeneous polymers resulted in a decrease in avidity but 
an increase in the inhibition of RCA120 compared to the isovalent homogeneous polymers. 
The relationship between mannose density, inhibition, and, avidity was non-linear and was 
ascribed to an increased association rate, while the rate of dissociation stayed constant.  
Meanwhile no inhibition of CTxB was observed, but BLI analysis was used to demonstrate 
that the heterogeneous polymers do have ~10 μM avidity towards CTxB. This highlights that, 
in line with other reports, that the structure of the polymer scaffold and its ability to match the 
geometry of the receptors can have a greater impact on the binding than the isomerism of the 
sugar units.   
235 
 
In chapter three we have shown the development of a high-through put gold nanoparticle 
based, label free, screening system for the analysis of protein-carbohydrate interactions.  The 
lower limit on the concentration of gold required for detection of binding was established and 
it was shown that multivalent binding effects can effectively be used to out compete 
monosaccharide interactions and reduce the need for time consuming purification steps that 
result in a loss of nanoparticle concentration.  This helps move this process towards a large 
scale system appropriate for use in industry to screen huge libraries of heterogeneous 
environments. Several ‘lead’ heterogeneous sugar combinations of mannose and galactose 
where identified for studying the interactions of DBA, RCA120 and SBA lectins.  Further to 
this it was shown that increasing the flexibility of the linker between the sugar and the 
particles resulted in a loss of binding towards all five lectins. This again highlights that for 
multivalent receptor binding, offering a rigid scaffold with the correct orientation over a 
flexible linker can have a dramatic impact on the binding. This highlights the need to 
consider both the scaffold and ligand when attempting to rationally design inhibitors and 
biosensors. The use of high through-put libraries as developed here may lead to the discovery 
of unexpected scaffolds and/ or heterogeneous ligand combinations that would be difficult to 
predict otherwise.  
Finally in chapter four, we have shown that the polymeric modification of the cell 
glycocalyx is possible via metabolic engineering of O-linked glycans and sialic acid 
biosynthesis. It was shown that polymeric modification of A549 cells did not inhibit cell 
surface accessibility and opens the door to ‘hybrid’ cells with augmented, abiotic cell 
functionality for probing the cell and its environment. This circumvents the issues 
encountered when attempting cell-surface initiated polymerisations.  
Overall this work has highlighted and explored the challenges associated with glycan and 
multivalent receptor interactions that must be met, in order to successfully overcome some of 
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the most pressing issues in healthcare science; including the diagnosis and treatment of 
diseases such as cancer, and the mounting antibiotic resistance crisis.    
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Appendix One 
Chapter Two Supplementary Information 
 
Figure S1. RCA120 inhibitory data by total galactose concentration. A) Comparison of all 
inhibitory curves. C-E, fitted curves.  
A 
B C 
D E 
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Figure S2: RCA, Homogeneous polymers in Galactose Concentration.  
 
Figure S3: Percentage specific binding (i.e. percent inhibition) vs concentration for both 
heterogeneous and homogenous libraries.  
A B 
C 
A B 
C 
D E F 
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Glycopolymer-Lectin Interactions using Bilayer Interferometry  
To enable off rates to be calculated the dissociation phase was fitted independently. The fits 
are shown below. 
 
Figure S6. RCA120 with PGal25. Concentrations shown in legend, as [Polymer]. 
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Figure S RCA120 with PGO25. Concentrations shown in legend, as [Polymer].  
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Figure S7. RCA120 with PGal50. Concentrations shown in legend, as [Polymer]. 
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Figure   RCA120 with PGO50. Concentrations shown in legend, as [Polymer].  
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Figure   RCA120 with PGO75. Concentrations shown in legend, as [Polymer].  
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Figure S8. RCA120 with PGal75. Concentrations shown in legend, as [Polymer]. 
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Figure S9. RCA120 with PGal100. Concentrations shown in legend, as [Polymer]. 
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Figure S10. CTXB with PGal25 Concentrations shown in legend, as [Polymer]. 
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Figure S11. CTXB with PGal50 Concentrations shown in legend, as [Polymer]. 
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Figure S12. CTXB with PGal75 Concentrations shown in legend, as [Polymer]. 
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Figure S13. CTXB with PGal100 Concentrations shown in legend, as [Polymer]. 
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To provide an additional measure of affinity, KD was approximated by the steady state 
treatment. In short, the final BLI signal intensity (after dissociation phase had plateaued) 
verse both polymer and galactose concentration. Fits of this are shown below.  
 
Figure S14. KD by steady state of RCA glycopolymers, by polymer concentration 
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Figure S15. KD by steady state of RCA glycopolymers, by galactose concentration 
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Figure S16. KD by steady state of CTXB with glycopolymers, by polymer concentration 
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Figure S17. KD by steady state of CTXB with glycopolymers, by galactose concentration 
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Appendix Two 
Table S2.1: Consortium for functional glycomics nomenclature 
Sugar Hexose N-Acetylhexosamine Hexosamine 
Galactose    
Glucose    
Mannose    
Fucose    
Xylose    
 
Table S2.2: Acidic Sugars 
Acidic Sugars Symbol 
NeuAc   
NeuGc  
KDN  
GlcA  
IdoA  
GalA  
ManA  
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